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3. Abstract − Zusammenfassung 
3.1. Abstract 
This cumulative dissertation summarizes three peer-reviewed publications addressing different 
aspects of the prodromal and manifest phase of Parkinson’s disease with special emphasis on the 
vulnerability of the noradrenergic locus coeruleus. The first publication represents an original article 
describing the establishment and characterization of the first ever α-synuclein overexpression mouse 
model for the locus coeruleus. Narrative articles two and three discuss the importance of the locus 
coeruleus in context of prodromal Parkinson’s disease, and the heterogeneity of the affected 
mesencephalic and extramesencephalic dopaminergic systems in manifest Parkinson’s disease. 
The first publication entitled “A53T-α-synuclein overexpression in murine locus coeruleus 
induces Parkinson’s disease-like pathology in neurons and glia” describes the establishment of 
the first locus coeruleus α-synucleinopathy mouse model. The data show that viral vector mediated 
focal overexpression of human A53T-α-synuclein triggered time-dependent neurodegeneration of 
noradrenergic locus coeruleus neurons, accompanied by progressive α-synuclein phosphorylation, 
formation of proteinase K-resistant α-synuclein-aggregates, accumulation of Ubi-1- and p62-positive 
inclusions in microglial cells and induction of progressive micro- and astrogliosis. Apart from this 
local pathology, we observed abundant α-synuclein positive axons in LC output regions, indicating 
rapid anterograde axonal transport of A53T-α-synuclein.  
The second publication entitled “The locus coeruleus – another vulnerability target in 
Parkinson’s disease” addresses the role of the locus coeruleus noradrenergic system in prodromal 
and manifest Parkinson’s disease. Within this review we provide a comprehensive description of the 
neuroanatomical basis of the locus coeruleus system and its implication in Parkinson’s disease, 
summarize highly relevant vulnerability factors, and list all animal studies conducted so far 
investigating locus coeruleus pathology in experimental research. Further, we provide a therapeutic 
outlook on how noradrenergic replacement therapy has already been successfully tested in manifest 
Parkinson’s disease patients and how locus coeruleus dysfunction can be of use for the development 
of disease modifying therapy approaches and disease progression biomarkers.  
Within the third publication entitled “Mesencephalic and extramesencephalic dopaminergic 
systems in Parkinson’s disease”, we provide a historical overview over the key milestones of 
Parkinson’s disease pathogenesis and therapy, dissect the dopaminergic basis of the cardinal 
parkinsonian motor symptomatology, summarize the anatomical features of the ten dopaminergic 
systems of the mammalian central nervous system and their involvement in Parkinson’s disease, 
illustrate how the advanced dopaminergic imaging techniques contribute to optimized differential 
diagnosis and pathogenetic knowledge, and explain how dopaminergic replacement therapy improves 
the cardinal motor symptomatology while simultaneously inducing a new set of symptoms based on 
a hyperdopaminergic status.             
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3.2. Zusammenfassung 
Diese kumulative Dissertation fasst drei von Fachleuten begutachtete Veröffentlichungen 
zusammen, die sich mit verschiedenen Aspekten der prodromalen und manifesten Phase der 
Parkinson-Krankheit befassen, wobei der Schwerpunkt der Dissertation auf der Betroffenheit des 
noradrenergen locus coeruleus liegt. Die erste Veröffentlichung stellt einen Originalartikel dar, der 
die Etablierung und Charakterisierung des weltweit ersten α-Synuclein-Überexpressionsmodells im 
noradrenergen locus coeruleus der Maus beschreibt. In den Veröffentlichungen zwei und drei wird 
die Bedeutung des locus coeruleus im Kontext der prodromalen Krankheitsphase und die 
Heterogenität der betroffenen mesencephalen und extramesencephalen dopaminergen Systeme im 
Rahmen der manifesten Parkinson-Krankheit erörtert.  
Die erste Veröffentlichung mit dem Titel “A53T-α-synuclein overexpression in murine locus 
coeruleus induces Parkinson’s disease-like pathology in neurons and glia”  beschreibt die 
Etablierung des ersten α-Synucleinopathie-Mausmodells im noradrenergen locus coeruleus. Die 
gewonnenen Daten zeigen, dass eine viral vermittelte fokale Überexpression von humanem A53T-α-
Synuclein im murinen locus coeruleus eine zeitabhängige Neurodegeneration noradrenerger locus 
coeruleus Neurone auslöste, begleitet von einer zunehmenden Phosphorylierung des 
überexprimierten α-synuclein und Bildung von Proteinase-K resistenten α-synuclein-Aggregaten. Es 
zeigte sich zudem eine Akkumulation von Ubi-1- und p62-positiven Einschlüssen in Mikrogliazellen 
sowie eine Induktion einer fortschreitenden Mikro- und Astrogliose. Abgesehen von dieser lokalen 
Pathologie beobachteten wir zahlreiche α-synuclein-positive Axone in locus coeruleus-
Projektionsregionen, was auf einen schnellen anterograden axonalen Transport von A53T- α-
synuclein hinweist.   
Die zweite Veröffentlichung mit dem Titel “The locus coeruleus – another vulnerability target 
in Parkinson’s disease” befasst sich mit der Rolle des noradrenergen locus coeruleus-Systems im 
Rahmen der prodromalen und manifesten Parkinson-Krankheit. Im Rahmen dieser Publikation 
stellen wir eine umfassende Beschreibung der neuroanatomischen Grundlagen des locus coeruleus-
Systems und seiner Beteiligung im Rahmen der Parkinson-Krankheit bereit, fassen die relevantesten 
Vulnerabilitätsfaktoren zusammen und listen alle Tierstudien, die bisher zur Untersuchung der locus 
coeruleus-Pathologie in der experimentellen Parkinson-Forschung durchgeführt wurden. Darüber 
hinaus geben wir einen therapeutischen Ausblick darauf, wie die noradrenerge Substitutionstherapie 
bereits an manifesten Parkinson-Patienten erfolgreich getestet wurde und wie eine locus coeruleus-
Dysfunktion für die Entwicklung krankheitsmodifizierender Therapieansätze und 
Progressionsmarker von Nutzen sein kann.  
In der dritten Veröffentlichung mit dem Titel “Mesencephalic and extramesencephalic 
dopaminergic systems in Parkinson’s disease“ gebe ich zunächst einen historischen Überblick 
über die wichtigsten Meilensteine der Pathogenese und Therapie der Parkinson-Krankheit, analysiere 
dann die dopaminerge Grundlage der kardinalen motorischen Symptomatik und fasse die 
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anatomischen Merkmale der zehn dopaminergen Systeme und ihre Beteiligung an der Parkinson-
Krankheit zusammen. Zudem veranschauliche ich wie neue dopaminerge Bildgebungstechniken zur 
Optimierung der Differentialdiagnose und des pathogenetischen Wissens beigetragen haben, und 
erläutere, wie die dopaminerge Substitutionstherapie die kardinalmotorische Symptomatik verbessert 
und gleichzeitig eine Reihe neuer hyperdopaminerger Symptome hervorruft. 
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4. Theoretical background 
4.1. Parkinson’s disease 
4.1.1. Clinical presentation  
In 1817, James Parkinson described the clinical symptomatology of six patients which suffered from 
a movement disorder that presented with involuntary trembling of one or more body parts, general 
slow- and weakness of the limb muscles, the inability to walk with normal pace, and an altered 
bending forward posture (Parkinson, 1817). In honor of James Parkinson, Jean-Martin Charcot 
suggested the term Parkinson’s disease (PD). In retrospective, Parkinson’s “An Essay on the Shaking 
Palsy” marks the starting point for the long history of PD. Over 200 years later, idiopathic PD 
represents the most common movement disorder worldwide affecting over 1% of those individuals 
older than 65 years of age with a slight preference for the male gender (Benito-León et al., 2003; Samii 
et al., 2004; Lau and Breteler, 2006). Still today PD represents a clinical diagnosis relying on the 
presence of the classical motor symptomatology: 1) brady- or hypokinesia, 2) muscular rigidity, 3) 
rest tremor, and 4) postural instability (Kalia and Lang, 2015). Specified diagnostic criteria containing 
defined inclusion and exclusion criteria were recently ratified by the Movement Disorder Society 
(MDS) (Postuma et al., 2015). Importantly, PD motor symptomatology is not limited to the 
aforementioned disease defining symptoms, but can include several other heterogeneous motor 
manifestations like reduced arm swinging, short stride length, decreased blinking rate, reduced facial 
expressions, or a general reduction of daily life movements (Rodriguez-Oroz et al., 2009). Despite 
the fact that the parkinsonian motor symptoms represent core features of PD, it is noteworthy to 
highlight that PD patients exhibit numerous daily life impairing non-motor symptoms including but 
not limited to, reduced gastro-enteral motility, hyposmia, sleep disturbances, autonomic dysfunction, 
cognitive decline, depression, and apathy (Martinez‐Martin et al., 2007; Chaudhuri and Schapira, 
2009; Schapira et al., 2017).  
Figure 1  Scheme depicting PD diagnostic steps defined by the MDS criteria    
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4.1.2. Neuropathological hallmarks  
On a neuropathological basis, PD represents a progressive neurodegenerative disorder which is 
predominantly characterized by degeneration of dopaminergic midbrain neurons in the Substantia 
nigra pars compacta (SNc) leading to dopamine (DA) deficiency in the nigrostriatal network (Carlsson 
et al., 1957; Hornykiewicz, 1963; Trétiakoff, 1919; Kordower et al., 2013). Apart from the 
characteristic nigrostriatal degeneration, histological analysis of postmortem PD brain tissue has 
revealed another important neuropathological hallmark of PD; the formation of eosinophilic 
intracytoplasmic protein inclusions, termed Lewy-bodies in honor of their first describer Friedrich 
H. Lewy (Lees et al., 2009; Wakabayashi et al., 2013). These proteinaceous deposits can be found in 
cell somata (Lewy-bodies) and neuronal axons (Lewy-neurites), and consist predominantly of 
aggregated α-synuclein (aSYN) (Spillantini et al., 1997), a physiologically presynaptic protein involved 
in neurotransmitter release at the synaptic cleft (Bartels et al., 2011; Wang and Hay, 2015). During 
the pathogenesis of PD misfolded aSYN starts to accumulate forming insoluble intracytoplasmic 
protein aggregates (Peelaerts et al., 2015). Interestingly, first signs of Lewy pathology are not observed 
within the SNc, but in regions of the caudal medulla, olfactory bulb and the peripheral nervous system 
(PNS) (Braak et al., 2003; Beach et al., 2009; Hawkes et al., 2009; Beach et al., 2010). Based on the 
characteristic distribution of Lewy-bodies and neurites in post mortem brain samples of over 160 
individuals, Braak et al. (Braak et al., 2003) developed a neuropathological staging system (Braak stage 
I – VI) which depicts the temporospatial progression pattern of Lewy pathology from early involved 
structures in the brainstem to late stage pathology in the neocortex. 
 
Figure 2  Neuropathological hallmarks of PD 
A. Midbrain sections depicting the SNc of a PD patient and a healthy control. 
B. SNc of a PD patient containing Lewy bodies (arrows) and Lewy neurites (arrowhead), stained with an 
antibody directed against aSYN. Scale bar = 50µm. Extracted from Ingelsson et al. (Leire Almandoz Gil, 
CC BY) 
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One important conclusion drawn from the Braak staging scheme is that Lewy pathology is not limited 
to the SNc or the basal ganglia, but affects multiple neurotransmitter systems in different brain 
regions over time in an ascending caudo-rostral hierarchical pattern. The Braak scheme implies that 
Lewy pathology evolves within defined brain regions and spreads over time to connected brain 
structures. However, without an available aSYN tracer or other valid biomarkers this is currently not 
testable in PD patients. Despite of the great value for PD, three aspects of the Braak scheme should 
be considered: 1) the pattern of Lewy-pathology in PD is much more variable than Braak’s staging 
predicts, i.e. only half of the PD patients possess a distribution of Lewy-pathology that clearly 
matches the Braak staging (Kalaitzakis et al., 2008; Halliday et al., 2012), 2) the mere presence of 
aSYN inclusions in a given brain region does not correlate well with loss of neurons in that brain 
region (Surmeier et al., 2017b), and 3) Lewy pathology is not limited to the central nervous system 
(CNS), but affects also the enteric nervous system (ENS), sympathetic ganglia, autonomic nervous 
system of the heart, salivary glands and cutaneous nerve fibres (Beach et al., 2010; Donadio et al., 
2014; Doppler et al., 2014).  
4.1.3. Pathogenesis  
While the knowledge on motor and non-motor symptomatology, dopaminergic replacement therapy, 
and neuropathology expanded enormously within the last decades, the etiology and pathogenesis of 
PD remain unsolved problems (Kalia and Lang, 2015). Over the last decades several risk factors have 
been identified including but not limited to aging, pesticide or herbicide exposure, melanoma, 
traumatic brain injury, methamphetamine consumption, and postmenopausal hormones (Lees et al., 
2009; Ascherio and Schwarzschild, 2016). Factors which are associated with a decreased risk for 
developing PD are smoking, caffeine intake, high plasma urate concentration, physical activity, and 
calcium channel blockers (Ascherio and Schwarzschild, 2016). Apart from these factors which in- or 
decrease the risk for sporadic PD, several genetic alterations causing inherited forms of PD have 
been discovered (Polymeropoulos et al., 1997; Warner and Schapira, 2003). Mutations in the leucine 
rich repeat kinase 2 (LRRK-2) gene or a heterozygous loss of function mutation of the 
glucocerebrosidase (GBA) gene are clearly linked to hereditary PD. Furthermore, duplications, 
triplications or missense mutations of the aSYN gene (SNCA) can cause genetic forms of PD (Farrer, 
2006; Ascherio and Schwarzschild, 2016; Schneider and Alcalay, 2017). The observation that 
mutations of the aSYN gene can cause PD in combination with experimental in vitro and in vivo 
findings of retro- and anterograde transport of defined aSYN protein species has fueled the idea that 
PD progression might rely on prion-like spreading of Lewy pathology from one affected brain region 
to another synaptically connected brain region (Brundin et al., 2016; Brundin and Melki, 2017). In 
contrast to this, a second group of authors (Surmeier et al., 2017a, 2017b; Giguere et al., 2018) 
proposes that not neuronal connectivity but rather certain shared cell-autonomous factors, like thin 
myelinated but extensively branched axons, constant autonomous pacemaking, or low intrinsic 
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calcium buffering capacity, render these neuronal populations particularly vulnerable to the disease 
process.  
4.1.4. Therapy 
The finding of dopaminergic deficiency in PD had and still has enormous implications for the 
employed therapeutic strategies. In the absence of any neuroprotective approaches, PD therapy is 
primarily focused on the reduction of motor symptomatology by restoring dopaminergic 
neurotransmission. In 1961 L-DOPA (L-Di-HydrOxy-Phenyl-Alanine), the direct precursor of DA, 
was introduced as the first rationally derived PD therapy (Birkmayer and Hornykiewicz, 1961). 
Notably, still today administration of L-DOPA, in combination with peripheral dopamine 
decarboxylase inhibitors, represents a key approach for treatment of PD motor symptomatology as 
it is recommended in all stages of the disease regardless of the presence or absence of motor 
fluctuations or dyskinesia (Oertel and Schulz, 2016). Apart from the gold standard L-DOPA, several 
DA agonists were developed and successfully implemented. Out of those, the non-ergot DA agonists 
(pramipexole, ropinirol, piribedil, apomorphine, and rotigotine) are in common use, whereas the 
ergot agonists (bromocriptine, cabergoline, lisuride, pergolide, and α-dihydroergocriptine) are hardly 
used anymore due to their adverse effect profile (e.g. cardiac and non-cardiac fibrotic reactions). DA 
agonists are used as a monotherapy in early PD patients, as an ad on approach with L-DOPA in 
fluctuating and non-fluctuating patients, and in the advanced stages of PD (Oertel and Schulz, 2016). 
However, based on the side effect profile and the tendency to require supplementary L-DOPA to 
achieve sufficient symptomatic relief, monotherapy with DA agonists is not considered superior 
compared to L-DOPA monotherapy. Other valuable approaches to enhance and restore 
dopaminergic neurotransmission include monoamine-oxidase-B inhibitors (rasagiline, safinamide, 
and selegiline) and catechol-O-methyltransferase inhibitors (entacapone, opicapone, and tolcapone), 
which delay the degradation of DA and L-DOPA thereby increasing dopaminergic 
neurotransmission (Oertel, 2017). In contrast to the well-established symptomatic treatment options 
for PD motor symptomatology, therapy options for the numerous non-motor symptoms remain a 
major challenge. Due to the little number of randomized-controlled trials which address non-motor 
symptomatology in the therapeutic context evidence based recommendations are sparse (Seppi et al., 
2011). The current individual treatment options for the broad non-motor symptomatology have 
recently been reviewed elsewhere (Seppi et al., 2011; Sauerbier et al., 2017).   
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4.2. The concept of prodromal PD 
It becomes increasingly clear that PD affects multiple transmitter systems, in different brain regions 
or even outside of the CNS, years before pathology reaches the SNc and the characteristic motor 
phenotype becomes overt. This latency, in which affected individuals present with early non-motor 
or subtle motor signs not yet qualifying as PD, is called the prodromal phase of PD (Mahlknecht et 
al., 2015). Based on the MDS criteria for prodromal PD (Berg et al., 2015) this phase is characterized 
by initial neurodegeneration of structures other than the SNc, detectable non-motor and or subtle 
motor symptomatology, and the tendency to progress slowly over many years till the prodromal 
patient converts to manifest PD (Goldman and Postuma, 2014). Frequently observed non-motor 
symptoms during the prodromal phase are hyposmia, constipation, depression, anxiety and REM-
sleep-behavior disorder (Postuma and Berg, 2016). As prodromal PD may take up to 20 years, it is 
highly relevant for disease modifying therapeutic approaches, which are aimed on decreasing or 
stopping the underlying neurodegeneration. At the moment, prodromal PD patients are considered 
to represent an ideal study population given that they have a broader therapeutic window and do not 
yet receive symptomatic treatment (Postuma and Berg, 2016). However, the neurobiological 
correlates of the prodromal symptomatology are still largely unclear. If we apply the Lewy pathology 
staging of Braak (Braak et al., 2003) on the prodromal setting, prodromal PD patients should be 
located in Braak stage 1 (olfactory bulb, dorsal motor nucleus of the vagus, intermediate reticular 
zone) and 2 (locus coeruleus, gigantocellular nucleus, caudal raphe), since stage 3 is already 
characterized by beginning Lewy pathology in the SNc.  
Figure 3  Time course of PD and clinical symptomatology [Adapted from (Kalia and Lang 2015)].   
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4.3. The noradrenergic locus coeruleus   
4.3.1. Physiological role of LC neurons 
The human noradrenergic locus coeruleus (LC), a small structure located in the formatio reticularis 
of the pontine brainstem close to the 4th ventricle, provides the major source of noradrenaline (NA) 
for vast parts of the human brain (Berridge and Waterhouse, 2003; Benarroch, 2009, 2017). Despite 
the small size, on average 35 000 neurons per hemisphere in a healthy human individual (Aston-Jones 
and Cohen, 2005; Espay et al., 2014) and 1500 neurons per hemisphere in mice (Berridge and 
Waterhouse, 2003), the LC system possesses an enormous axonal projectome (Jones and Moore, 
1977; Aston-Jones and Cohen, 2005). Tract tracing studies in mice revealed ascending LC 
noradrenergic projections into the periaqueductal grey, superior colliculus, ventral tegmental area, 
thalamus, hypothalamus, hippocampus, basal forebrain, amygdala, olfactory bulb and the complete 
neocortex. Descending projections were observed in the cerebellum, caudal medulla and spinal cord. 
The LC targets almost all brain regions from the olfactory bulb to the spinal cord. Exceptions from 
this are the striatum, globus pallidus, nucleus accumbens, and the substantia nigra which receive 
almost no noradrenergic innervation from the LC (Szabadi, 2013; Schwarz and Luo, 2015). 
Interestingly, NA cannot only be released at LC synaptic terminals but also at non-synaptic release 
sites, termed varicosities, along LC axons. Comparable to the LC output connectome, the projection 
pattern for incoming afferent input is similarly broad. The murine LC receives information from over 
100 different brain regions (Schwarz et al., 2015) spanning the complete rostro-caudal extent of the 
neuroaxis. It has been suggested that the anatomical organization of the LC noradrenergic system 
provides the basis for a working neuromodulatory system, in which incoming environmental 
information can be broadcasted to distinct target nuclei to evoke behavioral and autonomic 
adaptations (Sara, 2009; Sara and Bouret, 2012). In addition, the LC is involved in several highly 
preserved brain functions like generation of arousal and vigilance, facilitation of behavioral adaptions 
following new sensory information or environmental stress, memory consolidation, learning, 
modulation of motor control, and regulation of local blood flow in the brain (Benarroch, 2009; 
Weinshenker, 2018).  
4.3.2. LC dysfunction and degeneration in PD 
Loss of LC neurons is a prominent feature of several neurodegenerative disorders, including PD, 
progressive supranuclear palsy and corticobasal degeneration, but also dementia with Lewy bodies, 
Alzheimer’s disease, and Down syndrome (Vermeiren and Deyn, 2017). In PD, first aSYN positive 
inclusions are found in LC neurons during Braak stage 2 (Braak et al., 2003), implying that the initial 
pathological alterations occur already in the prodromal phase of PD. Moreover, occurring Lewy 
pathology was found to be associated with axonal loss of noradrenergic projections and altered 
synaptic morphology in LC output targets, going along with decreased noradrenergic 
neurotransmission (Delaville et al., 2011; Espay et al., 2014; Weinshenker, 2018). Notably, despite 
these early alterations the majority of LC neurons can survive the pathological process for many years, 
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thereby even outliving the loss of other vulnerable brain regions like the SNc (Halliday et al., 1990). 
Post mortem histological studies report 21-93% cell loss of LC neurons in late stage PD (Halliday et 
al., 1990; Paulus and Jellinger, 1991; German et al., 1992). However, sufficient postmortem data of 
prodromal or de novo PD patients is still lacking. The resulting noradrenergic deficiency in PD is 
thought to be associated with several important non-motor symptoms of PD, including cognitive 
impairment, depression, anxiety, apathy, fatigue, and REM-sleep-behavior-disorder (Benarroch, 
2009; Weinshenker, 2018). Furthermore, dysfunctional noradrenergic neurotransmission is also 
implicated in impaired motor control and freezing of gait (Espay et al., 2014). While loss of LC 
neurons has been commonly reported over the past decades, the mechanisms and etiology are still 
largely unknown. Compared to other vulnerable brain regions known to degenerate in PD, LC cells 
are thought to belong to a group of brain nuclei which possess a shared phenotype which could 
mediate the observed vulnerability (Surmeier et al., 2017b). Increasing evidence, mainly from research 
on dopaminergic SNc cells, suggests that certain cell-autonomous factors function as vulnerability 
traits increasing the basal rate of cellular stress and mediating the neurodegenerative process in PD. 
For the LC noradrenergic system these include an extensive axonal arborization with multiple 
synaptic and paracrine neurotransmitter release sites, the electrophysiological phenotype of a 
pacemaker neuron continuously generating slow tonic spiking, the burden to generate and metabolize 
a highly reactive neurotransmitter, high amounts of intracellular neuromelanin, and its location 
directly next to the 4th ventricle (Sanchez-Padilla et al., 2014; Weinshenker, 2018). However, it is still 
largely unclear if the aforementioned vulnerability factors are cause or bystander of LC degeneration 
in PD. Compared to dopaminergic SNc neurons LC cells exhibit a considerable time lag between 
initial Lewy pathology in the prodromal phase of PD and final cell loss in the advanced PD stages 
(Halliday et al., 1990), leaving the LC for many years in a dysfunctional state. Further, experimental 
research revealed that toxin-induced LC cell loss sensitizes dopaminergic SNc neurons for 
neurodegeneration whereas noradrenergic hyperinnervation resulted in neuroprotective effects (Bing 
et al., 1994; Fornai et al., 1996; Kilbourn et al., 1998; Rommelfanger and Weinshenker, 2007). Similar 
observations were made in Alzheimer’s disease animal models (Jardanhazi-Kurutz et al., 2010; 
Kummer et al., 2014; Bharani et al., 2017; Chalermpalanupap et al., 2018). This implies that LC cell 
loss in PD could play a double role by firstly being responsible for several non-motor symptoms, and 
secondly for accelerating the progression of the disease (Gesi et al., 2000). Based on the histological 
data indicating early occurring LC Lewy pathology in the course of PD, the profound noradrenergic 
cell loss in manifest PD, and the increasing evidence for a causative role of noradrenergic deficiency 
in context of non-motor symptomatology, noradrenergic replacement therapy has been discussed as 
a new therapeutic target and clinical trials in manifest PD patients have been conducted (Espay et al., 
2014). Despite promising effects showing symptomatic improvement of cognitive symptoms, mood, 
and distinct motor complications, noradrenergic replacement therapy has not become a topic of 
major interest, yet.   
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4.4. Classical and new animal models of PD 
4.4.1. Neurotoxin based animal models 
Over the last two decades several animal models have been established to mimic the core pathology 
of PD, i.e. aSYN aggregation, progressive neurodegeneration, and evolvement of behavioral motor 
or non-motor alterations (Przedborski, 2017). Since PD has been traditionally considered a disease 
of the nigrostriatal system, the first characterized animal models were designed to reproduce 
neurodegeneration of the SNc resulting in striatal DA deficiency. In regard to this the most 
extensively studied models are based on the administration of neurotoxins which cause cell loss of 
dopaminergic SNc neurons (Blesa et al., 2012). Substances frequently used to induce dopaminergic 
deficiency include 6-OHDA (6-hydroxydopamine) (Ungerstedt, 1968; Sachs and Jonsson, 1975) and 
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (Langston et al., 1983), while rotenone, 
paraquat, isoquinoline derivates, and methamphetamine are less often used (Bezard et al., 2013). The 
advantages of neurotoxin models are the reliable reproduction of severe nigrostriatal dopaminergic 
denervation in combination with the evolvement of robust parkinsonian behavioral alterations (Bove 
and Perier, 2012). Moreover, they offer a simple way to study dopaminergic replacement therapy and 
L-DOPA induced dyskinesia (Bezard et al., 2013). The major limitation of these models lies within 
the lack of mimicking the etiology of PD, as intoxication, e.g. with MPTP, might only account for 
rare cases of parkinsonism. Neurotoxin based models have been widely used to test neuroprotective 
compounds which protected SNc neurons from toxin induced cell loss. However, none of these 
substances has shown efficacy in clinical trials (Athauda and Foltynie, 2015). Another important point 
is that neurotoxin based models do not model the multisystem disease aspect of PD, i.e. 
neurodegeneration and Lewy pathology outside of the SNc.    
4.4.2. Genetic animal models 
With the growing demand to develop disease modifying therapy, experimental PD research has seen 
major changes regarding the employed animal models. It has become evident that the absence of 
understanding the mechanisms leading to the neurodegenerative process in PD presents a crucial 
limitation for the development of new therapeutic approaches (Bezard et al., 2013). Based on this 
and the general interest to understand the cause of PD, experimental PD research has shifted its 
focus to etiologic animal models (Dawson et al., 2010; Blesa et al., 2012). The discovery that genetic 
alterations can cause familial forms of PD (Polymeropoulos et al., 1997), and that aSYN constitutes 
a major component of the observed Lewy pathology (Spillantini et al., 1997), has formed the opinion 
that genetic aSYN models might better mimic the pathophysiological mechanisms of PD. Various 
transgenic mouse models have therefore been developed using different promotors (Thy1, PRION, 
PDGF, TH) to conditionally overexpress human wild-type or different mutated forms of aSYN in 
the mouse brain (Bezard et al., 2013). The main novelty of these models at that time was that the role 
of aSYN aggregation but also its physiological function played a central role. Furthermore, they 
provided new aspects on induced toxicity by the different mutated aSYN forms and offered new 
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possibilities for drug development (Visanji et al., 2016). Based on the employed promotor but also 
on the characteristics of the transgene model, severe differences in the degree of aSYN 
overexpression, local protein distribution and behavioral phenotype have been observed (Fernagut 
and Chesselet, 2004). Notably, no transgene mouse line has fulfilled all criteria of a proper PD animal 
model, i.e. aSYN aggregation, progressive neurodegeneration, and evolvement of behavioral motor 
or non-motor alterations. While most transgene mouse models have shown progressive accumulation 
of aggregated aSYN without dopaminergic cell loss, some models report DA degeneration in the 
absence of aSYN aggregation. Another major limitation of these models is that they do not replicate 
the stereotyped propagation pattern of the Braak staging scheme, as the aSYN overexpression is 
highly dependent on the used promotor.  
4.4.3. Viral vector mediated models 
The development of new lentiviral or recombinant adeno-associated viral (rAAV) vectors allowing 
overexpression of aSYN in locally defined brain regions had a major impact on experimental research 
in PD. While the aforementioned transgene mouse lines used conditional overexpression of aSYN 
which generally required several months of survival time for the aSYN pathology to develop, 
stereotactic injection of viral vectors offered the advantage to induce the α-synucleinopathy within 
several weeks. Furthermore, it was now possible to restrict the initial overexpression to PD relevant 
brain regions, e.g. the striatum, SNc, or dorsal motor nucleus of the vagus. Since the first study of 
Kirik et al. (Kirik et al., 2002) numerous studies were published investigating wild-type or mutated 
aSYN forms (A30P, A53T, A56P) (Koprich et al., 2010; Taschenberger et al., 2012; Ulusoy et al., 
2013; Helwig et al., 2016). One core observation made was that aSYN overexpression in SNc neurons 
resulted in prominent SNc neurodegeneration in combination with loss of striatal dopaminergic 
terminals and behavioral alterations like forepaw asymmetry or apomorphine-induced rotations 
(Kirik et al., 2002). Notably, synaptic abnormalities and axonal degeneration in the striatum preceded 
SNc cell loss, indicating a dying back mechanism. In some studies local neuron loss was additionally 
associated with signs of neuroinflammation, a prominent feature observed in postmortem brains of 
PD patients (Theodore et al., 2008; Thakur et al., 2017). Regarding the induced local pathology, AAV-
mediated overexpression of aSYN has thereby proven to recapitulate many features of human PD. 
A completely new observation compared to all the other animal models before was that locally 
induced aSYN aggregation could develop with time into a brain-wide α-synucleinopathy affecting 
neuronal systems distant to the injection side (Ulusoy et al., 2013). While most studies reported that 
the overexpressed aSYN is only transported towards the synaptic terminals but does not spread to 
interconnected neurons (Uchihara and Giasson, 2016), some authors hypothesized that AAV 
mediated overexpression of aSYN in the vagal nerve could induce spreading of aSYN to other 
neuronal systems (Ulusoy et al., 2013; Helwig et al., 2016; Rusconi et al., 2018). Despite the promising 
results, there are also important limitations of the viral vector mediated model systems. First, the 
strength and extent of local aSYN overexpression depends highly on the accuracy of the stereotactic 
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injection of the AAV’s, meaning a misplaced injection can cause a considerable amount of mouse to 
mouse variability. Depending on the employed serotype and promotor, aSYN overexpression cannot 
be fully limited to neurons and an unintended co-transduction of glial cells can occur. Furthermore, 
induced aSYN aggregates do not fully recapitulate all features of human Lewy-bodies or neurites 
(Volpicelli-Daley et al., 2016).  
4.4.4. Preformed aSYN fibril model 
In the first landmark study, Luk et al. (Luk et al., 2012) revealed that local injection of pre-formed 
aSYN fibrils into the striatum of C57BL6/C3H mice resulted in formation of Lewy-body like 
inclusions in the SNc but also in anatomically interconnected brain regions, suggesting cell-to-cell 
transmission of the aSYN pathology. The observed Lewy pathology was associated with 
neurodegeneration of the ipsilateral SNc, a decrease of striatal DA, and alterations of motor behavior. 
Subsequent studies revealed that the induced aSYN inclusions exhibited several features of those 
observed in PD patients, e.g. hyperphosphorylation, ubiquitination, and insolubility (Masuda-
Suzukake et al., 2013; Holmqvist et al., 2014; Recasens et al., 2014; Rey et al., 2016). The aSYN fibril 
model has therefore been suggested to most accurately reproduce the human Lewy-pathology 
compared to all in vivo models discussed so far (Volpicelli-Daley et al., 2016). Furthermore, it is 
considered a relatively mild model, as it does not induced massive cell loss in a short time frame like 
the toxin models, or drives the cells to extreme protein translation, like the aSYN overexpression 
models. The observation of cell-to-cell transmission does not only offer the possibility to investigate 
the mechanisms of disease propagation it further opens up new targets for disease modifying therapy 
(Koprich et al., 2017), e.g. antibodies which bind and thereby prevent spreading of pathological aSYN 
species. Regarding in vitro models, aSYN fibrils offer the unique possibility to induce Lewy-body 
formation in primary neuron cultures (Volpicelli-Daley et al., 2014; Mao et al., 2016). While the aSYN 
fibril model has drastically improved the field of experimental PD research, there are important 
limitations to consider. First, high quality aSYN fibrils are currently (2019) not commercially available. 
Further, monomeric aSYN species are generally used as a control, but monomeric aSYN can start to 
form oligomeric and fibrillar aSYN under the influence of room temperature and thereby induce false 
positive results. Further, the inherent tendency to form insoluble aSYN aggregates which induce 
brain-wide pathology affords increased safety precautions for the person who performs the 
stereotactic surgeries and further handling of the mice (Polinski et al., 2018). While all of the 
aforementioned animal models generally require Biosafety Level 1 laboratories, production, handling 
and injection of aSYN fibrils has to be performed on Biosafety Level 2 standards.  
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5. Summary of the publications  
5.1. A53T-α-synuclein overexpression in murine locus coeruleus induces 
Parkinson’s disease-like pathology in neurons and glia 
Henrich MT*, Geibl FF*, Lee B, Chiu W-H, Koprich JB, Brotchie JM, Timmermann L, Decher 
N, Matschke LA, Oertel WH: A53T-α-synuclein overexpression in murine locus coeruleus induces 
Parkinson’s disease-like pathology in neurons and glia. (*shared first authors). Acta Neuropathol 
Commun. 2018 May 10;6(1):39. doi: 10.1186/s40478-018-0541-1                                                       
                                                                                                Impact factor: 5.883 (2018) 
 
5.1.1. Aim of the study 
PD is a multisystem disorder characterized by dopaminergic, serotonergic, and noradrenergic 
deficiency. Decreased noradrenergic neurotransmission is thought to result majorly from loss of 
noradrenergic LC neurons and accompanied Lewy pathology within the remaining LC cells (Espay 
et al., 2014). Degeneration of the noradrenergic LC is seen as a key event in the early prodromal phase 
of PD (Rommelfanger and Weinshenker, 2007). During this phase LC dysfunction and early cell loss 
play a crucial role firstly by being responsible for several non-motor symptoms (e.g. depression, 
reduced arousal, and REM-sleep-behavior-disorder) and secondly for accelerating the progression of 
PD (Gesi et al., 2000). Despite the comprehensive data set on nigral aSYN overexpression models 
(Kirik et al., 2002; Koprich et al., 2010; Ip et al., 2017; Thakur et al., 2017), LC function and 
dysfunction in PD has not been investigated in an aSYN overexpression mouse model, yet. The main 
aim of the presented original research article entitled “A53T-α-synuclein overexpression in murine 
locus coeruleus induces Parkinson’s disease-like pathology in neurons and glia” was to establish and 
characterize the first aSYN overexpression model in the noradrenergic LC which should replicate 
cardinal morphological features of the human LC neuropathology, provide sufficient information 
about the time course of noradrenergic neurodegeneration and finally lead to robust histological 
markers which can be used to further test disease modifying therapy approaches in rodents or non-
human primates.  
5.1.2. Methods  
Two different rAAV vectors of a mixed 1/2 serotype were stereotactically injected in the right LC of 
male C57BL/6N wild-type mice to overexpress human mutant-A53T-aSYN (rAAV1/2-CMV/CBA-
human-A53T-aSYN-WPRE-BGH-pA) or luciferase (rAAV1/2-CMV/CBA-luciferase-WPRE-
BGH-pA) (Koprich et al., 2010; He et al., 2015; Ip et al., 2017). To investigate the time dependent 
effects of the evolving neuropathology, mice were sacrificed at pre-defined time-points (1, 3, 6, and 
Summary of the publications 
12 
 
9 weeks post-injection). Double immunofluorescence stainings against tyrosine hydroxylase (TH) and 
human aSYN or luciferase were employed to confirm successful protein overexpression after viral 
vector delivery. To assess potential aSYN induced LC cell loss TH positive LC neurons were 
quantified for each time point using the optical fractionator workflow (StereoInvestigator version 9, 
MicroBrightField Biosciences). Different immunofluorescence stainings were then used to 
investigate the development of aSYN phosphorylation and formation of Lewy-body like aggregates. 
To assess the induction of reactive micro- or astrogliosis a triple immunofluorescence staining for 
IbA1 (microglial marker), GFAP (astroglial marker) and TH was carried out and the intensity of 
fluorescence signal was quantified. To address the question whether a viral vector mediated focally 
induced α-synucleinopathy in the LC can trigger brain-wide propagation of aSYN, predetermined 
brain sections were stained against human aSYN or luciferase and the occurrence of aSYN or 
luciferase positive axons or cell bodies was rated. For all experiments differences were considered 
significant at p < 0.05. Statistical significance of differences between two groups was analyzed by 
Student’s t-Test. Multiple comparisons were made by one-way or two-way ANOVA analysis followed 
by Tukey’s or Sidak’s multiple comparisons test. To calculate correlations scatterplots and Pearson’s 
correlation coefficient with 95% confidence interval was used. 
5.1.3. Results  
First, we confirmed that both vectors entered LC neurons equally, validating a comparable infection 
efficacy of the applied viral vectors (Fig. 1a-d) (for A53T-aSYN group 85.17 ± 2.53% and for 
luciferase group 83.87 ± 3.31%; p = 0.77, unpaired t-test). Next, double immunofluorescence 
stainings against TH and human aSYN or TH and luciferase showed that both vectors induced 
protein expression with similar strength, as depicted by the respective transduction rates (Fig. 1e-h) 
(for A53T-aSYN group 59.89 ± 2.95% and for luciferase group 54.39 ± 3.57%; p = 0.30, unpaired 
t-test). While aSYN signal was mainly restricted to the LC region, structures directly next to the LC 
(ncl. parabrachialis, Barrington’s nucleus, mesencephalic trigeminal nucleus and vestibular nuclei) also 
exhibited some aSYN. To assess the induction of LC cell loss as a consequence of protein 
overexpression unbiased stereological quantification of TH positive cells 1, 3, 6 and 9 weeks after 
viral vector delivery (Fig. 2 a,b) were carried out. This data revealed a progressive loss of 
noradrenergic LC neurons for the A53T-aSYN injected animals starting 3 weeks after viral vector 
delivery with 15.86 ± 2.09% cell loss compared to control side (p < 0.01, two-way ANOVA analysis 
followed by Tukey’s post-hoc test), increasing up to 56.25 ± 5.19% after 9 weeks (p < 0.001, Two-
way ANOVA analysis followed by Tukey’s post-hoc test). Moreover, LC cell loss was accompanied 
by qualitative changes of neuronal morphology, including dystrophic axons and pyknotic perikarya 
(Fig. 2c). To assess posttranslational modifications of the overexpressed aSYN, like S129-
phosphorylation or ubiquitination, several immunofluorescence stainings were carried out for the 
respective time points. Overexpression of A53T-aSYN resulted in strong and progressive 
phosphorylation of aSYN being evident as early as 1 week after viral vector delivery (Fig. 3). The 
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degree of aSYN phosphorylation correlated strongly with the degree of noradrenergic 
neurodegeneration (r = 0.67, p < 0.05, Pearson’s correlation coefficient with 95% confidence 
interval). Further, proteinase K digestion experiments revealed formation of insoluble p62 and 
ubiquitin positive aggregates that were restricted to the ipsilateral LC region (Fig. 4). Notably, these 
small circular aggregates with an immuno-negative core were not located in LC neurons but IbA1 
positive microglial cells (Fig. 5). As activation of micro- and astroglia are core features not only of 
clinical PD but also experimental animal models, we investigated the involvement of micro- and 
astroglia by triple immunofluorescence stainings for IbA1 (microglial marker), GFAP (astroglial 
marker) and TH. Notably, overexpression of A53T-aSYN lead to a strong increase of micro- and 
astroglial signal intensities in a time-dependent manner within the LC region (Fig. 6a-c). First glial 
reactions were observed already 3 weeks after viral vector delivery. 3D reconstructed high 
magnification confocal images revealed a dense glial network in A53T-aSYN overexpressing animals, 
in which the remaining TH positive LC neurons were embedded 3 weeks after rAAV injection (Fig. 
6d). The degree of microgliosis was further found to correlate strongly with noradrenergic LC cell 
loss for the respective time points (Fig. 6f,g). Importantly, overexpression of luciferase was not 
associated with induction of micro- or astrogliosis at any time point when the injected side was 
compared against the non-injected side or when 1 week of luciferase overexpression was compared 
against 9 weeks of luciferase overexpression (Fig. 6a-d). After assessing the local histopathological 
alteration, we aimed to address the question if a locally induced aSYN pathology can induce a brain-
wide propagation of aSYN. Therefore, we performed aSYN immunofluorescence stainings on 
predetermined brain sections and systematically analyzed all sections for signs of transported aSYN. 
Already one week after initiation of A53T-aSYN overexpression in the right LC region, abundant 
aSYN positive axons were observed in various brain regions which are known LC output regions, 
indicating rapid anterograde transport of the human aSYN (Fig. 7). Despite the increase of axonal 
aSYN signal at later time points, no aSYN positive cell bodies were detected outside of the LC region 
at any investigated time point. In contrast, luciferase overexpressing animals exhibited no aSYN signal 
at any time point. In addition, the luciferase staining pattern was limited to the injection side 
suggesting no axonal protein transport. Since dopaminergic SNc cells were densely surrounded by 
aSYN positive axons already 1 week after viral vector delivery we systematically quantified 
dopaminergic SNc cells after the 9 week time point (Fig. 8b). Notably, our stereological quantification 
revealed no significant difference of TH-immunoreactive neurons between A53T-aSYN 
overexpressing animals compared to luciferase control mice, neither for the left nor for the right SNc 
(p > 0.05, One-way ANOVA).  
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5.1.4. Own contribution 
All experimental data from Figs. 1-6 of the summarized publication were generated, analyzed and 
interpreted by me. This included the establishment of the framework (rAAV titer, rAAV volume, 
stereotactic coordinates) for the stereotactic surgeries to achieve a focal overexpression of A53T-
aSYN or luciferase in the LC region, as well as handling and sacrificing of the experimental animals. 
For the data presented in Figs. 1-6 I established and performed the respective immunohistochemical 
(IHC) stainings, acquired all epifluorescence and confocal images, performed the complete data 
analysis, and carried out all parts of the statistical analysis. Regarding the manuscript, I compiled Figs. 
1-6 and wrote the first draft of the manuscript and the revised version after peer-review. Dr. med. 
univ. Fanni F. Geibl contributed to data collection, analysis and interpretation of the brain-wide 
aSYN pathology presented in Figs. 7-8. Further, she wrote the first draft of the respective parts for 
the submitted manuscript and the revised version after peer-review. Dr. rer. nat. Bolam Lee 
conducted several experiments, which were finally not included in this publication but necessary for 
data validation. James B. Koprich PhD, and Jonathan M. Brotchie PhD, provided the viral vectors 
and technical expertise. Dr. rer. nat. Wei-Hua Chiu, Prof. Dr. med. Lars Timmermann, Prof. Dr. rer. 
nat. Niels Decher, Dr. rer. nat. Lina A. Matschke, and Prof. Dr. med. Wolfgang H. Oertel were 
involved in the conception, planning and supervision of the study. Prof. Dr. med. Wolfgang H. Oertel 
was the lead supervisor of this project.   
 
Martin T. Henrich and Fanni F. Geibl are shared first authors on this publication. 
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5.2. The locus coeruleus – another vulnerability target in Parkinson’s disease 
 
5.2.1. Aim of the publication  
Despite the central role of noradrenergic deficiency within the prodromal and motor phase of PD 
(Benarroch, 2009; Delaville et al., 2011; Weinshenker, 2018), the majority of clinical and basic PD 
research is still focused on the causes, consequences and therapeutic implications of dopaminergic 
cell loss in the SNc. Consequences of the missing awareness of LC dysfunction and cell loss in PD 
are e.g. a lack of treatment options for the majority of symptoms based on noradrenergic deficiency 
(Espay et al., 2014) and the absence of knowledge on the whereabouts of LC degeneration during 
the course of PD (Weinshenker, 2018). The main aims of the article entitled “The locus coeruleus – 
another vulnerability target in Parkinson’s disease” were: to highlight the unique role of the LC in the 
prodromal and manifest phase of PD, to emphasize its contribution to the symptomatology and 
progression of PD, to point out the potential for the development of new therapeutic approaches, 
and to address findings and questions so far neglected in basic and clinical PD research. 
5.2.2. Viewpoint   
To address the aforementioned aims we firstly summarized the key neuroanatomical features of the 
LC noradrenergic system including its small size with only 35 000 neurons per hemisphere in the 
human (Aston-Jones and Cohen, 2005; Espay et al., 2014), the characteristic location next to the 4th 
ventricle, the extensive input output connectome (Aston-Jones and Cohen, 2005; Schwarz et al., 
2015), and the involvement in highly preserved brain functions like generation of arousal, behavioral 
adaptations to incoming sensory information, and memory consolidation (Berridge and Waterhouse, 
2003; Berridge, 2008; Sara, 2009). We then depicted the resulting consequences of noradrenergic 
deficiency in PD regarding several PD non-motor and motor symptoms, including but not limited to 
depression, anxiety, cognitive deficits, REM-sleep-behavior disorder, and freezing of gait (Espay et 
al., 2014). While keeping in mind that the causes of LC Lewy pathology and cell loss are still unclear, 
we summarized the most relevant vulnerability factors which are thought to mediate LC dysfunction 
and degeneration in PD (Weinshenker, 2018), and the so far employed animal models which 
investigated LC pathology in the experimental setting. Another major concern of this article was to 
emphasize that Lewy pathology within the LC and the clinical symptoms relating to decreased 
noradrenergic neurotransmission are not only features of the manifest motor phase of PD, but are 
also highly relevant in context to the early prodromal phase (Delaville et al., 2011; Weinshenker, 
Oertel WH, Henrich MT, Janzen A, Geibl FF: The locus coeruleus – another vulnerability target 
in Parkinson’s disease. Mov Disord. 2019 24(2):197. doi:10.1002/mds.27785 
                                                              Impact factor: 8.061 (2018) 
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2018). Therefore, we discussed three key topics related to the involvement of the LC in prodromal 
and manifest PD: 1) new opportunities for improved symptomatic treatment over noradrenergic 
replacement therapy, 2) development of disease modifying therapy approaches (Qian et al., 2011; 
Feinstein et al., 2016; Mittal et al., 2017), and 3) identification and characterization of new disease 
progression biomarkers. To provide a comprehensive overview about the clinical research related to 
the LC noradrenergic system in PD, we summarized the most important clinical trials investigating 
different approaches for noradrenergic replacement therapy and their outcome (Fornai et al., 2007; 
Rommelfanger and Weinshenker, 2007). Since the LC exhibits Lewy pathology early in the prodromal 
phase of PD while neurodegeneration is commonly observed in manifest late stage PD, this 
noradrenergic structure seems to represent a suitable candidate for research on disease progression 
biomarkers. Therefore, we discussed three possible opportunities to use the involvement of the LC 
system in prodromal PD for the development of new disease progression markers. These include 1) 
neuromelanin-sensitive MRI approaches (Schwarz et al., 2017; Sulzer et al., 2018), 2) noradrenergic 
PET imaging (Pavese et al., 2011; Nahimi et al., 2018) and, 3) attentional set shifting (Owen et al., 
1993) to monitor LC function in vivo.  
5.2.3. Own contribution  
For this publication I wrote the following sections of the first draft of the manuscript: “Introduction”, 
“The noradrenergic LC – a structure to be rediscovered for PD research”, and “Determinants of LC 
vulnerability in PD”. I further assisted in the design and editing of Figure 1 and both tables, and 
contributed to the review and editing of the final manuscript. Prof. Wolfgang H. Oertel wrote the 
final manuscript and supervised the project. Dr. med. Annette Janzen assisted in the conception of 
the project and reviewed the final manuscript. Dr. med. univ. Fanni F. Geibl wrote the following 
sections for the first draft of the manuscript: “LC pathology in prodromal and manifest PD – 
opportunities for improved symptomatic treatment and neuroprotection” and “Kinetics of LC 
neurodegeneration – Potential for novel LC progression biomarkers?” She further compiled Tables 
1 and 2 and created Figure 1.     
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5.3. Mesencephalic and extramesencephalic dopaminergic systems in 
Parkinson’s disease 
 
5.3.1. Aim of the publication 
Since Arvid Carlsson demonstrated in 1957 (Carlsson et al., 1957) that administration of reserpine 
resulted in manifest striatal DA depletion which was accompanied by parkinsonian symptomatology 
(Fig. 1), PD and its cardinal motor symptoms have been linked to DA deficiency in the nigrostriatal 
system (Rodriguez-Oroz et al., 2009). Despite the central role of DA in PD, it became evident that 
the neurodegenerative alterations do not affect all dopaminergic systems of the mammalian CNS (A8 
– A17) to the same extent (Halliday et al., 1996; McRitchie et al., 1997; Seidel et al., 2015). This applies 
to the distribution of Lewy pathology within the different dopaminergic populations as well as to the 
distribution of dopaminergic cell loss. The narrative publication “Mesencephalic and 
extramesencephalic dopaminergic systems in Parkinson’s disease” dissects the cardinal motor 
symptomatology of PD, summarizes their neuroanatomical and neuropathological correlates within 
the different mammalian dopaminergic systems, and discusses the neurobiological diversity of the 
dopaminergic neurons and their susceptibility to the disease mechanisms in PD.   
5.3.2. Review 
Despite the fact that PD is now seen as a multisystem disease affecting the CNS, PNS (Comi et al., 
2014; Del Tredici and Braak, 2016), and ENS (Wakabayashi et al., 1990; Derkinderen et al., 2011), it 
has traditionally been considered a disease of dopaminergic deficiency based on the degeneration of 
the SNc. To explain this monocentric view, we first summarized key milestones of the 200 years long 
history of PD, beginning with its first description by James Parkinson in 1817 (Parkinson, 1817), over 
the discovery of the characteristic Lewy body, and Arvid Carlsson’s DA depletion studies (Carlsson 
et al., 1957) which paved the way for the dopaminergic replacement era. We then discussed the PD 
defining cardinal motor symptomatology (bradykinesia or akinesia, resting tremor, and rigidity) which 
are commonly seen as the consequence of nigrostriatal degeneration and following DA deficiency 
(Rodriguez-Oroz et al., 2009). The article highlights that, while bradykinesia and rigidity are clearly 
linked to decreased striatal DA, there is increasing evidence that tremor is not related to DA 
deficiency (Rinne et al., 1989; Politis, 2014), suggesting that even the cardinal motor symptomatology 
cannot be fully explained by single loss of DA. A major aim of this publication was to summarize the 
neuroanatomical knowledge on the ten different dopaminergic systems of the brain (A8-A17) 
(Björklund and Dunnett, 2007) and to systematically illustrate the neuropathological alterations of 
Geibl FF*, Henrich MT*, Oertel WH: Mesencephalic and extramesencephalic dopaminergic 
systems in Parkinson’s disease. (*shared first authors). J Neural Transm (Vienna). 2019 
Apr;126(4):377-396. doi: 10.1007/s00702-019-01970-9 
                                                              Impact factor: 2.903 (2018) 
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each system in PD. Since dopaminergic systems outside of the midbrain have not been systematically 
investigated for Lewy pathology and neurodegeneration, the article aimed to clearly depict the existing 
evidence for PD pathology within each of the extramesencephalic dopaminergic systems, but also 
the mesencephalic complex. Based on the studies conducted so far we report a strong heterogeneity 
regarding Lewy pathology and occurring neurodegeneration. While the ventral tegmental area (Seidel 
et al., 2015) and the SNc (Hirsch et al., 1988; Halliday et al., 1996) exhibit moderate to severe cell 
loss, the dopaminergic retrorubral field neurons (McRitchie et al., 1997) or the dopaminergic cells in 
the olfactory bulb (Ubeda-Bañon et al., 2010) seem to be spared of PD pathology. Therefore, we 
suggested speaking of a spectrum of susceptibility, in which the dopaminergic SNc seems to be the 
most vulnerable structure followed by the dopaminergic ventral tegmental area neurons. The article 
highlights that PD is not simply a disease of dopaminergic deficiency and neither are all dopaminergic 
systems affected in PD. While most of the results presented here are based on postmortem 
histological analysis, new dopaminergic imaging approaches, like PET-, SPECT- or MRI-techniques, 
can now be applied to investigate alterations of the dopaminergic systems and metabolic changes 
caused by PD (Stoessl et al., 2011; Weingarten et al., 2015). Since dopaminergic neuroimaging gains 
increasing relevance, we discussed three key applications for dopaminergic imaging in PD: 1) clinical 
research on dopaminergic dysfunction in PD (Politis, 2014), 2) diagnosis of PD and its distinction 
from atypical parkinsonian syndromes (Scherfler et al., 2007), and 3) the identification of subclinical 
dopaminergic deficits in prodromal PD patients (Heller et al., 2017). Another opportunity which has 
proven useful for the identification of distinct symptoms associated with dysfunctional dopaminergic 
neurotransmission, are dopaminergic medication studies. Within the article we summarized the effect 
of dopaminergic medication with special emphasize on the resulting symptomatology in the “on and 
off state”.  
5.3.3. Own contribution  
For this publication I wrote the following sections of the manuscript: “Parkinsonism as the core 
feature of PD”, “The dopaminergic systems of the brain”, “Neuropathological alterations of the 
dopaminergic systems in PD”, and “Symptomatology ‘off’/‘on’ dopaminergic medication: 
conclusions of clinical studies”. I further compiled Table 1 and created Figures 2, 3, 6. Dr. med. univ. 
Fanni F. Geibl wrote the following sections of the manuscript: “Introduction”, “A long road to go”, 
“What we can learn from neuroimaging studies”, and “Concluding remarks”. She further designed 
and created Figures 1, 4, 5. Prof. Wolfgang H. Oertel supervised the project including review and 
editing of the final manuscript.  
 
Martin T. Henrich and Fanni F. Geibl are shared first authors on this publication.  
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6. Discussion 
6.1. A53T-α-synuclein overexpression in murine locus coeruleus induces 
Parkinson’s disease-like pathology in neurons and glia 
In this study, we present the first targeted LC α-synucleinopathy mouse model that replicates cardinal 
histopathological features of human PD pathology. Firstly, we confirmed that LC cells are susceptible 
to viral vector mediated overexpression of mutant A53T-aSYN, a feature which has been commonly 
shown for other vulnerable cell groups, like dopaminergic SNc neurons (Koprich et al., 2010; Ip et 
al., 2017). In contrast to most of the previously published models, we observed strong overexpression 
of aSYN already a few days after viral vector delivery, indicating a high transcription rate of the 
injected genomic particles. Since the employed viral vector system was based on a chicken β-actin 
promoter hybridized with a CMV immediate early enhancer sequence (CMV/CBA), it was not 
possible to restrict the evolving proteinopathy completely to TH positive LC neurons and adjacent 
structures like the ncl. parabrachialis or Barrington’s nucleus also exhibited some aSYN positive cells 
(van der Perren et al., 2015). However, the majority of aSYN positive cells were clearly located within 
the LC region. In addition, co-transduction of adjacent neuronal populations is a known 
phenomenon when non-neurotransmitter specific vector systems are applied. After initiation of the 
α-synucleinopathy in the murine LC, we characterized the development of aggregated aSYN, a core 
hallmark of human Lewy pathology. We therefore conducted immunofluorescence stainings to detect 
phosphorylated aSYN, a posttranslational modification characteristic for pathological aSYN forms 
(Fujiwara et al., 2002; Anderson et al., 2006), and performed proteinase K digestion experiments 
(Fernagut et al., 2007; Taschenberger et al., 2012) to visualize aggregated aSYN. While LC neurons 
exhibited extensive amounts of phosphorylated-aSYN, proteinase K-resistant and Ubi-1 and p62 
positive aSYN aggregates were only found in microglial cells. Two important conclusions can be 
drawn from these experiments. First, the observed discrepancy between strong phosphorylation of 
aSYN and the relative sparse number of proteinase K-resistant aggregates suggest that S129-
phosphorylation of aSYN does not necessarily indicate aggregation or insolubility of aSYN (Uchihara 
and Giasson, 2016). This is of high importance since aSYN phosphorylation is commonly equated 
with formation of insoluble aSYN aggregates. Second, neuronal excretion and glial uptake of 
pathological aSYN seem highly relevant for the clearance of excessive intracellular aSYN (Zhang et 
al., 2005; Bruck et al., 2016). Supporting this hypothesis we observed direct physical contacts between 
LC cells and micro- and astroglia being evident 3 weeks after rAAV injection. The presence of aSYN 
within micro- and astroglia implies that glial dysfunction or failure could be a potential contributor 
of PD progression, once the local glial protein degradation system is overburdened (Halliday and 
Stevens, 2011). We observed a loss of TH positive LC cells starting 3 weeks after injection of the 
A53T-aSYN-gene containing rAAV’s. The quantified neurodegeneration progressed continuously 
over the investigated time points and affected the entire length of the LC. In contrast, overexpression 
of our control protein luciferase did not result in LC cell loss at any investigated time point. This 
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clearly indicates that LC cells are vulnerable to artificially increased amounts of intracellular A53T-
aSYN, an observation so far not reported. Our model thereby replicates characteristic features of the 
human PD pathology. Since recent evidence suggested that pathological aSYN species can be 
transported to interconnected brain regions (Desplats et al., 2009; Freundt et al., 2012; Volpicelli-
Daley et al., 2014; Rey et al., 2016) mediating the progression of the disease, we performed a whole-
brain aSYN distribution analysis which revealed massive axonal aSYN signal in LC output target 
regions in combination with lack of aSYN in cell somata of interconnected brain regions. This finding 
suggests that the overexpressed human A53T-aSYN, once produced in the cytoplasm of LC neurons, 
is transported axonally in the anterograde direction towards the synaptic terminals but does not 
spread over the synapse to interconnected brain regions within the investigated time frame of 9 
weeks. This is in line with previous studies (Kirik et al., 2002; Maingay et al., 2006; Uchihara and 
Giasson, 2016) and stands in clear contrast to the aSYN fibril model, in which injection of pre-formed 
aSYN fibrils leads to trans-synaptic spreading of aSYN pathology to anatomically interconnected 
brain regions (Brundin et al., 2016; Rey et al., 2016; Rey et al., 2018). Notably, based on the intention 
to characterize the initial histopathological alterations of the noradrenergic LC, we have limited our 
analysis to the first 9 weeks after onset of aSYN overexpression. Increasing evidence (Rusconi et al., 
2018) suggests that longer survival times might allow trans-synaptic spreading and consequent 
neurodegeneration of interconnected neuronal systems also in rAAV based aSYN mouse models. 
Therefore, it would be of interest to reevaluate the established histological markers after 6 or 12 
months of A53T-aSYN overexpression. Another aspect which should be considered during the 
interpretation of this study is that we have used an rAAV system which leads to overexpression of 
the mutant-human-A53T-form of aSYN and not human-wildtype-aSYN, thereby probably inducing 
a more aggressive α-synucleinopathy (Li et al., 2001; Coskuner and Wise-Scira, 2013).  
Taken together, degeneration of the LC noradrenergic system occurs early in PD and a notable 
amount of the PD non-motor symptoms are associated with dysfunction or degeneration of neurons 
in the LC (Espay et al., 2014; Weinshenker, 2018). The current study is the first to describe the 
occurrence of PD-like pathology in a murine model in which human A53T-aSYN is acutely 
overexpressed in the LC region. Furthermore, our data shed the first light on the vulnerability of 
noradrenergic LC neurons in an aSYN overexpression rodent model, provide neuronal and glial 
markers which allow testing of potentially neuroprotective substances, and represent the first in vivo 
evidence of p62- and Ubi1-positive inclusions in microglial cells.  
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6.2. The locus coeruleus – another vulnerability target in Parkinson’s disease 
Compared to the dopaminergic SNc the noradrenergic LC represents a neglected research target in 
PD. A pubmed literature search conducted in 2019 revealed 11,221 search results for “Parkinson’s 
disease AND substantia nigra”, but only 500 results for “Parkinson’s disease AND locus coeruleus”. 
Despite the increasing interest in prodromal PD and the clear evidence for noradrenergic deficiency 
in the early phase of PD, research on the LC in context of PD remains sparse with only around 20 
publications per year (Fig. 4).  
Data from human post mortem samples indicate early and profound Lewy pathology within the LC 
noradrenergic system which is accompanied by early loss of noradrenergic axons in output projection 
targets (Braak stage 2) (Braak et al., 2003; Braak et al., 2004). In addition, most studies investigating 
loss of LC neurons reported LC cell death from 21 to 93% (Hirsch et al., 1988; Chan-Palay and Asan, 
1989; Paulus and Jellinger, 1991). Notably, decreased LC cell numbers were predominantly observed 
in advanced PD stages, indicating that the LC may possess specific cellular characteristics which 
facilitate partial resilience to the disease process and thereby provide the capacity to survive the 
pathological processes for many years. Importantly, this stands in clear contrast to the dopaminergic 
SNc, where nigral Lewy pathology is promptly followed by loss of SNc neurons (Braak et al., 2003). 
Based on this assumption, noradrenergic symptomatology evolving during the prodromal phase is 
likely mediated by cellular dysfunction of the affected LC system and not based on mere cell loss. 
Noradrenergic deficiency contributes to several non-motor and motor symptoms e.g. cognitive 
impairment, depression, anxiety, apathy, fatigue, REM-sleep-behavior-disorder, impaired motor 
control, and freezing of gait (Espay et al., 2014). While Lewy pathology seems to be one factor for 
LC vulnerability in PD, most neuronal groups at risk share a common anatomical and 
electrophysiological phenotype including several intrinsic cellular factors that are thought to mediate 
the vulnerability to the disease process. LC neurons have been identified to possess several of those 
vulnerability features which are thought to render them susceptible to PD: 1) extensively branched 
and thinly myelinated axons composing a huge output projectome, 2) intrinsic pacemaking activity 
(3-4 Hz), generating continuously action potentials, 3) low Ca2+ buffering capacity, 4) high amount 
of intracellular heavy metals and neuromelanin, and 5) the burden to generate the highly reactive 
neurotransmitter (Surmeier et al., 2017b; Weinshenker, 2018). Potential vulnerability factors which 
are not shared with dopaminergic SNc neurons include: 1) extensive varicosities for paracrine 
signaling, 2) dense innervation of blood vessels, and 3) close proximity to the 4th ventricle (Fig. 1) 
(Weinshenker, 2018).  Animal models conducted so far reveal that LC cells are additionally 
susceptible to administration of neurotoxins which are commonly used to ablate the nigrostriatal 
system and overexpression of aSYN (Table 1). Apart from the contribution to the pathophysiology 
and symptomatology of PD, research on the LC offers further opportunities. While dopaminergic 
replacement therapy is the gold standard treatment for PD, there is mounting evidence that 
noradrenergic replacement or enhancement of noradrenergic neurotransmission leads to 
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improvement of several non-motor and motor complications of PD, e.g. improvement of global 
cognition and executive functions or gait and motor symptoms (Table 2). Importantly, these studies 
were conducted in de novo or manifest PD patients where noradrenergic neurodegeneration is 
generally advanced. Since several clinical manifestations of decreased noradrenergic 
neurotransmission, such as depression, anxiety, or cognitive impairment are already present in the 
prodromal phase of PD, based on early loss of noradrenergic axons in output projection targets, we 
suggest that trials employing noradrenergic replacement therapy should also be conducted in 
prodromal PD patient cohorts. The presence of LC pathology during the prodromal and manifest 
phase of PD offers another intriguing possibility. Based on the kinetic of LC dysfunction and cell 
loss we argue that the LC represents a suitable structure for characterization of new disease 
progression biomarkers which allow monitoring the ongoing neurodegenerative alterations from the 
prodromal phase to manifest motor and late stage PD. First promising attempts made in de novo or 
manifest PD patients include structural neuromelanin-sensitive MRI of the LC region, PET imaging 
to measure noradrenergic LC function, or attentional set shifting assessed with the Wisconsin Card 
Sorting Test or the Intra-/Extra-Dimensional Attentional Set-Shifting Task. 
Taken together, this narrative publication summarizes key histopathological features of LC cell loss 
in PD patients, discusses specific vulnerability factors likely implicated in noradrenergic 
neurodegeneration, recapitulates the experimental and clinical studies conducted so far, and suggests 
new opportunities for improved symptomatic treatment and development of biomarkers to monitor 
the progression of PD. 
Figure 4  Overview of the publication history for LC and SN in PD  
A. Number of search results for “Parkinson’s disease AND locus coeruleus” and “Parkinson’s disease AND 
substantia nigra” cumulated for the years 1980-2018.  
B. Number of search results for “Parkinson’s disease AND locus coeruleus” and “Parkinson’s disease AND 
substantia nigra” per year for the years 1980-2018.  
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6.3. Mesencephalic and extramesencephalic dopaminergic systems in 
Parkinson’s disease 
Loss of dopaminergic SNc neurons and consequent striatal dopamine deficiency are core features of 
PD and clearly linked to the cardinal parkinsonian motor abnormalities. Furthermore, the presence 
of nigrostriatal neurodegeneration and its consequences are central for PD diagnosis (Table 1) and 
onset of DA replacement therapy (Postuma et al., 2015). PD pathology is not observed in all neuronal 
populations of a patients’ CNS, neither is the pathology randomly distributed. Lewy pathology and 
associated neurodegeneration appears to be limited to distinct dopaminergic, noradrenergic, 
serotonergic and cholinergic neuronal systems. Even within these affected neurotransmitter systems 
only distinct cell groups exhibit Lewy pathology or cell loss. This spectrum of susceptibility to the 
disease process has been firstly shown for the dopaminergic systems. Within the mammalian CNS 
dopaminergic neurons are clustered into ten dopaminergic systems (A8-A17) which are distributed 
over the ventral mesencephalon, diencephalon, olfactory bulb and retina (Fig. 2). In regard to PD, 
the most extensively studied dopaminergic systems include the retrorubral field (A8), the SNc (A9), 
and the ventral tegmental area (A10). All three of them form a continuum of morphologically 
indistinguishable dopaminergic neurons referred to as the ventral mesencephalic dopaminergic 
complex (A8-A10) (Fig. 3). While the SNc (A9) exhibits cell loss between 41% and 79% across 
studies, on average 67% with disproportionately high neurodegeneration in the ventrolateral and 
caudal subregion (70-90% cell loss) (Bogerts et al., 1983; Javoy-Agid et al., 1984; Hirsch et al., 1988; 
Waters et al., 1988; German et al., 1989; Kempster et al., 1989; Gibb and Lees, 1991; Halliday et al., 
1996; Damier et al., 1999; Zarow et al., 2003; Alberico et al., 2015), dopaminergic neurons in the 
retrorubral field (A8) show no or only minor neurodegeneration (McRitchie et al., 1997). In contrast, 
dopaminergic neurons in the ventral tegmental area (A10) exhibit a moderate degree of Lewy 
pathology  and neurodegeneration (Seidel et al., 2015), on average 53% which is consistently below 
the observed neurodegeneration in the SNc (Javoy-Agid and Agid, 1980; Bogerts et al., 1983; Javoy-
Agid et al., 1984; Uhl et al., 1985; Hirsch et al., 1988; Waters et al., 1988; German et al., 1989; 
McRitchie et al., 1997; Damier et al., 1999; Alberico et al., 2015). The post mortem histopathological 
reports uniformly suggest a spectrum of susceptibility, in which the dopaminergic cells of the ventral 
SNc (A9) are the most vulnerable, followed by the ventral tegmental area neurons (A10), the dorsal 
tier of the SNc (A9), and the dopaminergic retrorubral field neurons (A8). On a pathophysiological 
level the observed heterogeneity could be based on the neurobiological diversity of the cellular 
subgroups, taking into account that there is not one general type of dopaminergic neuron but rather 
a spectrum of different dopaminergic phenotypes. Classically a dopaminergic neuron is characterized 
by several cellular features (Fig. 4): (a) DA as the main neurotransmitter, (b) a DA synthetizing 
machinery (tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC)), (c) DA 
degrading enzymes, (d) DA transporters (i.e. vesicular monoamine transporter 2 (VMAT2), DA 
transporter (DAT)), and (e) autoreceptors (i.e. D2-receptor) (Vernier et al., 2004). Notably, not all 
dopaminergic populations possess all of the aforementioned features thereby only partially fulfilling 
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all criteria for a classical dopaminergic neuron, e.g. A11 neurons lack AADC or DAT expression, 
suggesting that L-DOPA is not converted to DA, making these neurons L-DOPAergic rather than 
dopaminergic (Barraud et al., 2010). Apart from the observed neurotransmitter related alterations 
there are several other proteomic and metabolic differences between the different dopaminergic 
systems. The highly vulnerable ventral tier of the SNc (A9) exhibits a significantly higher intracellular 
Ca2+-burden compared to the dorsal SNc (A9) or the ventral tegmental area (A10). It has been 
hypothesized that this could mainly result from lower expression of parvalbumin and calretinin, two 
calcium binding proteins (Yamada et al., 1990; McRitchie et al., 1996; Parent et al., 1996; Chung et 
al., 2005). In addition, SNc (A9) neurons show an almost 3-fold increased basal oxidative 
phosphorylation rate leading to a significantly lower respiratory reserve compared to ventral 
tegmental area neurons (A10) (Pacelli et al., 2015). The studies conducted so far suggest that there is 
neither one general type of dopaminergic neuron but rather a spectrum of different dopaminergic 
phenotypes, nor is the PD pathology distributed homogenously over the different dopaminergic 
systems. This also brings important implications for DA replacement therapy. Based on the 
inhomogeneous loss of dopaminergic neurons within the different dopaminergic systems, doses of 
L-DOPA which are needed to replace the dopaminergic deficit in the severely affected SNc (A9) 
simultaneously ‘overdose’ the better preserved dopaminergic networks, resulting in symptoms of 
hyperdopaminergism such as dyskinesia, impaired learning, impulse control disorders, or mania (Fig. 
6) (Gotham et al., 1988; Swainson et al., 2000; Vaillancourt et al., 2013; Vriend et al., 2014; Joutsa et 
al., 2015; Voon et al., 2017). Especially in the advanced disease stages, PD symptomatology fluctuates 
between hypodopaminergic states as a consequence of disease progression and hyperdopaminergic 
states as a side effect of DA replacement therapy. 
Taken together, neurodegeneration of the nigrostriatal dopaminergic system and concurrent DA 
deficiency in the basal ganglia represent core hallmarks of PD with implications for PD diagnosis, 
DA replacement strategies, and therapeutic complications. The conducted studies so far, suggest a 
spectrum of susceptibility, in which the dopaminergic neurons of the ventral SNc (A9) are the most 
vulnerable, followed by ventral tegmental area neurons (A10), the dorsal SNc (A9), and the 
retrorubral field cells (A8). The degree of susceptibility is associated with a rich neurobiological 
diversity of the different dopaminergic systems, suggesting that there is not one general type of 
dopaminergic neuron but rather a spectrum of different dopaminergic phenotypes. However, despite 
the notable amount of data on the midbrain dopaminergic systems (A8-A10), the diencephalic, 
olfactory bulbar and retinal dopaminergic systems have not been thoroughly investigated in regard 
to Lewy pathology or neurodegeneration, yet.    
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Abstract  
Degeneration of noradrenergic locus coeruleus neurons occurs during the prodromal phase of 
Parkinson’s disease and contributes to a variety of non-motor symptoms, e.g. depression, anxiety and 
REM sleep behavior disorder. This study was designed to establish the first locus coeruleus α-
synucleinopathy mouse model, which should provide sufficient information about the time-course 
of noradrenergic neurodegeneration, replicate cardinal histopathological features of the human 
Parkinson’s disease neuropathology and finally lead to robust histological markers, which are 
sufficient to assess the pathological changes in a quantitative and qualitative way. We show that 
targeted viral vector-mediated overexpression of human mutant A53T-α-synuclein in vivo in locus 
coeruleus neurons of wild-type mice resulted in progressive noradrenergic neurodegeneration over a 
time frame of 9 weeks. Observed neuronal cell loss was accompanied by progressive α-synuclein 
phosphorylation, formation of proteinase K-resistant α-synuclein-aggregates, accumulation of Ubi-
1- and p62-positive inclusions in microglia and induction of progressive micro- and astrogliosis. Apart 
from this local pathology, abundant α-synuclein-positive axons were found in locus coeruleus output 
regions, indicating rapid anterograde axonal transport of A53T-α-synuclein. Taken together, we 
present the first model of α-synucleinopathy in the murine locus coeruleus, replicating essential 
morphological features of human Parkinson’s disease pathology. This new model may contribute to 
the research on prodromal Parkinson’s disease, in respect to pathophysiology and the development 
of disease-modifying therapy.  
 
 
Keywords 
Parkinson’s disease; locus coeruleus; alpha-synuclein; adeno-associated viral vectors; prodromal 
mouse model; microglia, noradrenergic neurons 
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Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder [1] characterized 
by progressive degeneration of dopaminergic (DA) substantia nigra (SN) neurons and their striatal 
axon terminals [2, 3]. One characteristic neuropathological hallmark of PD are intracytoplasmic 
eosinophilic inclusions, the so-called Lewy bodies, which develop in specific brain regions in a spatio-
temporal pattern and consist predominantly of misfolded α-synuclein (aSYN) [4, 5]. The finding that 
duplications, triplications or missense mutations (e.g. A53T, A30P or G46L) of the aSYN gene 
(SNCA) cause familial forms of PD [6, 7] has justified the assumption that aSYN plays a crucial role 
in the pathogenesis of PD.  
Only within the last 20 years it is accepted that PD cannot solely be understood as a disease associated 
with the degeneration of DA SN neurons, as the PD pathology involves the central, peripheral, 
autonomic and enteric nervous system [5, 8–11]. The degeneration of DA SN neurons and the onset 
of motor dysfunction are preceded by a latency of several years, if not decades, in which the PD 
pathology develops in brain regions outside the DA SN. This phase, termed prodromal PD, is 
clinically characterized by the occurrence of certain non-motor symptoms, e.g. hyposmia, 
constipation, depression and idiopathic REM sleep behavior disorder [12–14]. Since the prodromal 
phase is seen as the ideal time window for applying disease-modifying therapy [15, 16], it is of high 
importance to establish animal models, which allow testing of new and future therapeutic approaches 
on brain structures that are affected during prodromal PD. The noradrenergic locus coeruleus (LC), 
a monoaminergic nucleus located in the pontine brainstem [17, 18], plays a crucial role during the 
prodromal phase of PD and represents therefore an ideal brain structure for such in-depth 
characterization in an experimental animal model [19]. Dysfunction and degeneration of neurons in 
the LC region are associated with several of the above listed non-motor symptoms, including 
depression, signs of reduced arousal, anxiety and REM sleep behavior disorder (RBD) [20–22]. 
Neuropathological analysis of human PD brain samples revealed up to 80% LC neuronal cell loss in 
PD patients, thereby exceeding the degree of SN neurodegeneration in the same individuals [23, 24]. 
Moreover, experimental evidence indicates that toxin-induced LC cell loss sensitized DA SN neurons 
for neurodegeneration [25, 26], whereas noradrenergic hyperinnervation resulted in neuroprotective 
effects [27]. This data implies that LC neurodegeneration itself plays a double role by firstly being 
responsible for several non-motor symptoms and secondly for accelerating the progression of PD at 
the nigral level [21]. LC cells exhibit a common at-risk phenotype compared to other neuronal 
populations such as the DA nigral neurons and the cholinergic neurons of the dorsal motor nucleus 
of the vagal nerve which undergo neurodegeneration in PD [28, 29]. LC neurons integrate 
information from a broad range of different brain regions and broadcast information with extensively 
branched and thinly myelinated axons throughout the complete neuroaxis [18, 30]. Furthermore, they 
exhibit an intrinsic pacemaking activity, generating action potentials continuously [31] thereby raising 
their basal metabolic stress level [28].  
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In this study, we have characterized the first model of α-synucleinopathy in the murine LC. We show 
that targeted viral vector-mediated overexpression of human mutant A53T-aSYN in vivo in LC 
neurons of wild-type mice resulted in progressive LC neurodegeneration over a time frame of 9 
weeks. Observed LC cell loss was accompanied by prominent and over time increasing micro- and 
astrogliosis. In addition, our data revealed accumulation of phosphorylated aSYN, progressive 
aggregation of aSYN as demonstrated by proteinase K-resistant aSYN aggregates and Ubi-1- and 
p62-positive inclusions comparable with findings from human PD samples. Co-staining with 
different cellular markers revealed that the p62- and Ubi-1-positive aggregates were found exclusively 
in microglial cells, while being absent in neurons, astrocytes and oligodendrocytes. Beside this local 
LC pathology, we observed abundant aSYN-positive axons in a high number of LC output regions, 
indicating rapid anterograde axonal transport of the human aSYN. In conclusion, our new murine 
LC model replicated cardinal morphological features of human PD pathology.  
 
Methods 
Animals 
A total of 70 wild-type male C57BL/6N mice (Charles River, Sulzfeld, Germany), 8 weeks old at the 
beginning of the experiment, were used. Mice were housed in individually ventilated cages with ad 
libitum access to food and water under a 12 h/12h light-dark cycle. All procedures performed in 
studies involving animals were in accordance with the ethical standards of the institution at which 
the studies were conducted (Regierungspräsidium Giessen, Germany V54-19 c 20 15 h 01 MR 20/15 
Nr. 66/2015). 
 
Recombinant adeno-associated viral (rAAV) vectors and stereotactic injection 
Two different recombinant adeno-associated viral (rAAV) vectors of a mixed 1/2 serotype were used 
to overexpress human mutant-A53T-aSYN (rAAV1/2-CMV/CBA-human-A53T-aSYN-WPRE-
BGH-pA (rAAV1/2-A53T-aSYN); viral titer 5.1 x 1012 gp/ml, purchased from GeneDetect) or 
luciferase (rAAV1/2-CMV/CBA-luciferase-WPRE-BGH-pA (rAAV1/2-Luc), viral titer 5.0 x 1012 
gp/ml, purchased from GeneDetect). Each of the two vectors was driven by a chicken beta actin 
(CBA) promoter combined with a cytomegalovirus (CMV) immediate early enhancer sequence and a 
woodchuck post-transcriptional regulatory element (WPRE) to assess a high transcription rate [32, 
33]. For stereotactic delivery of the rAAV vectors, mice were anesthetized with 100 mg/kg ketamine 
and 5 mg/kg xylazine via intraperitoneal injection. A volume of 1.25 µl of rAAV1/2-A53T-aSYN or 
rAAV1/2-Luc was stereotactically injected in the right LC region using a microinjector (UltraMicro 
Pump UMP3, World Precision Instruments) with a velocity of 125 nl/min based on the following 
coordinates: ML -0.9 mm, AP -5.4 mm and DV -3.65 mm relative to Bregma [34].  
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Tissue preparation  
Mice were sacrificed through transcardial perfusion with 0.1 M phosphate-buffered saline (PBS) for 
5 minutes followed by 4% ice-cold paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) (pH 7.4) 
for 5 minutes using a supply pump at a rate of 10 ml/min. Brains were carefully removed and post-
fixed in 4% PFA for 3 days and then transferred to 30% sucrose solution for 3 days for 
cryoprotection. Brains were cut into 20 μm thick coronal sections using a cryostat microtome (Leica 
CM3050 S, Nussloch, Germany). Sections were then stored at 4 °C in cryoprotect-solution (1:1:3 
volume ratio of ethylenglycol, glycerol and 0.1 M PB) until further processing. 
 
Immunohistochemistry with 3,3-diaminobenzidine (DAB) 
Free-floating sections containing the LC/SN region were washed in 0.1 M PB and quenched with 
3% H2O2 and 10% methanol for 15 minutes. After a second wash, sections were blocked in 5% 
normal donkey serum with 0.3% Triton X-100 in 0.1 M PB for 1 hour before incubating them 
overnight with primary antibodies against TH, p-aSYN, Ubi-1 or p62 (Table 1) at 4 °C in the same 
blocking solution. On the second day, sections were washed in 0.1 M PB for 20 minutes and then 
incubated with the appropriate biotinylated secondary antibody (Table 1) for 1 hour, followed by 
incubation in avidin-biotin-peroxidase solution (ABC Elite, Vector Laboratories) for 1 hour before 
initiating the color reaction with 5% DAB (Serva), diluted in 0.1 M PB with 0.02% H2O2. All DAB-
stained sections were mounted, dried, counterstained with cresyl-violet and coverslipped with 
mounting gel (Corbit-Balsam, Eukitt). Brightfield images were acquired using an AxioImager M2 
microscope (Zeiss) equipped with an Axiocam 506 color camera (Zeiss). 
 
Immunofluorescence staining 
Sections were washed in 0.1 M PB, then blocked in 10% normal donkey serum with 0.3% Triton X-
100 in 0.1 M PB for 1 hour before incubating them with primary antibodies (Table 1) at 4 °C in the 
same blocking solution overnight. On the second day, sections were washed in 0.1 M PB containing 
0.3% Triton X-100 and then incubated with fluorophore-conjugated, species-specific secondary 
antibodies (Table 1) for 2 hours at room temperature in 0.1 M PB containing 0.3% Triton X-100 and 
10% normal donkey serum. Before mounting sections were washed for 25 minutes in 0.1 M PB 
containing 0.3% Triton X-100. Exceptions from this general protocol were made for staining 
luciferase, p-aSYN, IbA1 and Olig2, where after primary antibody incubation a biotinylated species-
specific secondary antibody was used to further improve signal to noise by conjugation with 
streptavidin. Images were acquired using an AxioImager M2 microscope (Zeiss) equipped with an 
ORCA-Flash4.0 LT CMOS camera (Hamamatsu C11440-42U). For confocal images, a TCS SP8 
microscope (Leica) was used. Images were processed with FIJI image software [35] to enhance signal-
to-noise. Image data for 3D reconstructions were obtained with a Zeiss Spinning Disc Microscope 
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(Axio Observer Z1) equipped with an Axiocam MRm (Zeiss) and an Evolve 512 EMCCD Camera 
(Photometrics) and post-processed with ZEN 2012 software (Zeiss). 
Antigen Host Cat. No. Manufacturer Dilution 
     
Tyrosine Hydroxylase Rabbit AB152 Merck Millipore 1:1000 
Tyrosine Hydroxylase Sheep AB1542 Merck Millipore 1:1000 
AAV VP1/VP2/VP3 Rabbit 61084 Progen 1:250 
Alpha-synuclein (p-S129) Rabbit ab51253 Abcam 1:2000 
Alpha-synuclein (syn211) Mouse AHB0261 ThermoFisher 1:1000 
Luciferase Goat NB100-1677 Novus Biologicals 1:250 
GFAP Chicken ab4674 Abcam 1:2000 
IbA1 Rabbit 019-19741 Wako 1:500 
Ubiquitin (Ubi-1) Mouse ab7254 Abcam 1:2000 
SQSTM1/p62 Mouse ab56416 Abcam 1:2000 
Olig2 Rabbit ab109186 Abcam 1:500 
MAP2 Chicken ab5392 Abcam 1:2000 
     
Anti-rabbit AlexaFluor488 Donkey A-21206 Invitrogen 1:1000 
Anti-goat AlexaFluor488 Donkey A-11055 Invitrogen 1:1000 
Anti-mouse AlexaFluor488 Donkey A-2102 Invitrogen 1:1000 
Anti-chicken Cy3 Donkey 703-165-155 Jackson ImmunoResearch 1:1000 
Anti-mouse Cy3 Donkey 715-165-150 Jackson ImmunoResearch 1:1000 
Anti-goat Cy3 Donkey 705-165-147 Jackson ImmunoResearch 1:1000 
Biotinylated anti-rabbit Donkey 711-065-152 Jackson ImmunoResearch 1:1000 
Biotinylated anti-mouse Donkey 715-065-151 Jackson ImmunoResearch 1:1000 
Biotinylated anti-goat Donkey 705-065-147 Jackson ImmunoResearch 1:1000 
Streptavidin AlexaFluor647 Donkey 016-600-084 Jackson ImmunoResearch 1:1000 
Table 1 | Characteristics of the primary and secondary antibodies 
  
Proteinase K treatment  
To analyze the formation of insoluble aggregates, sections were digested with Proteinase K (PK) 
using a modified protocol described elsewhere [36, 37]. 20 µm thick sections with 120 µm interslice 
distance containing the complete LC region were washed in 0.1 M PB and subsequently digested in 
0.1 M PB containing 0.3% Triton X-100 and 12 µg/ml PK (Cat. No. 4333793, Invitrogen) at 65°C 
for 10 min. To visualize insoluble aggregates, digested sections were double stained against human 
aSYN, p62, Ubi-1 or luciferase in combination with TH (Table 1), following the fluorescence staining 
protocol described above. Complete absence of TH immunoreactivity served as an indicator for 
successful PK digestion, thus sections in which TH immunoreactivity was still visible were excluded 
from analysis implicating an incomplete protein digestion. Images were acquired using an AxioImager 
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M2 microscope (Zeiss) equipped with an ORCA-Flash4.0 LT CMOS camera (Hamamatsu C11440-
42U).  
 
Stereology  
To quantify TH-positive LC and SN neurons, the optical fractionator workflow (StereoInvestigator 
version 9, MicroBrightField Biosciences) was used. Therefore, tissue sections were stained against 
TH with DAB and counterstained with cresyl-violet as described above. To quantify LC cell numbers, 
five sections per animal containing the complete rostro-caudal extent of the LC region, separated by 
120µm, were selected. Contours including all TH-positive neurons of the LC were drawn, excluding 
neurons of the SubLC region. For quantification of TH-positive SN neurons, seven sections 
separated by 240 µm covering the complete caudo-rostral extent of the SN were used. Contours were 
drawn based on the cytoarchitectonic distribution of SN neurons [38] including SN pars compacta 
but excluding SN pars reticulata or ventral tegmental area neurons. Parameters used for counting 
were: grid size 100 × 100 μm, counting frame 85 × 85 μm, and 2 μm guard zones.  
 
Quantification of reactive micro- and astrogliosis 
Triple immunofluorescence stainings were performed to visualize astro- and microgliosis using 
antibodies directed against GFAP for astroglia, IbA1 for microglia and TH to label LC neurons 
(Table 1). To quantify signs of reactive gliosis, we evaluated 5 LC sections of 6 animals per time point 
by measuring the optical density (OD) of the injected versus the non-injected side using FIJI. First, 
greyscale images were converted to 8 bit and the LC region was outlined with a rectangular contour 
(1200px x 800px). Then, OD was measured and lastly a background correction was performed by 
subtracting the mean background signal for every section. The background corrected OD values of 
all 5 sections of the injected side were summed and compared to the summed value of the non-
injected side.   
 
Quantification of S129-phosphorylated aSYN  
To analyze the degree of p-aSYN, a triple immunofluorescence staining against p-aSYN, human 
aSYN and TH was performed (Table 1). Five sections of 4 animals per time point, containing the 
complete rostro-caudal extent of the LC region, were selected for analysis. First, images were 
converted to 8 bit before making them binary. By using a preset intensity threshold, pixels were given 
either an intensity value of 255 (when positive for p-aSYN) or 0 (when negative for p-aSYN). The 
resulting p-aSYN signal intensity value was then divided by the area positive for non-phosphorylated 
aSYN. This ratio was calculated for all five sections and averaged per animal.  
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Quantification of aSYN transport 
Seven coronal sections (Bregma: +4.28, +2.86, +1.18, +0.38, -0.58, -3.16 and -7.56) covering the 
complete mouse brain were stained against human aSYN (Syn 211) or Luc (Table 1) and the degree 
of aSYN accumulation was assessed by scoring human aSYN positive axons/cell bodies as follows: 
‒ no positive axons; + sparse (few positive axons); ++ mild (more positive axons); +++ moderate 
(many positive axons, covering almost the complete brain region) and ++++ severe pathology (large 
number of positive axons densely covering the complete brain region). (+) describes an intermediate 
state. Six animals per time point were analyzed and the scores for each brain region were averaged. 
 
Statistical analyses 
In general, all data values are expressed as mean ± SEM or mean ± min/max. Differences were 
considered significant at p < 0.05. Multiple comparisons were made by one-way or two-way ANOVA 
analysis followed by Tukey’s or Sidak’s multiple comparisons test. To calculate correlations, Pearson’s 
correlation coefficient with 95% confidence interval was used. All statistical analyses were performed 
using GraphPad Prism version 7.00 (GraphPad Software, La Jolla California USA). Figures were 
created with Adobe Illustrator version 21.1 (Adobe Systems). 
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Results 
rAAV vector-mediated overexpression of human A53T-aSYN in LC neurons  
To determine whether and in which time frame aSYN overexpression induces PD-like pathology in 
LC neurons we chose to overexpress human mutant A53T-aSYN by injecting rAAV1/2-A53T-aSYN 
[32, 33] unilaterally in the right LC region of wild-type mice (Fig. 1a, b). To verify that the resulting 
cellular effects were attributable to the aSYN protein itself, luciferase (Luc) was used as a control 
protein. To investigate time-dependent effects, animals were consecutively sacrificed after 3 days, 1, 
3, 6 and 9 weeks (Fig. 1b).  By analyzing the first set of animals 3 days after viral injection, we 
confirmed that both vectors entered LC neurons equally (Fig. 1c, d), resulting in infection rates of 
85.17 ± 2.53% for A53T-aSYN and 83.87 ± 3.31% for Luc (unpaired t-test, p = 0.77) (Fig. 1d). 
Double immunofluorescence stainings against TH and human aSYN or TH and Luc (Fig. 1e, f) 
revealed that both vectors induced protein expression already at this early time point with similar 
strength (A53T-aSYN 59.89 ± 2.95% and Luc 54.39 ± 3.57%, unpaired t-test, p = 0.30). Protein 
expression was mainly restricted to the LC covering the whole nucleus (Fig. 1g, h). In addition, a 
variable number of immuno-reactive cells were observed in the adjacent regions (ncl. parabrachialis, 
Barrington’s nucleus, mesencephalic trigeminal nucleus and vestibular nuclei) (Fig. 1g). In LC 
neurons, cell bodies, as well as axons and dendrites were robustly labeled, indicating strong protein 
expression. Similar findings were observed for rAAV1/2-Luc injected animals. Notably, there was 
no aSYN or Luc signal in LC cells on the non-injected side at any time point (Fig. 1g). This allowed 
us to use the non-injected (left) side as an internal control.   
 
A53T-aSYN overexpression causes LC neurodegeneration 
In the first set of experiments, the extent of aSYN induced LC cell loss was assessed with unbiased 
stereological quantification of TH-positive LC cells 1, 3, 6 and 9 weeks after viral vector delivery. In 
the A53T-aSYN group, significant degeneration of TH-positive LC cells was measured already 3 
weeks post-injection, with 15.86 ± 2.09% cell loss compared to control side. Neurodegeneration 
increased progressively reaching 34.84 ± 3.39% after 6 weeks and 56.25 ± 5.19% after 9 weeks (Fig. 
2a, b). Cell loss was homogenously distributed over the complete rostro-caudal extent of the LC. No 
cellular pathology was observed in the Luc control group at any investigated time point, confirming 
that neither the viral vector nor overexpression of a cytoplasmic protein was able to induce 
neurodegeneration in our model (Fig. 2a, b).  
Moreover, immunofluorescent TH-stainings and subsequent confocal imaging revealed that A53T-
aSYN, but not Luc overexpression was accompanied by qualitative changes of neuronal morphology, 
including dystrophic axons and pyknotic perikarya (Fig. 2c).   
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Figure 1 | Locally induced protein overexpression via injection of rAAV vectors in the LC region. 
a rAAV1/2 vectors contain a chicken β-actin promoter hybridized with a CMV immediate early enhancer 
sequence (CMV/CBA) to drive expression of either A53T-aSYN or luciferase (control). ITR, inverted terminal 
repeat; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element; BGH-pA, bovine growth 
hormone polyadenylation sequence. b Experimental design and schematic illustration of the injection site. 
Animals were consecutively sacrificed after 3 days, 1, 3, 6 and 9 weeks for immunohistochemical evaluation. c-
f Analysis of the infection or transduction rates via double immunofluorescence staining for TH (red) and viral 
coating proteins (VP, green) (c, d) or TH (red) and human A53T-aSYN (green) or luciferase (green) (e, f), 
respectively. Co-localization of TH and VP indicates successful entry of viral particles, whereas co-localization 
of TH and A53T-aSYN/luciferase indicates successful protein expression. Student’s t-test revealed no 
significant difference between the transduction rates of the two vectors (p > 0.05, n = 3 animals per protein) 
(d, f). Values (mean ± SEM) represent the percentage (%) of TH-positive neurons that were also positive for 
VP, aSYN or Luc. g Overview of the pontine brainstem (Bregma: -5.30 mm) stained against TH (red) and 
human aSYN (green) depicting the transduced area 3 days post-injection. Abbreviations: L, left; R, right; PB, 
parabrachial nucl.; SUV, superior vestibular nucl.; MV, medial vestibular nucl.; DTN, dorsal tegmental nucl.; 
LDT, laterodorsal tegmental nucl. h Higher magnification overview image of the TH-positive LC region (red) 
transduced with human A53T-aSYN (green). Scale bars 25 µm in c, e; 500 µm in g and 100 µm in h. 
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Figure 2 | Progressive loss of TH-immunoreactive LC cells after rAAV1/2-A53T-aSYN injection. 
a, b Representative images (Bregma -5.40 mm) and unbiased stereology of TH-positive LC-neurons in A53T-
aSYN (red bars, right column) or Luc (black bars, left column) overexpressing animals. Values (mean ± SEM) 
are expressed as cell numbers on the injected side compared to non-injected side (%). n = 8 per time point and 
group, two-way ANOVA analysis followed by Tukey’s post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001. c 
Representative confocal images of neuronal morphology after 9 weeks of protein overexpression. Pyknotic cell 
bodies and dystrophic axons were observed in A53T-aSYN, but not in Luc overexpressing animals. Scale bars 
250 µm in a, 50 µm in c. 
 
 
Accumulation of phosphorylated-aSYN in the LC region 
Phosphorylation of aSYN at amino acid serine 129 (p-aSYN) is a commonly observed phenomenon 
in human PD brain tissue and in animal models artificially overexpressing aSYN [39–43]. In these 
models, the S129 phosphorylation is frequently used as an indicator for aSYN aggregation. In our 
current study, we measured the signal intensity of p-aSYN systematically via double 
immunofluorescence stainings for TH and p-aSYN. Our data revealed that A53T-aSYN 
overexpression led to strong and progressive phosphorylation of aSYN in LC neurons (Fig. 3a, b). 
Accumulation of p-aSYN started early with positive cells being observable already 1 week post-
injection, reaching highest levels at the latest time point. Generally, the p-aSYN signal was 
homogenously distributed in the cytoplasm of TH-positive LC cells. In addition, robust labeling of 
the nucleus was observed (Fig. 3d, e). To exclude the possibility of non-specific antibody labeling we 
analyzed rAAV-Luc injected animals, which showed no signal for p-aSYN at any time point (Fig. 3d, 
e). Next, we wanted to quantify if the degree of phosphorylation correlated with the degree of 
noradrenergic cell loss. Therefore, the p-aSYN signal intensity values were plotted and correlated 
with the percentage of LC cell loss (Fig. 3c). The strong correlation (r = 0.67, p < 0.05) indicates that 
the degree of aSYN phosphorylation can be used as a predictor of aSYN toxicity in our model.  
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Figure 3 | Progressive accumulation of phosphorylated aSYN (p-aSYN) in the LC region.  
a, b Representative images (Bregma -5.40 mm) and quantification of p-aSYN in the LC region via double 
immunofluorescence staining for TH (green) and p-aSYN (magenta). Values are presented as mean ± SEM, n 
= 4 per time point and group, one-way ANOVA analysis followed by Tukey’s post-hoc test, * p < 0.05. 
c Robust correlation was observed between loss of  TH-positive LC cells and accumulation of p-aSYN (r = 
0.67, p < 0.05). d Confocal microscopy confirmed accumulation of p-aSYN (magenta) in TH-positive LC cells 
(green) 3 weeks post injection in A53T-aSYN (red) overexpressing animals (lower row). e p-aSYN 
immunoreactivity in the LC-region of A53T-aSYN overexpressing animals (lower row) 9 weeks post injection. 
No A53T-aSYN or p-aSYN immunoreactivity was observed in Luc overexpressing animals (upper row) at any 
time point. Scale bars 250 µm in a, 25 µm in d-e.  
 
Formation of proteinase K (PK)-resistant, p62-, Ubi-1- and aSYN-positive aggregates  
Lewy bodies in human PD brain tissue are characterized by immunoreactivity for insoluble (PK-
resistant) aSYN, but also for a variety of other proteins, such as ubiquitin-1 (Ubi-1) and 
p62/SQSTM1/sequestosome-1 (p62) [44, 45]. Both of the latter proteins are implicated in the cellular 
clearance of aSYN. Occurrence of PK-resistant Ubi-1-positive aggregates indicates an overburdened 
proteasomal clearing system, while dysfunction of the lysosomal system can result in accumulation 
of p62-positive aggregates [46]. To test whether proteasomal and/or lysosomal clearance might be 
impaired in our model, we systematically screened A53T-aSYN and Luc overexpressing animals for 
p62- and Ubi-1-immunoreactivity. A53T-aSYN, but not Luc injected mice showed abundant p62- 
and Ubi-1-positive aggregates starting 3 weeks after viral vector delivery reaching highest numbers at 
the latest time point (Fig. 4a, b). Ubi-1-, as well as p62-positive inclusions appeared as small circular 
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objects surrounding the nuclei of the cells (Fig. 4b) and were restricted to the ipsilateral side of 
injection. As in the previous experiments most of the p-aSYN signal was seen in TH-positive neurons 
(Fig. 3a, d), we expected a high rate of co-localization for p62 and Ubi-1 with the LC marker TH. 
However, the majority of p62 and Ubi-1 immunoreactivity was located next to TH-positive LC cells, 
suggesting that other cells are involved in this process (Fig. 4a). To elucidate in which cell type the 
p62-positive aggregates were located, double immunofluorescence stainings for p62 with MAP2 
(neuronal marker), Olig2 (oligodendroglial marker), GFAP (astrocytic marker) or IbA1 (microglial 
marker) were performed. While p62 did not co-localize with MAP2 (Fig. 5a), Olig2 (Fig. 5b) or GFAP 
(Fig. 5c), we observed clear co-localization with IbA1 (Fig. 5d), indicating that the p62-positive 
inclusions were located in microglial cells. Moreover, we further confirmed that Ubi-1-positive 
aggregates were also located in microglia (Fig. 5e). Double immunofluorescence stainings for IbA1 
and aSYN (Syn211) (Fig. 5f, arrow) and GFAP and aSYN (Syn211) (Fig. 5g, arrow) revealed that 
microglia, as well as astroglia exhibited human aSYN after 3 weeks of aSYN overexpression. 
 
Figure 4 | Formation of insoluble protein aggregates in A53T-aSYN overexpressing animals.  
a Staining for p62 (red, upper row) and Ubi-1 (red, lower row) revealed abundant p62- and Ubi-1-positive 
aggregates in the LC-region. These aggregates were found in close proximity to, but did not co-localize with 
TH-positive (green) LC cells, which were positive for p-aSYN (magenta). b Representative images of p62- 
(upper left) and Ubi-1 (lower left) positive aggregates in A53T-aSYN animals. No aggregates were observed in 
Luc overexpressing animals at any time point (right column). c p62-, Ubi-1 and aSYN stainings after proteinase 
K (PK) digestion or without digestion (Ø PK, lower right) confirmed that p62- (upper left), Ubi-1- (upper 
right) and human aSYN-positive (lower left) aggregates were insoluble. Scale bars 50 µm in a and c, 25 µm in 
b. 
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Figure 5 | p62- and Ubi-1 positive aggregates co-
localize with IbA1-positive microglia.  
a-c Representative confocal microscopy images of p62 
(green, second column) and MAP2 (a, red, first row), Olig2 
(b, gray, second row), or GFAP (c, red, third row) show 
no co-localization of p62 and the different cellular 
markers. In contrast, co-staining p62 (green) and IbA1 
(d, gray, fourth row) or Ubi-1 (green) and IbA1 (e, gray, 
fifth row) revealed clear co-localization. IbA1 positive 
microglial cells (f, gray, sixth row) and GFAP-positive 
astroglia (g, red, seventh row) also co-stained for aSYN 
(arrows in f, g). Scale bar for a-g 25 µm.  
Next, we aimed to investigate if the observed p62- and Ubi-1-positive inclusions indeed consisted of 
insoluble aggregated proteins. Since PK resistance is accepted as a valid marker for the formation of 
insoluble aggregates in human PD samples and animal models [33, 36, 47], we digested tissue samples 
of A53T-aSYN and Luc injected mice of all time points with PK. As a result, numerous PK-resistant 
insoluble aggregates positive for p62, Ubi-1 and aSYN were found in A53T-aSYN injected mice (Fig. 
4c). Notably, PK-resistant aSYN aggregates had the same shape and size as Ubi-1- and p62-
inclusions. Further, all three kinds of aggregates started to appear 3 weeks after initiation of A53T-
aSYN overexpression and were restricted to the site of viral injection. PK digestion and subsequent 
analysis of rAAV-Luc injected animals revealed no signal for aSYN, p62, Ubi-1 or Luc in any analyzed 
section.  
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Targeted α-synucleinopathy induces reactive micro- and astrogliosis in the LC region 
Microglia activation and reactive astrocytes have been observed by respective PET imaging in human 
prodromal and manifest PD patients [48, 49], post-mortem PD brain samples [50, 51] and aSYN 
animal models [52–54]. Most of the studies using animal models focused on the impact of microglia 
activation following nigrostriatal degeneration. In the current study, we aimed to investigate whether 
a focally induced α-synucleinopathy in the LC region would lead to reactive micro- and astrogliosis. 
Therefore, a triple immunofluorescence staining for IbA1 (microglial marker), GFAP (astroglial 
marker) and TH was carried out and the intensity of fluorescence signal was quantified (Fig. 6a-c). 
Already 3 weeks of A53T-aSYN overexpression were sufficient to induce a 3.5-fold increase of 
astroglial signal intensity in the injected LC region compared to Luc control. The astrogliosis further 
progressed up to a 6-fold increase after 9 weeks (Fig. 6b). Simultaneously, a 3-fold signal increase for 
microglia was measured after 3 weeks of A53T-aSYN overexpression and a 5-fold increase after 9 
weeks, compared to Luc (Fig. 6c). 3D reconstructed high magnification confocal images revealed a 
dense glial network in A53T-aSYN overexpressing animals, in which the remaining TH-positive LC 
neurons were embedded already 3 weeks after viral vector delivery (Fig. 6d). Abundant direct physical 
contacts between TH-positive LC neurons and astro- and microglia could be resolved. In addition, 
numerous LC cells appeared to be nearly completely engulfed by microglial processes (Fig. 6d, 
arrows). In contrast, overexpression of Luc did not lead to any significant increase of astro- or 
microglia intensity values (Fig. 6a-d). Besides the interaction of astro- and microglia with LC neurons, 
we also observed direct physical contacts between astrocytes and microglial cells (Fig. 6e, arrow).  
To underline our hypothesis that the degree of aSYN-induced pathology is closely associated with 
the degree of microgliosis, we correlated the microglial intensity values with the percentage of LC 
neurodegeneration (Fig. 6f, g). This revealed a correlation coefficient of r = 0.80 (p < 0.05) for A53T-
aSYN, whereas for the Luc overexpressing animals no significant correlation was found (r = 0.09, p 
> 0.05). 
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Figure 6 | A53T-aSYN overexpression leads to a pronounced reactive micro- and astrogliosis in the 
LC-region. 
a Representative images of the LC region of Luc (left column) or A53T-aSYN (right column) injected animals 
stained for TH (green), IbA1 (gray) and GFAP (red) display a marked increase of micro- and astroglia over 
time in A53T-aSYN overexpressing mice. Quantification of GFAP (b) and IbA1 (c) signal intensity revealed a 
progressive increase of astro- and microglia signal in A53T-aSYN injected animals (red boxes) compared to 
Luc control (black boxes). Values (mean ± min/max) are expressed as the signal intensity ratio of the injected 
side compared to the non-injected side. n = 6 animals per time point and group. Two-way ANOVA analysis 
followed by Tukey’s post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. d Reconstructed 
high magnification confocal images of the LC region showing physical contacts between TH-positive (green) 
LC cells and IbA1-positive micro- (gray) and GFAP-positive astroglia (red) after 3 weeks of A53T-aSYN 
overexpression (lower right). Engulfment (arrow) of TH-positive neurons by glial cells was only observed in 
A53T-aSYN expressing animals and not in Luc control mice (upper row). e Direct physical contacts were also 
observed between micro- and astroglia (arrow). f, g Correlating TH cell loss with the microglia intensity values 
indicates a strong association between increase of microglia and severity of TH cell loss in A53T-aSYN 
overexpressing animals (r = 0.80, p < 0.05), whereas there was no correlation in Luc expressing animals (r = 
0.09, p > 0.05). Pearson’s correlation coefficient with 95% confidence interval. Scale bars 100 µm in a, 25 µm 
in d and e. 
Appendix 
50 
 
Extensive transport of human A53T-aSYN to efferent brain regions    
After investigating the local effects of A53T-aSYN overexpression, we addressed the question 
whether the aSYN pathology can propagate to anatomically connected brain regions. A variety of 
studies using overexpression of rAAV-aSYN or injection of preformed aSYN fibrils (PFF’s) have 
described transport or spread of aSYN to anatomically connected brain regions [41, 55–59]. To 
investigate the propagation of human A53T-aSYN after inducing the α-synucleinopathy in LC 
neuronal somata, we stained predetermined brain sections against human aSYN (Syn211) or Luc and 
rated the occurrence of aSYN- or Luc-positive axons or cell bodies (Table 2). While overexpression 
of Luc resulted in a staining pattern, which was limited to the injection site and absent in distant brain 
regions, we observed aSYN signal in a high number of brain regions in A53T-aSYN injected mice 
(Fig. 7). One week after injection of rAAV-A53T-aSYN in the right LC region, abundant aSYN-
positive axons were observed in various brain regions which are known output regions of LC neurons 
[60]. The human aSYN signal was solely axonal and no aSYN-positive cell bodies were detected. 
Regions showing the strongest aSYN signal included the main olfactory bulb, lateral septal nucleus, 
diagonal band nucleus, bed nuclei of the stria terminalis, central amygdalar nucleus, periaqueductal 
gray, midbrain reticular nucleus, substantia nigra (SN) pars compacta and the ventral tegmental area 
(Table 2). We counted 36 brain regions, which contained human aSYN-positive axons after one week, 
indicating that human A53T-aSYN was transported rapidly along the axons towards the synaptic 
terminals in an anterograde direction. Despite the increase of axonal aSYN signal, no aSYN-positive 
cell bodies were detected outside of the LC region at any investigated time point, arguing against the 
hypothesis that human A53T-aSYN is released in LC output regions and taken up by synaptically 
connected cells in the short time frame of 9 weeks. This is highlighted by the finding that staining 
against p-aSYN revealed no signs of phosphorylation or aggregation of endogenous aSYN in distant 
brain regions after 9 weeks whereas the axons containing human (non-phosphorylated) A53T-aSYN 
stained positive for TH (Fig. 8c). 
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Figure 7 | Widespread transport of human A53T-aSYN to interconnected brain regions. 
a-d Representative images of analyzed brain sections stained against human aSYN (Syn211) (Bregma +0.50 
mm a, Bregma -0.94 mm b, Bregma -3.16 mm c, Bregma -7.56 mm d). Scale bars 1 mm in a-d, 25 µm in all 
high magnification images. Abbreviations: CTX, cortex; CP, caudoputamen; LS, lateral septal nucleus; MS, 
medial septal nucleus; aco, anterior commissure; BST, bed nuclei of stria terminalis; HY, hypothalamus; SI, 
substantia innominata; OT, olfactory tubercle; HPF, hippocampal formation; DG, dentate gyrus; fi, fimbria 
hippocampi; int, internal capsule; TH, thalamus; GP, globus pallidus; sAMY, striatum-like amygdalar nuclei; 
LHA, lateral hypothalamic area; CEA, central amygdalar nucleus; SC, superior colliculus; APN, anterior 
pretectal nucleus; PAG, periaqueductal gray; MRN, midbrain reticular nucleus; VTA, ventral tegmental area; 
SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata; AP, area postrema; NTS, nucleus of 
the solitary tract; CU, cuneate nucleus; ECU, external cuneate nucleus; DMX, dorsal motor nucleus of the 
vagus nerve; XII, hypoglossal nucleus; SPV, spinal nucleus of the trigeminal; MDRNd, medullary reticular 
nucleus, dorsal part; MDRNv, medullary reticular nucleus, ventral part; IRN, intermediate reticular nucleus; IO, 
inferior olivary complex; py, pyramid; RA, raphe nuclei; mlf, medial longitudinal fascicle; LRN, lateral reticular 
nucleus; sptV, spinal tract of the trigeminal nerve; icp, inferior cerebellar peduncle; L, left (contralateral); R, 
right (ipsilateral). 
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Injected (right) hemisphere 
Time of A53T-aSYN overexpression 
Non-injected (left) hemisphere 
Time of A53T-aSYN overexpression 
  1 wk 3 wks 6 wks 9 wks 1 wk 3 wks 6 wks 9 wks 
Bregma  Main olf. bulb, gr. layer + ++ ++(+) ++ (+) + + (+) 
+4.28 mm Inner plexiform layer ‒ +(+) +(+) + ‒ (+) (+) (+) 
 Outer plexiform layer (+) + + + ‒ (+) (+) (+) 
          Bregma  Cortex + ++ ++(+) ++ (+) + + (+) 
+2.96 mm Main olf. bulb + ++ ++(+) ++ (+) (+) + (+) 
 Ant. olf. nucleus + +(+) +(+) + ‒ (+) (+) (+) 
 Lateral olf. tract (+) +(+) + + ‒ ‒ ‒ ‒ 
          
Bregma  Cortex + ++(+) ++(+) ++(+) ‒ + + + 
+1.18 mm Taenia tecta, dors. part + ++ ++ +(+) ‒ + + (+) 
 Corpus callosum (+) +(+) + + ‒ (+) (+) (+) 
 Lateral septal nucleus +(+) ++(+) +++ ++(+) (+) + +(+) +(+) 
 Diagonal band nucleus +(+) ++(+) +++ ++(+) (+) + +(+) +(+) 
 Nucleus accumbens + + + + ‒ (+) (+) (+) 
 Caudoputamen (+) + + (+) ‒ (+) (+) (+) 
          Bregma  Medial septal nucleus + +(+) ++ +(+) (+) + +(+) + 
+0.38 mm Cortex (+) ++(+) ++(+) ++ ‒ + + + 
 Bed ncl. of stria term. ++ +++ +++(+) +++ (+) + ++ ++ 
 Magnocellular ncl. (+) + ++ ++ ‒ (+) + + 
 Hypothalamus + ++(+) ++(+) +++ ‒ +(+) +(+) ++ 
 Lateral septal nucleus (+) ++ ++(+) ++(+) ‒ + +(+) +(+) 
 Caudoputamen (+) + + (+) ‒ (+) (+) (+) 
 Subst. innominata + + +(+) +(+) (+) (+) + + 
          Bregma  Central amygdalar ncl. + ++ +++ +++(+) (+) +(+) ++ ++ 
‒0.58 mm Subst. innominata +(+) ++ ++(+) +++ + +(+) ++ ++ 
 Globus pallidus (+) + + + ‒ (+) (+) (+) 
 Hypothalamus + ++ ++(+) ++ (+) + +(+) +(+) 
 Lat. hypothalamic area +(+) ++ +++ ++(+) (+) + ++ ++ 
 Fimbria (+) + (+) (+) (+) + (+) (+) 
 Stria terminalis + +(+) +(+) +(+) ‒ (+) + + 
 Corpus callosum ‒ + + + ‒ ‒ (+) (+) 
 Cortex (+) ++(+) ++(+) ++ ‒ + + + 
          Bregma  Cortex ‒ +(+) +(+) + ‒ (+) (+) (+) 
‒3.16 mm Sup. colliculus, sens. ‒ +(+) +(+) + ‒ + + + 
 Sup. colliculus, motor (+) +(+) ++ ++ (+) +(+) ++ ++ 
 Periaqueductal gray +(+) ++ ++(+) ++(+) (+) +(+) ++ ++ 
 Midbrain reticular ncl. +(+) ++ ++ ++(+) + +(+) ++ ++ 
 Red nucleus (+) + +(+) + + ++ ++(+) ++ 
 Ventral tegmental area + +(+) ++ ++(+) +(+) ++ ++(+) ++(+) 
 Subst. nigra, pars compacta +(+) +(+) ++ ++ (+) + +(+) +(+) 
 Subst. nigra, pars reticulata (+) + + (+) (+) (+) (+) (+) 
 Hippocampus ‒ + +(+) + ‒ (+) + + 
 Interpeduncular ncl. (+) +(+) ++ ++(+) (+) +(+) ++(+) ++(+) 
 Thalamus (+) +(+) ++ ++ (+) + +(+) +(+) 
          Bregma  Dorsal motor ncl. of n. X ‒ + +(+) +(+) ‒ (+) + + 
‒7.56 mm Hypoglossal ncl. ‒ + + + (+) (+) + (+) 
 Parvicell. reticular ncl. +(+) +(+) +(+) +(+) (+) (+) + + 
 Intermediate ret. ncl. + + ++ +(+) ‒ (+) + + 
 Medullary reticular ncl. + +(+) +(+) +(+) ‒ + + + 
 Lateral ret. ncl. ‒ (+) + (+) ‒ (+) (+) (+) 
 Ncl. of the solitary tract ‒ (+) + +(+) ‒ (+) + + 
 Spinal ncl. of the n. V ‒ (+) (+) (+) ‒ ‒ (+) (+) 
 Area postrema (+) (+) + + (+) (+) + + 
 Arbor vitae ‒ + + + ‒ + + + 
 Gr. layer (cerebellum) + +(+) +(+) +(+) (+) + + + 
 Mol. layer (cerebellum) ‒ + + + ‒ + + + 
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Table 2 | Semiquantitative analysis of human aSYN-pathology in distant brain regions.  
Occurrence of human aSYN-positive axons was graded out of seven coronal brain sections as follows: ‒ no 
positive axons; + sparse (few positive axons); ++ mild (more positive axons); +++ moderate (many positive 
axons, covering almost the complete brain region) and ++++ severe pathology (large number of positive axons 
densely covering the complete brain region); (+) describes an intermediate state between two categories to 
allow a more accurate description. n = 6 per time point. Abundance of aSYN-positive axons increased over 
time and was more prominent in the injected (right) hemisphere. The signal for human aSYN was solely axonal 
and no aSYN-positive cell bodies were detected. 
 
No substantia nigra (SN) cell loss after 9 weeks of human A53T-aSYN overexpression in LC 
neurons 
Already after 1 week of A53T-aSYN overexpression in LC neurons, human aSYN positive axons 
passing by DA SN neurons could be detected. After 9 weeks, SN neurons were densely surrounded 
by aSYN containing axons (Fig. 8a) but no human aSYN signal was observed in the somata of SN 
cells. Stereological quantification of TH-positive SN neurons (Fig. 8b) revealed no significant 
difference of TH-immunoreactive neurons between A53T-aSYN compared to Luc overexpressing 
mice neither for the left nor for the right SN (One-way ANOVA; p > 0.05). This result points out 
that LC degeneration, in combination with profound local axonal aSYN accumulation was not 
sufficient to induce degeneration of DA SN neurons within the relatively short period of 9 weeks. 
 
Figure 8 | No SN cell loss after 9 weeks of A53T-
aSYN overexpression in LC region.  
a Abundant human aSYN-positive (red, upper right) axons 
were observed in the TH-positive SN region (green, upper 
left) after 9 weeks of A53T-aSYN overexpression in the 
LC. In contrast, no aSYN-positive cell bodies could be 
detected. b Quantification of TH-positive SN neurons 9 
weeks post injection revealed no significant difference 
between A53T-aSYN group (red bars) and Luc control 
group (black bars) for either side. Values are presented as 
mean ± SEM, n = 8 per group and side. One-way 
ANOVA analysis (p > 0.05). c Representative image of 
TH and human aSYN axonal co-localization in distant 
brain regions, exemplified for midbrain reticular nucleus 
(MRN). The majority of aSYN positive axons co-stained 
for TH indicating that they origin from the LC. Scale bars 
250 µm in a, 25 µm in c. 
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Discussion 
Degeneration of the LC noradrenergic system is a key event during PD pathogenesis in the prodromal 
phase of the disease. In this study, we present the first targeted LC α-synucleinopathy mouse model, 
which replicated cardinal features of human PD pathology. We have designed our rAAV vector-
based overexpression model to generate robust and rapid induction of aSYN pathology, including 
phosphorylation and aggregation of aSYN, noradrenergic neurodegeneration, development of 
dystrophic axon morphology, signs of proteasomal and lysosomal dysfunction and prominent 
neuron-glial interactions. Furthermore, the herein characterized aSYN transport pattern allows 
investigating the effects of aSYN-induced LC neurodegeneration on anatomically connected LC 
output structures. 
 
Progressive S129 phosphorylation and formation of PK-resistant aSYN-positive aggregates 
Phosphorylation of aSYN at amino acid S129 is a dominant pathological modification of aSYN [40] 
since approximately 90% of aSYN in human Lewy bodies is phosphorylated at this position, whereas 
only 4% of soluble aSYN exhibits this posttranslational modification [39]. In PD animal models, 
phosphorylation at S129 is used as a key marker to investigate an induced α-synucleinopathy and its 
occurrence has often been interpreted as formation of aSYN aggregates [41, 42, 54, 61, 62]. In our 
current study, we show abundant and over time increasing S129-phosphorylation of aSYN in the 
cytoplasm and nucleus of LC cells (Fig. 3a, d). Previous studies have pointed out that aSYN has 
different cellular localizations. Beside the presynaptic and cytoplasmic localization, a nuclear 
occurrence of aSYN is known [63]. Nuclear p-aSYN has been observed in previous studies where 
aSYN was overexpressed [64, 65] and it could be shown that nuclear aSYN interacts with histone 
molecules. It was even suggested that the S129-phosphorylation may play an important role for the 
nuclear translocation of aSYN [66]. To confirm that phosphorylation of aSYN was accompanied by 
formation of high molecular weight aSYN aggregates we performed PK digestion experiments that 
revealed small circular aSYN positive inclusion bodies restricted to the injection site (Fig. 4c). Our 
model thereby reproduces a key feature of the LC pathology observed in human PD patients. 
Importantly, since PK digestion led to the destruction of all soluble proteins it did not allow us to 
investigate if the developing aSYN-positive inclusions are located in neurons or glial cells. The 
observed discrepancy between a high amount of p-aSYN-positive cells and a relatively limited 
number of aSYN-positive PK-resistant inclusions raises the question whether aSYN S129-
phosphorylation can solely be used as a sufficient marker for aSYN aggregation. Our data indicate 
that S129-phosphorylation is an important indicator for aSYN pathology, but immunohistochemistry 
for other aggregation markers should be added to confirm the occurrence of aSYN aggregates [67, 
68].  
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Formation of p62- and Ubi-1-positive proteinaceous inclusions in microglia 
Additional markers, which are also commonly accepted to investigate protein aggregation and 
simultaneously serve as indicators for dysfunction of the proteasomal or lysosomal protein 
degradation system include Ubi-1 and p62 [44, 45]. Based on previous reports, which showed close 
co-localization of p-aSYN and Ubi-1 or p62  [56, 69], we expected to find overlap of these markers 
in our model. But notably, all p62 and Ubi-1 aggregates were located next to p-aSYN positive LC 
cells (Fig. 4a). Co-staining p62 and Ubi-1 with different glial and neuronal markers revealed that the 
p62 and Ubi-1 inclusions were located in IbA1-positive microglial cells (Fig. 5d, e). Further, we also 
show that microglia exhibited human aSYN, probably as a result of local aSYN uptake or 
phagocytosis of aSYN containing cellular debris. (Fig. 5f). The possibility that the microglial cells 
were transduced by rAAV1/2-A53T seems to be unlikely, since the used rAAV1/2 vector possesses 
a high neuronal tropism [32] and triple stainings for IbA1 (microglia), GFAP (astroglia) and aSYN 
revealed no aSYN-immunoreactivity 3 days after viral vector delivery within micro- or astroglial cells. 
Despite this, we cannot completely exclude the possibility of microglia transduction by the initial 
injection of rAAV1/2-A53T. Deposition of internalized aSYN aggregates in microglia has already 
been observed in vitro [70], but our study represents (to our knowledge) the first in vivo evidence of 
inclusion formation in microglial cells. We hypothesize that these p62- und Ubi-1-positive aggregates 
develop de novo in microglial cells possibly because of massive human aSYN uptake, which exceeds 
the lysosomal degradation capacities and leads to protein aggregation.  
Currently we can only speculate why p62 and Ubi-1 reactivity was observed in microglia but absent 
in LC neurons. Previous studies have shown that p62-positive inclusions co-localize with Ubi-1 not 
only in neuronal but also in glial cells in neurodegenerative diseases including Alzheimer's disease, 
dementia with Lewy bodies and PD [44]. Furthermore, it has been shown that microglia rapidly 
internalize aSYN thereby representing the most efficient scavengers of neuronal released aSYN [71, 
72]. By clearing aSYN, microglia might actively delay accumulation of aSYN and maturation of aSYN 
aggregates in LC neurons. One could hypothesize that in our model aSYN is rapidly released from 
LC neurons and taken up by microglia, which in turn leads to microglial but not neuronal 
accumulation of p62 und Ubi-1 aggregates. A longer duration of the experiment may clarify the 
question, whether Ubi-1- and p62-positive inclusions might also develop in LC neurons. 
 
Reactive astro- and microglia and their implication in aSYN-induced LC pathology 
Another key aspect in several animal models in which aSYN was injected or overexpressed [52, 54, 
73] is the profound involvement of reactive astro- and microgliosis during the development of the 
aSYN pathology. It has been shown that activated microglial cells, besides their implication in clearing 
aSYN, are able to trigger the release of inflammatory cytokines and accelerate the production of 
reactive oxygen species, thereby likely contributing to the process of neurodegeneration [73–75]. In 
our model, LC cells were surrounded by a massive network of astro- and microglia already after 3 
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weeks of aSYN overexpression, with many microglial cells almost completely engulfing the surviving 
LC neurons (Fig. 6d, arrows). This early induction of microgliosis (Fig. 6c) is in line with previous 
findings where microgliosis even preceded the onset of neurodegeneration [53, 76]. Furthermore, we 
observed a strong correlation between the increase of microglial signal and LC cell loss (Fig. 6g), 
implying the conclusion that reactive microglial cells are important modulators of aSYN-induced 
toxicity not only in the dopaminergic SN but also in the noradrenergic LC. Microgliosis was 
accompanied by severe and progressively increasing astrogliosis. Reactive astrocytes surrounded and 
partially engulfed LC neurons. Furthermore, they formed direct physical contacts with reactive 
microglia (Fig. 6e, arrow) and exhibited clear signal for human aSYN (Fig. 5g). Importantly, reactive 
astrocytes can also take part in clearing aSYN by endocytosis and degradation in their lysosomal 
system [77, 78]. Furthermore, they interact closely with microglia and release pro- and anti-
inflammatory molecules [79, 80]. Our LC model exemplifies this close interdependency between 
neurons, micro- and astroglia. We show that glial cells are highly involved in the process of aSYN 
degradation and that glial dysfunction or failure could be a factor of PD progression. However, it 
should also be considered that the LC itself plays a central role in decreasing neuroinflammation [81]. 
Noradrenaline is able to suppress the expression of pro-inflammatory cytokines in glial cells while 
simultaneously elevating the expression of anti-inflammatory markers [82, 83]. Hence, it is reasonable 
to assume that loss of LC neurons additionally increases the neuroinflammatory response and 
contributes to the progressive increase of micro- and astroglial activity seen in our model.  
 
Anterograde axonal transport of aSYN to LC output regions 
To slow or prevent the progression of PD, it is essential to investigate if and how the α-
synucleinopathy propagates within the brain. Recent evidence [41, 56, 58, 84, 85] suggests that toxic 
aSYN species formed in a small number of cells can spread trans-synaptically to distant but 
anatomically connected brain regions where they act as seeds to trigger the formation of insoluble 
aSYN aggregates [56, 86]. Furthermore, cell culture experiments have demonstrated that aSYN can 
be taken up by cells and transported in both the retrograde and anterograde direction [87–89]. The 
noradrenergic LC has a broad input-output connectome [60, 90] making this brain region suitable to 
investigate trans-neuronal spread. Moreover, Iba and colleagues [91] have demonstrated in a 
tauopathy model that injections of synthetic tau fibrils were able to induce tau pathology in LC 
neurons which then propagated to LC afferents and efferents. To investigate if this also translates 
into our LC aSYN overexpression model we systematically analyzed and scored the aSYN pathology 
after 1, 3, 6 and 9 weeks (Fig. 7, Table 2). Our results indicate that the overexpressed human A53T-
aSYN, once produced in the cytoplasm of LC neurons, is only transported in the anterograde 
direction towards the synaptic terminals, as abundant aSYN-positive axons and terminals in efferent 
LC regions co-stained for TH (Fig. 7, Fig. 8c, Table 2). The broad LC output connectome [60] likely 
explains this high amount of aSYN-positive axons in distant brain regions of the ipsilateral but also 
contralateral hemisphere. The mild aSYN pathology of the contralateral (non-injected) side can be 
Appendix 
57 
 
explained by LC projections crossing the midline and innervating brain structures of the contralateral 
hemisphere [92]. In contrast to the profound axonal aSYN immunoreactivity, we found no aSYN-
positive cell bodies outside of the LC region, arguing against trans-neuronal spread of aSYN in the 
relatively short time frame of 9 weeks. The absence of Luc-positive axons in LC output regions might 
be explained on one hand by protein size (Luc 62 kDa vs. aSYN 15 kDa) and on the other hand by 
the naturally presynaptic localization of aSYN [93, 94]. We therefore conclude that the aggregation 
prone aSYN species created by overexpression of human A53T-aSYN in the LC region are not 
transferred to other neuronal populations within the investigated 9 weeks. A longer time period and 
subsequently higher aSYN burden in the LC system may be necessary to enable such a transfer at 
later time points. This is in line with the finding that despite the severe degree of axonal aSYN 
accumulation in the SN region after 9 weeks of A53T-aSYN overexpression in the LC region, no 
statistically significant SN neurodegeneration was observed (Fig. 8).  
 
Open questions and limitations 
In this study, we have decided to overexpress human mutant A53T-aSYN by injection of a previously 
well-established rAAV vector. The vector used in this study has proven effective in inducing 
progressive neurodegeneration of SN neurons by several groups in several PD animal models [32, 
33, 95–97]. In this context, it would be of relevance to investigate whether overexpression of wild-
type aSYN in the LC would have led to a different histopathological phenotype. Considering the 
lower rate of β-sheet and fibril formation of wild-type aSYN compared to the A53T-aSYN variant 
[98, 99], one could hypothesize that overexpression of wild-type aSYN might lead to milder 
histopathological alterations, but this has to be demonstrated in the LC model in a further study. For 
this initial study we have focused on a relatively short time frame of up to 9 weeks which allowed us 
to characterize the initial, local and time-dependent histopathological alterations of LC neurons 
caused by A53T-aSYN. Since 9 weeks is likely too short to observe the full neuropathology, a future 
study containing longer observation times of up to 52 weeks or even longer would be suggested. This 
would allow to further investigate whether trans-synaptic spread of aSYN and subsequent 
degeneration of dopaminergic SN neurons occur at a later time-point. As our study primarily aims to 
address the histopathological consequences of A53T-aSYN overexpression in LC neurons, we have 
not carried out a behavioral assessment. Nevertheless, the model would benefit from a thoroughly 
carried out behavioral characterization, including sleep recordings covering the possible occurrence 
of any non-motor or subtle motor symptoms. 
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Conclusions 
In a time, in which on one hand the clinical research focus shifts away from the neurodegeneration 
of the dopaminergic nigrostriatal pathway towards the prodromal stages of PD and on the other hand 
the first potentially disease modifying therapies enter clinical testing [100], animal models mimicking 
the prodromal phase of PD are needed. In this study, we have reproduced cardinal histopathological 
features of the human LC PD-pathology, delineated the time-course of noradrenergic 
neurodegeneration and characterized robust histological markers, which are sufficient to assess the 
pathological changes in a quantitative and qualitative way. Taken together, this animal model may 
contribute to the research on the pathophysiology of the prodromal stage of PD. Further studies 
with longer observation times and additional characterization (e.g. behavioral assessment, 
biochemical analyses) are required to determine whether the herein presented model will prove 
helpful in the development and testing of disease-modifying therapy. 
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Introduction 
The α-synucleinopathy Parkinson’s disease (PD) affects, in addition to the dopaminergic substantia 
nigra pars compacta (SNc), other vulnerable neurotransmitter systems in the CNS, for example the 
noradrenergic locus coeruleus (LC) or cholinergic neurons in the vagal nuclear complex. The 
histopathological distribution of α-synuclein (aSYN) aggregates containing Lewy-bodies and neurites, 
the pattern of neurodegeneration, various imaging studies, and the broad symptomatology indicate 
that PD neuropathology does not develop simultaneously in all vulnerable brain regions, but rather 
in a sequential way.1 In REM sleep behavior disorder (RBD), a specific prodromal stage of PD, both 
clinical (imaging studies) and neuropathological evidence indicates that the region of the 
noradrenergic LC system is involved early in the topographical sequence of pathological changes, 
years before the dopaminergic SNc is affected and motor symptoms become apparent.2–4 The 
resulting central deficiency of noradrenergic neurotransmission contributes to both the non-motor 
and motor symptomatology of PD.5,6 Furthermore, experimental evidence from PD animal models 
suggests that deficient LC-noradrenergic neurotransmission enhances the nigral toxicity of several 
neurotoxins (e.g. MPTP or 3,4-Methylendioxy-N-methylamphetamin),7–9 whereas an increase of 
noradrenergic neurotransmission may exert a neuroprotective effect on the SNc.10 This introduces 
an intriguing possibility for disease-modification.  
This viewpoint article argues that the early involvement of the LC in the progression of PD and its 
contribution to the pathophysiology and symptomatology places the LC in a unique position. Future 
research on the LC-noradrenergic system should include: 1) testing of symptomatic therapy for 
alleviating noradrenergic deficiency; 2) the development of disease-modifying therapeutic approaches 
at the LC level based on the reported potential neuroprotective effect of the LC on the dopaminergic 
SNc; and 3) the search for LC-related disease progression biomarkers. 
  
The noradrenergic LC – a structure to be rediscovered for PD research  
The human noradrenergic LC, a small nucleus in the pontine brainstem, contains only around 35 000 
neurons per hemisphere11 while representing the major source of noradrenaline (NA) for vast parts 
of the human brain. LC cells are involved in several highly preserved brain functions including, but 
not limited to, generation of arousal, facilitation of behavioral adaptions following new sensory 
information, memory consolidation, learning, modulation of motor control, and regulation of local 
blood flow. In PD, Lewy-body formation, axonal loss of noradrenergic projections, and altered 
synaptic morphology of LC cells are features of the early phase of the disease.12,13 Several lines of 
evidence indicate that accumulation of pathological aSYN in LC cells occurs not just in early disease 
stages, but it also exceeds the observed Lewy pathology in the SNc.1,14 The resulting decrease of NA 
in the neocortex, thalamus, hypothalamus, and cerebellum contributes to several non-motor 
symptoms of PD, including cognitive impairment, affective symptoms such as depression, anxiety, 
apathy, fatigue, and REM sleep behavior disorder.15–18 Furthermore, dysfunctional noradrenergic 
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neurotransmission is also implicated in impaired motor control and freezing of gait.5,6 Notably, 
despite the early and profound burden of Lewy pathology and loss of noradrenergic axons in output 
projection targets, the majority of LC neurons can survive the pathological process for many years, 
thereby even outliving the loss of SNc neurons.14,19 Although unbiased stereological quantifications 
are lacking, reported LC cell loss ranges from 21-93% and is commonly observed in advanced PD 
stages.20 The time lag between early alterations of LC neurons and the final cell loss during advanced 
disease stages leaves the LC for many years in a dysfunctional state.1,14,19 It is therefore tempting to 
speculate that LC neurons may have so far unidentified intrinsic properties which render them 
partially resilient to the disease process. This could explain the significantly longer duration between 
cellular pathological changes (Lewy body formation) and neuronal cell death in the noradrenergic LC 
compared to the dopaminergic SNc. 
 
Determinants of LC vulnerability in PD 
Noradrenergic LC cells share common morphological, electrophysiological, and metabolic features 
with other neuronal cell groups known to degenerate in PD. These intrinsic cellular factors are 
thought to render certain neuronal populations particularly vulnerable to the disease process. For the 
LC system, these include an extensive axonal arborization with multiple synaptic and paracrine 
neurotransmitter release sites that lead to high energetic demand, the electrophysiological phenotype 
of a pacemaker neuron continuously generating slow tonic spiking, the burden to generate and 
metabolize a highly reactive neurotransmitter, high amounts of intracellular neuromelanin and heavy 
metals, and its location directly next to the 4th ventricle (Fig. 1).12,21 All of these features combined 
set the LC in a critical at-risk position regarding energetic failure, metabolic burden, and possible 
exposure to toxins or inflammatory cytokines.12,21 The studies conducted so far on LC vulnerability 
and degeneration in PD animal models (Table 1) further reveal that neurotoxins which are commonly 
used to lesion the nigrostriatal system, e.g. MPTP or the pesticide rotenone, also cause degeneration 
of the LC. Furthermore, aSYN-overexpression models demonstrate that LC cells are susceptible to 
artificially increased intracellular aSYN levels.22 Compared to the wealth of studies conducted on the 
SNc, research on the LC in the preclinical as well as in the clinical setting is sparse. This situation 
offers the unique opportunity to transfer the existing expertise on catecholaminergic neurons and the 
fast growing body of knowledge on the nigrostriatal system to research on the LC-noradrenergic 
system.  
LC pathology in prodromal and manifest PD – opportunities for improved 
symptomatic treatment and neuroprotection 
The increasing knowledge of noradrenergic deficiency in PD has resulted in several promising 
attempts to restore noradrenergic neurotransmission for improved control of certain non-motor and 
motor manifestations (Table 2). The studies conducted so far employed mainly three distinct 
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pharmacological strategies: 1) direct increase of NA by administration of NA precursor substances 
(droxidopa/L-threo-DOPS); 2) increasing the available concentration of NA in the synaptic cleft by 
synaptic reuptake inhibitors selective for NA alone (atomoxetine, reboxetine) or NA and serotonin 
(duloxetine, venlafaxine) or NA and dopamine (methylphenidate); or 3) enhanced synaptic release of 
NA by presynaptic α2-adrenoreceptor antagonists (idazoxan, fipamezole). The results obtained 
indicate that enhancement of noradrenergic neurotransmission can alleviate several non-motor and 
motor manifestations of PD while simultaneously increasing patients’ quality of life. Notably, all of 
the trials listed were conducted in de novo or manifest PD patients. We therefore argue that efforts 
should be increased and noradrenergic replacement therapy should be carried forward in prodromal 
PD patient groups as manifestations of noradrenergic shortage, such as depression, anxiety, or 
cognitive impairment are already evident.23,24  
 
Figure 1 | Vulnerability factors of noradrenergic LC neurons. 
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 Species Reference 
LB/LN
-like 
struc-
tures 
Loss of 
neurons in 
the SNc (%) 
Loss of 
neurons in 
the LC (%) 
Loss of 
neurons in 
other 
regions (%) 
Biochemical / 
electrophysiolo-
gical alterations 
Toxin-
based 
models 
MPTP i.p. 
NHP Forno et al. 198641 
In 
LC/SNc 
Moderate to 
severe 
degeneration 
Focal lesions, 
degree 
comparable 
to SNc 
‒ ‒ 
NHP Mitchell et al. 198542 ‒ 
Considerable 
damage 
Obvious 
damage in 
1/3 monkeys 
Considerable 
damage to the 
cells of the 
VTA 
50% ↓ NA in 
CTX, and ACB 
>90% ↓ DA in 
vSTR and dSTR 
Swiss 
Webster 
mice 
German et 
al. 200043 ‒ 47 None ‒ 
48% ↓ NA in 
CTX 
68% ↓ DA in 
STR 
C57Bl/6J 
mice 
Seniuk et 
al. 199044 ‒ 
Dose-
dependent 
degeneration 
Dose-
dependent 
degeneration 
Dose-
dependent 
degeneration 
of VTA, A13 
↓ NA in CTX 
↓ DA in STR 
C57Bl/6 
mice 
Gupta et 
al. 198645 ‒ 
86 
 64 66 (VTA) ‒ 
C57Bl/6J 
mice 
Fornai et 
al. 200446 
In 
SNc/LC ~90 ~60 ‒ 
Marked decline of 
DA, DOPAC, 
HVA in STR 
Up to 80% ↓ NA 
in forebrain 
Rotenone 
s.c
. Wistar rats 
Lin et al. 
200847 SNc ~10 ~60 ‒  
i.v. Lewis rats 
Betarbet 
et al. 
200048 
SNc Mild to severe Mild to moderate 
VTA 
relatively 
spared 
Striatal 
dopaminergic 
denervation from 
partial to 
complete 
Paraquat i.p. Mice 
Fernagut 
et al. 
200749 
None 26.7 26.2 ‒ ‒ 
6-OHDA 
intraventricular 
Sprague-
Dawley rats 
Chiodo et 
al. 198350 ‒ ‒ ‒ ‒ 
increase in firing 
frequency of LC 
neurons 
85-90% ↓ NA in 
HC and CBX 
No change of NA 
in LC 
Sprague-
Dawley rats 
Descarries 
et al. 
197251 
‒ ‒ 20-85 (time-dependent) ‒ ‒ 
Genetic 
models 
Parkin‒/‒ 
Mice 
Von 
Coelln et 
al. 200452 
‒ None ~20 ‒ 
No change in 
striatal DA, 
DOPAC, HVA 
No change of NA 
in CTX, BS, HC, 
CBX 
~30% ↓ NA in 
OB 
~20% ↓ NA in 
spinal cord 
Mice Key et al. 201953 ‒ ‒ ‒ ‒ 
Acceleration of 
the spontaneous 
pacemaker 
frequency of LC 
neurons 
PINK1‒/‒ Rats Grant et al. 201554 
In 
LC/SNc
/ 
PAG/A
MB 
None 41 ‒ ‒ 
Thy1-WT-aSYN Mice 
Fernagut 
et al. 
200749 
In 
SNc/LC None None ‒ ‒ 
PrP-A53T-aSYN Mice Sotiriou et al. 201055 ‒ None None ‒ 
↓ NA (-33% STR, 
-40% OB, -31% 
spinal cord) 
No change of NA 
in CTX 
No change of 
DA, DOPAC, 
HVA in STR 
Over-
expression 
models 
CMV-A53T-
aSYN in the LC 
C57Bl/6N 
mice 
Henrich 
et al. 
201822 
In LC None Up to 56.25 ‒ ‒ 
Syn1-WT-aSYN 
in vagal nerve 
Sprague-
Dawley rats 
Rusconi 
et al. 
201756 
‒ ‒ Up to 15 
Up to 30 in 
DMV 
No cell loss in 
AMG 
‒ 
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Table 1 | Involvement of the LC-noradrenergic system in animal models of PD 
Abbreviations: ACB, nucleus accumbens; AMG, amygdala; CBX, cerebellar cortex; CTX, cortex; DA, 
dopamine; DMV, dorsal motor nucleus of the vagal nerve; DOPAC, 3,4-Dihydroxyphenylacetic acid; HC, 
hippocampus; HVA, homovanillic acid; LB, Lewy body; LN, Lewy neurite; OB, olfactory bulb; STR, striatum; 
vSTR, ventral striatum; VTA, ventral tegmental area. 
 
Another aspect to be considered is the growing body of experimental evidence that suggests the LC 
exerts neuroprotective effects on the nigrostriatal system. Early research on the LC in MPTP-based 
animal models indicated a neuroprotective role of NA neurotransmission on SNc survival. Ablation 
of LC neurons by systemic N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) or local 6-
OHDA injection prior to systemic MPTP treatment resulted in enhanced neurodegeneration of DA 
SNc cells.7–9 In contrast, noradrenergic hyperinnervation reduced the MPTP-induced nigral toxicity.10 
While the NA neuroprotection hypothesis has not been followed up initially, a series of more recent 
experiments has put this idea on firmer footing. Administration of reboxetine decreased the 
magnitude of SNc degeneration in a progressive parkinsonian mouse model25 in which nigral 
neurodegeneration was induced by inhibition of rRNA synthesis due to genetic ablation of the 
transcription initiation factor IA (TIF-IA). In addition, the β2-agonists salmeterol and clenbuterol 
facilitated a reduction of MPTP-induced SNc cell loss.26,27 Taken together, these studies suggest that 
augmentation of noradrenergic neurotransmission might not only alleviate symptoms manifesting as 
a result of NA deficiency, but may even have disease-modifying efficacy by exerting neuroprotective 
effects on the SNc. Finally, ongoing trials and studies being planned of potentially disease modifying 
compounds that target aSYN in the oligomeric or aggregate form should assess LC-related outcome 
measures, since systemic treatment against α-synucleinopathy might not only improve the function 
of the dopaminergic, but also of the noradrenergic system.  
 
Kinetics of LC neurodegeneration – Potential for novel LC progression biomarkers?  
In the last 10 years, increasing efforts have been undertaken to identify new biomarkers that correlate 
with PD progression and thereby allow for monitoring ongoing neurodegenerative alterations and 
the therapeutic efficacy of a given neuroprotective compound in clinical trials.28 Ideally, such a marker 
should reflect the prodromal phase of the disease as well as the advanced stages, and its changes 
should be linked directly to the progressing neuropathology. In 2019, three groups of prodromal PD 
patients are, in principle, available for clinical research for identification and characterization of PD 
progression markers: the asymptomatic carriers of one of the numerous mutations of the 1) leucine-
rich repeat kinase 2 (LRRK2), or 2) glucocerebrosidase (GBA) genes, and 3) patients suffering from 
RBD. We argue that involvement of the noradrenergic LC, most likely in RBD, fulfills several key 
requirements for research on new disease progression markers. These consist of: 1) involvement in 
the prodromal phase of PD; 2) the long time lag between initial Lewy-pathology and 
neurodegeneration in advanced PD stages; 3) contribution to several early non-motor symptoms; and 
4) LC pathology in not only idiopathic PD but also in PD caused by genetic alterations (e.g. SNCA 
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duplication/triplication/point mutation carriers, LRRK2 and GBA mutation carriers)29 and RBD 
patients.2,3 
 
 
Table 2. Selected clinical trials with noradrenergic agents in PD 
Abbreviations: CO, crossover design; DB, double-blinded; DNRI, dopamine and noradrenaline reuptake 
inhibitor; FOG, freezing of gait; L-DOPS, L-threo-3,4-dihydroxyphenylserine; LID, levodopa induced 
dyskinesia; OL, open label; PC, placebo-controlled; R, randomized; SNRI, selective noradrenaline reuptake 
inhibitor; SSNRI, selective serotonin and noradrenaline reuptake inhibitors; QoL, quality of life. 
 
 
Mechanism of 
action Drug Reference Target Outcome 
Study 
design 
NA precursor Droxidopa /  
L-DOPS 
Biaggioni et al., 201757 Orthostatic 
hypotension 
Improved symptoms 
Increase in standing systolic BP 
DB, OL, 
PC 
Kaufmann et al., 201458 Orthostatic 
hypotension 
Improved symptoms 
Increase in standing systolic BP 
R, PC 
Fukada et al., 201259 FOG Improvement FOG only when co-administered 
with entacapone 
R, OL 
SNRI Atomoxetine Weintraub et al., 201060 Depression 
Global cognition 
Daytime 
sleepiness 
No significant change in depression 
Improvement in global cognition 
Improvement in daytime sleepiness 
R, PC, DB 
Kehagia et al., 201461 Impulsivity Improvement in distinct behavioral tasks DB, R, PC 
Marsh et al., 200962 Executive 
dysfunction 
Improvement in executive dysfunction OL 
Reboxetine Pintor et al., 200663 Depression Improvement of depressive symptoms OL 
Lemke et al., 200264 Depression Improvement of depressive symptoms OL 
SSNRI Duloxetine Djaldetti et al., 200765 Central pain Subjective pain relief 
Quantitative pain threshold did not change 
OL 
Venlafaxine Takahashi et al., 201966 Depression 
Apathy 
FOG 
Improvement in depression 
No change in apathy scores 
Improvement of FOG 
R, OL 
Richard et al., 201267 Depression Improvement of depressive symptoms R, DB, PC 
DNRI Methylphenida
te 
Devos et al., 200670 Gait disorders Improvement of gait and motor symptoms RM 
Moreau et al., 201271 Gait disorders, 
FOG 
Improvement of gait and FOG R, DB, PC 
Espay et al., 201168 Gait impairment No improvement of gait 
Worsening of motor function, sleepiness and 
QoL 
R, PC, DB 
Mendonça et al., 200769 Fatigue Significantly lower fatigue scores 
No change in motor function 
R, DB, PC 
α2-agonist Clonidine Riekkinen et al., 199972 Spatial working 
memory 
Attentional set 
shifting 
Improvement in spatial working memory 
No effect on attentional set shifting 
OL 
α2-antagonist Idazoxan Rascol et al., 200173 LID Improvement of LIDs 
No worsening of parkinsonism 
R, PC 
Fipamezole LeWitt et al., 201274 LID Improvement of LIDs 
No worsening of parkinsonism 
DB, R, PC 
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In the following, we will summarize three possible avenues for further potential disease progression 
biomarker development. 
Neuromelanin-sensitive MR imaging (NM-MRI) visualizes neuromelanin, a dark colored 
pigment found in high concentrations in the catecholaminergic neurons of the SNc and LC as T1 
hyperintense regions.30,31 Studies of LC dysfunction and degeneration in manifest PD patients report 
significant bilateral reduction of NM-MRI signal intensity in the LC region, suggesting a loss of 
pigmented noradrenergic neurons.32,33 Application of the NM-MRI technique in RBD cohorts has 
revealed similar results, thus indicating early involvement of neuromelanized LC neurons in the 
disease process.4,34 However, no data are available regarding LRRK2 or GBA prodromal patients, 
and follow-up studies in the RBD cohorts have not been reported. Therefore, a conclusion of 
whether NM-MRI imaging can be used as a progression marker of LC degeneration awaits further 
research. 
PET imaging to monitor noradrenergic LC function during the course of PD is now possible due 
to optimized monoaminergic radiotracers and general technological progress. The studies conducted 
to date in manifest PD patients showed an increase of tracer binding in the LC region in early motor 
PD, indicating a compensatory up-regulation of noradrenergic function in early disease stages.35,36 
Interestingly, a recent 3-year follow-up study reported that, after the initial increase, an annual decline 
of 7.8% of 18F-DOPA uptake in the LC region takes place, suggesting progressive degeneration of 
LC cells in manifest PD.36 Furthermore, the use of a newly developed noradrenergic-specific 
radiotracer on manifest PD patients37 revealed a significant decrease of tracer binding in known LC 
output regions, such as the red nucleus and the thalamus, likely reflecting noradrenergic denervation 
in those structures.37 In light of a lack of data in RBD, LRRK2 and GBA prodromal PD patients, it 
is essential to carry noradrenergic PET imaging forward into prodromal patient cohorts.  
Attentional set shifting refers to the ability of switching the focus of attention between different 
perceptual dimensions. When combined with pupillometry the Wisconsin Card Sorting Test (WCST) 
or the Intra-/Extra-Dimensional Attentional Set-Shifting Task (IED) can be used to investigate LC 
function in humans. According to rodent studies, performance in attentional set shifting is highly 
dependent on prefrontal cortical noradrenergic activity originating in the LC.38 Moreover, it is already 
known that PD patients perform worse in shifting their focus of attention during the WCST.39,40 
However, there is no pupillometric data available during attentional set shifting in manifest, not to 
speak of prodromal PD patient groups. 
 
Conclusion 
In this viewpoint article we argue that the LC represents a suitable structure for identification of 
prodromal disease progression markers in PD in order to monitor ongoing neurodegeneration during 
the prodromal phase of the disease. The wealth of information available on the physiology and 
pathophysiology of the dopaminergic nigrostriatal neurons is abundant, and a clinical phenotype 
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hallmarking a lesion at level of the LC, i.e. RBD, is available. Thus, by combining both assets, it 
should be possible to reach a level of knowledge on the LC which will have an impact on the discovery 
of prodromal PD progression markers and development of symptomatic or disease-modifying 
treatments. 
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Abstract 
Neurodegeneration of the nigrostriatal dopaminergic system and concurrent dopamine (DA) 
deficiency in the basal ganglia represent core features of Parkinson’s disease (PD). Despite the central 
role of DA in the pathogenesis of PD, dopaminergic systems outside of the midbrain have not been 
systematically investigated for Lewy body pathology or neurodegeneration. Dopaminergic neurons 
show a surprisingly rich neurobiological diversity suggesting that there is not one general type of 
dopaminergic neuron but rather a spectrum of different dopaminergic phenotypes. This 
heterogeneity on the cellular level could account for the observed differences in susceptibility of the 
dopaminergic systems to the PD disease process.   
In this review we will summarize the long history from the first description of PD to the rationally 
derived DA replacement therapy, describe the basal neuroanatomical and neuropathological features 
of the different dopaminergic systems in health and PD, explore how neuroimaging techniques 
broadened our view of the dysfunctional dopaminergic systems in PD, and discuss how dopaminergic 
replacement therapy ameliorates the classical motor symptoms but simultaneously induces a new set 
of hyperdopaminergic symptoms. 
 
 
 
Keywords 
Parkinson disease; dopamine; dopaminergic systems; motor symptoms; dopaminergic therapy; L-
DOPA  
 
 
List of abbreviations 
123I-IBZM, 123I-iodobenzamide; 18F-FDG, 18F-fluorodeoxyglucose; AADC, aromatic L-amino 
acid decarboxylase; DA, dopamine; DAT, dopamine transporter; ICD, impulse control disorder; LB, 
Lewy body; LID, L-DOPA induced dyskinesia; LN, Lewy neurite; MCI, mild cognitive impairment; 
MSA, mutiple system atrophy; PD, Parkinson’s disease; PDD, Parkinson disease dementia; PSP, 
progressive supranuclear palsy; RBD, REM sleep behavior disorder; RRF, retrorubral field; SN, 
substantia nigra; STR, striatum; TH, tyrosine hydroxylase; UPDRS, Unified Parkinson’s Disease 
Rating Scale; VMAT2, vesicular monoamine transporter 2; VTA, ventral tegmental area. 
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Introduction 
The basic clinical symptomatology of Parkinson’s disease (PD) is well-known for 200 years and has 
been expanded ever since. But how can we identify the neuropathological correlates of these 
symptoms? How can we link symptoms to certain brain circuit dysfunction, or vice versa, how can 
we predict the clinical manifestation of a dysfunctional system? The comprehension of the association 
of neuronal systems and physiological functions/dysfunctions is crucial for the rational development 
of therapy to alleviate disabling symptoms. To investigate the link between symptomatology and 
neuropathology in humans we own the following toolkit: (i) post-mortem neuropathological studies 
to explore neurodegeneration, distribution of Lewy bodies/neurites (LB, LN) and biochemical 
alterations; (ii) neuroimaging studies in combination with radiotracers to examine dysfunctional 
neurotransmission; and (iii) clinical studies investigating the potential of certain medications to 
alleviate, worsen or even provoke certain symptoms. 
In this review, we will briefly summarize the long road to the discovery of a dysfunctional 
dopaminergic system in PD laying the ground for the still up-to-date gold standard of therapy and 
then focus on the emerging evidence of the dysfunctional dopaminergic systems of the brain in PD. 
 
A long road to go 
The first medical description of PD dates back to 1817 when James Parkinson published his 
monograph entitled ‘An Essay on the Shaking Palsy’ based on the depiction of the clinical picture of 
six patients (Fig. 1) (Parkinson 1817). Fifty-five years later, in 1872, Jean-Martin Charcot identified 
bradykinesia as a defining feature of PD and suggested that tremor is not an obligate symptom of the 
disease. He therefore proposed the term “Parkinson’s disease” thereby arguing against the term 
‘shaking palsy’. At this time, neuropathological correlate(s) of the diverse symptoms had not been 
resolved and PD remained a highly debilitating disorder without effective treatment.  
Almost one hundred years after the first description, neuropathological studies brought a first 
breakthrough in PD linking degeneration of the substantia nigra (SN) to the characteristic 
parkinsonian motor symptoms. In 1893, Georges Marinesco and Paul Blocq were the first to suggest 
that a lesion of the midbrain could contribute to the motor symptoms seen in PD. Their hypothesis 
was based on an autopsy of a patient with unilateral parkinsonism, which revealed a tuberculous 
nodule confined to the right cerebral peduncle. Two years later, Edouard Brissaud hypothesized that 
the SN might be the major pathological site of PD. This hypothesis was validated by the pioneering 
work of Constantin Trétiakoff in 1919 who demonstrated substantial loss of pigmented nigral cells 
in post-mortem PD brains and inclusion bodies in the remaining neurons which he called ’corps de 
Lewy’ (Lewy body, LB), in honor of their first describer Friederich H. Lewy (Trétiakoff 1919). The 
neurochemical consequences of SN degeneration, that is, dopamine (DA) deficiency in the basal 
ganglia of PD patients however remained unknown until 1960. 
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Thus, almost forty years later, in 1957, Arvid Carlsson demonstrated in a pioneering work that 
administration of reserpine lead to depletion of brain DA levels and onset of motor deficits in animals 
mimicking the symptomatology of parkinsonism. He also proved that application of L-DOPA, a 
blood-brain barrier-passing precursor of DA and noradrenaline could alleviate these symptoms by 
restoring the brain DA to normal levels (Carlsson 1959, Carlsson et al. 1957). This work built the 
basis for the DA era of PD and was later honored with the Nobel Prize of medicine. Soon after this, 
Oleh Hornykiewicz and Herbert Ehringer demonstrated that DA is depleted in the putamen, caudate 
nucleus and SN of post-mortem brains of Parkinson patients (Hornykiewicz 1963, Ehringer and 
Hornykiewicz 1960). Subsequently, they intravenously administered L-DOPA to volunteering 
patients. The effect of this therapy was the complete abolishment of the akinesia (Birkmayer and 
Hornykiewicz 1961). Thus, they introduced L-DOPA to the field of neurology as the first rationally 
developed therapy of PD. In 1970, based on the elaborative work of George C. Cotzias (Cotzias et 
al. 1969), the US Food and Drug Administration (FDA) finally approved L-DOPA as the first drug 
to treat PD.  
Although we know for a long time that the dopaminergic system of the brain is neither among the 
first regions affected in the course of the disease, nor is it solely accountable for the wide spectrum 
of symptoms, the gold standard of therapy is still based on the restoration of dopaminergic 
neurotransmission by means of administration of L-DOPA or DA receptor agonists (Oertel 2017). 
 
Figure 1 | Milestones of PD pathogenesis and therapy 
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Parkinsonism as the core feature of PD 
PD is a clinical diagnosis based on the occurrence of the characteristic parkinsonian motor 
abnormalities plus at least two supportive criteria and the complete absence of absolute exclusion 
criteria and red flags (Table 1) (Postuma et al. 2015). The three cardinal motor features of PD are 
bradykinesia/hypokinesia, tremor, and rigidity. Typically, PD patients initially present with unilateral 
motor signs, most commonly with akinesia in combination with resting tremor affecting one of the 
upper extremities (Pallone 2007). The motor symptoms then gradually spread to the contralateral and 
lower limbs, but the initial asymmetry remains (Weintraub et al. 2008, Rodriguez-Oroz et al. 2009). 
Bradykinesia means slowness of movement, whereas hypo-/akinesia is defined as reduced or 
diminished amplitude and frequency of spontaneous movements (Rodriguez-Oroz et al. 2009). 
Patients often describe this as ‘weakening of the limb’, but upon examination, the muscle strength is 
not altered. Bradykinesia usually presents as a slowness in everyday routine activities and reduced 
unilaterally arm swing during walking (Lewek et al. 2010, Jankovic 2008). Other signs of this symptom 
can be a decreased blinking rate (Biousse et al. 2004, Karson 1983), reduced facial expressions 
(hypomimia) and gesturing, micrographia and a monotone, soft speech (hypophonia) (Ho et al. 1999). 
Resting tremor (4-6 Hz), representing the most obvious and therefore stigmatizing symptom of PD, 
is defined as an involuntary rhythmical movement of a body part, which affects usually one of the 
upper extremities in the early phase of the disease (Jankovic 2008). Tremor is commonly one of the 
first motor signs to appear, and starts generally in the fingers or the thumb, resulting in the typical 
“pill-rolling tremor” (Kalia and Lang 2015). It becomes apparent during resting state, weakens or 
even disappears during voluntary movement of the limb and worsens when the patient is stressed or 
anxious. Rigidity refers to an increased muscle tone in both the agonist- and antagonist muscles 
resulting in stiffness of the limb. Upon clinical examination, a resistance to passive movement in the 
extremity can be observed. The resistance may be either smooth (lead-pipe phenomenon) or 
fluctuating (cogwheel rigidity) (Weintraub et al. 2008), the latter rather representing a mixture of 
tremor and rigidity. 
STEP 1. DIAGNOSIS OF PARKINSONISM 
Bradykinesia/hypokinesia + one of the following: 
• Resting tremor 
• Rigidity 
STEP 2. SUPPORTIVE CRITERIA 
At least 2 out of 4 
• Clear and dramatic response (>30% in UPDRS 
III score) to dopaminergic therapy 
• L-DOPA-induced dyskinesia 
• Resting tremor of a limb 
• Positive test of either olfactory dysfunction or 
cardiac sympathetic denervation (scintigraphy) 
 
STEP 3. ABSENCE OF ABSOLUTE EXCLUSION CRITERIA 
 
STEP 4. ABSENCE OF RED FLAGS 
Table 1 | Diagnostic criteria for PD 
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As the disease advances, postural instability becomes progressively apparent, representing the most 
common cause of falls and significantly decreasing the quality of life (Williams et al. 2006, Koller et 
al. 1989, Michalowska et al. 2005). Although postural instability usually develops during the course 
of the disease, it is mostly not present in early PD and an early occurrence therefore suggests an 
alternative diagnosis (Jankovic 2008, Postuma et al. 2015). The combination of cardinal motor 
symptoms, impairment of balance and an anterior shift of the mean center of gravity position finally 
results in the fully evolved late-stage parkinsonian posture and gait: the patient is bending forward 
into a flexed truncal position and the stride length and walking pace substantially decrease. The 
patient begins to shuffle and may scrape the foot on the floor with reduced or absent arm swing 
(Morris et al. 1994, Jankovic 2008, Ebersbach et al. 2013, Błaszczyk et al. 2007).  
Apart from these motor symptoms, several non-motor features occur in PD, with a substantial impact 
on the quality of life of patients (Schrag 2000). The most prevalent non-motor features are the 
following: reduced gastric and bowel motility resulting in constipation, olfactory dysfunction, sleep 
disturbances (e.g. REM sleep behavior disorder (RBD)), forgetfulness (cognitive decline), depression, 
apathy, and symptoms of autonomic dysfunction (e.g. urinary urgency, dysfunctional 
thermoregulation, sweating, orthostatic hypotension, erectile dysfunction) (Martinez‐Martin et al. 
2007). Importantly, non-motor features often precede the motor symptoms and therefore the 
diagnosis of PD by decades (Siderowf and Lang 2012). 
In contrast to the well-known symptomatology of PD, it has been increasingly difficult to identify 
the neurobiological correlates underlying the parkinsonian symptoms and integrate them in a 
pathophysiological model that explains the origin of brady-/akinesia, tremor and rigidity. While 
striatal DA deficiency could be clearly linked to the onset of motor dysfunction, the wide spectrum 
of symptoms and compensatory mechanisms in PD cannot be attributed solely to the loss of DA. 
 
The dopaminergic systems of the brain 
To understand the link between symptoms and a dysfunctional neuronal brain circuit, it is essential 
to explore the neurotransmitter system and its physiological functions. Therefore, we will briefly 
summarize the dopaminergic systems of the brain and their implications in distinct physiological 
functions. The dopaminergic neurons of the mammalian central nervous system are distributed along 
ten distinct neuronal populations located in the ventral mesencephalon (A8-A10), diencephalon 
(A11-A15), olfactory bulb (A16) and retina (A17) (Fig. 2) (Björklund and Hökfelt, Björklund and 
Dunnett 2007, Dahlstroem and Fuxe 1964). All of these different subsystems are engaged in several 
biological functions such as motor, sensory and autonomic control, reward mechanisms, and 
cognition (Smeets and González 2000, Montague et al. 2004).  
The neurons of the ventral mesencephalic dopaminergic complex (A8-A10) are morphologically 
indistinguishable and rather form a continuum without clear anatomical boundaries. The A8 cell 
group is primarily located in the retrorubral field (RRF), whereas A9 neurons are found in the SN 
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pars compacta, and A10 refers to dopaminergic neurons within the ventral tegmental area (VTA) 
(Vogt Weisenhorn et al. 2016, Yetnikoff et al. 2014). All of them form one extensive 
mesotelencephalic dopaminergic projection system comprising three major pathways: (i) a ventral 
mesostriatal or mesolimbic system which is involved in motivated behaviors predominantly 
originating in the VTA (A10); (ii) a mesolimbocortical or mesocortical system responsible for 
memory and learning, mainly originating in the VTA (A10); and (iii) a dorsal mesostriatal or 
nigrostriatal pathway which is engaged in voluntary motor control mainly originating in the SN pars 
compacta (A9) (Fig. 3) (Björklund and Dunnett 2007, Zeiss 2005, Flückiger et al. 1985). The 
diencephalic dopaminergic system (A11-A15) contains five distinct cell groups. The neurons of A11 
are located in the periventricular gray of the caudal hypothalamus and thalamus and project mainly 
to the dorsal horn of the spinal cord giving rise to the diencephalospinal pathway (Flückiger et al. 
1985, Watson et al. 2012). It was suggested that these neurons contribute to anti-nociception, motor 
and autonomic reflexes (Clemens and Hochman 2004, Lindvall et al. 1983, Fleetwood-Walker et al. 
1988). The tuberoinfundibular dopaminergic neurons of the arcuate nucleus (A12) and the 
dopaminergic neurons of the preoptic area (A14) are engaged in neuroendocrine functions by 
secreting DA to the hypophyseal portal blood system thereby regulating prolactin (PRL) and growth 
hormone (GH) secretion (Ben-Jonathan and Hnasko 2001, Turiault et al. 2007). The A13 
dopaminergic cell group is located within the medial part of the zona incerta and projects locally into 
the hypothalamus forming the incertohypothalamic pathway (Flückiger et al. 1985). This subsystem 
is engaged in the regulation of gonadotropin-releasing hormone (GnRH) secretion (Turiault et al. 
2007). The neurons of the A15 cell group are located in the rostral hypothalamic periventricular area. 
Their function is not yet fully understood but they seem to be involved in the regulation of GnRH 
as well (Brown et al. 2015, Clarkson and Herbison 2011). 
 
Figure 2 | Localization and PD-pathology of the 
dopaminergic systems in mice (a) and humans (b).  
The color of the different nuclei refers to the presence or 
absence of pathology seen in PD. green – not affected, red 
– affected, blue – not sufficient data available. (a) modified 
from (Björklund and Dunnett 2007) 
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Figure 3 | Mesotelencephalic pathways. The A8-A10 dopaminergic cell groups are found in the ventral 
midbrain.  
They form one extensive mesotelencephalic pathway comprising three major pathways: (1) mesolimbic pathway 
projecting mainly from the VTA to the ventral STR; (2) mesocortical pathway mainly originating in the VTA 
and projecting to the prefrontal cortex (PFC); and (3) nigrostriatal pathway originating in the substantia nigra 
and projecting to the dorsal STR. Abbreviations: ACB – nucleus accumbens, CP – caudoputamen; VTA – 
ventral tegmental area, SNr – substantia nigra pars reticulata; SNc – substantia nigra pars compacta 
 
The A16 dopaminergic cells of the olfactory bulb are interneurons found in the periglomerular layer 
(Halász et al. 1981) and play a pivotal role in odor discrimination and odor processing (Wilson and 
Sullivan 1995, Tillerson et al. 2006, Taylor et al. 2009). The retinal dopaminergic cells (A17) are 
neurons of the amacrine subtype found in the inner nuclear and inner plexiform layers of the retina 
(Archibald et al. 2009). Retinal dopaminergic neurotransmission plays a central role for contrast 
sensitivity, visual acuity and retinal light adaption by induction of the transition from the rod-circuit 
(dark-adapted state) to the cone-circuit (light-adapted state) (Archibald et al. 2009, Jackson et al. 2012, 
Korshunov et al. 2017, Ribelayga et al. 2008). 
What are the prerequisite features a neuron has to possess to be considered dopaminergic? The 
classical dopaminergic neuron is defined by the presence of: (i) DA, (ii) DA synthetizing enzymes 
(i.e. tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC)), (iii) DA degrading 
enzymes (i.e. monoamino oxidases), (iv) DA transporters (i.e. vesicular monoamine transporter 2 
(VMAT2), DA transporter (DAT)), and (v) autoreceptors (i.e. D2-receptor) (Vernier et al. 2004). 
Simultaneously, dopaminergic neurons lack dopamine-β-hydoxylase and phenylethyl-N-methyl 
transferase, the two enzymes required for the conversion of DA into noradrenaline and subsequently 
adrenaline (Vernier et al. 2004). Importantly, not all of the above mentioned neuronal populations 
(A8-A17) contain the complete set of proteins involved in dopaminergic neurotransmission, that is, 
some cell groups only partially fulfill all of the criteria of a traditional dopaminergic phenotype. For 
example, in the non-human primate, the A11 neurons contain TH, but at the same time lack 
detectable levels of AADC or DAT, suggesting that these neurons are L-DOPAergic, rather than 
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dopaminergic (Barraud et al. 2010). Among all dopaminergic cell groups, the A8 (RRF), A9 (SN pars 
compacta) and A10 (VTA) neurons exhibit the most complete dopaminergic phenotype (Vernier et 
al. 2004). The above introduced traditional map of the brain’s dopaminergic system was generated 
based on detecting DA complemented with visualizing the distribution of TH immunoreactivity 
(Björklund and Dunnett 2007, Björklund and Hökfelt, Dahlstroem and Fuxe 1964). As a 
consequence, the map does not reflect the diversity of the different dopaminergic subsystems. The 
heterogeneity furthermore suggests that there is not one general type of dopaminergic neurons but 
rather a spectrum of different dopaminergic phenotypes. 
 
Figure 4 | A traditional dopaminergic neuron. 
Abbreviations: TH – tyrosine hydroxylase; AADC – 
aromatic acid decarboxylase; VMAT2 – vesicular 
monoamine transporter 2; DAT – dopamine transporter 
 
Neuropathological alterations of the dopaminergic systems in PD 
Neuropathological studies, given their cross-sectional nature, allow the investigation of the spatial 
pattern of pathology, i.e. the aspect of the localization of LB pathology, neurodegeneration and 
consequent biochemical alterations. The advantages of neuropathological studies are: (i) high 
resolution in space which enables the detection of pathology at single-cell level, and (ii) detection of 
LB/LN pathology distribution, which is currently not possible with in vivo neuroimaging studies due 
to the lack of an α-synuclein radiotracer.  
Although it is commonly accepted that a dysfunctional dopaminergic neurotransmission is one of the 
core features of PD, and that the dopaminergic systems of the brain are heterogeneous and therefore 
may have different susceptibility to neurodegenerative processes, the dopaminergic neuronal 
populations outside the midbrain have not been systematically investigated in PD.  
Since the discovery of DA depletion in the SN and striatum (STR) of Parkinson patients 
(Hornykiewicz 1963), several neuropathological studies were conducted to estimate dopaminergic 
neurodegeneration of the SN pars compacta. The average loss of pigmented nigral neurons compared 
to age-matched healthy controls ranges between 41% and 79% across studies, on average 67% (Javoy-
Agid et al. 1984, Bogerts et al. 1983, Waters et al. 1988, Hirsch et al. 1988, German et al. 1989, 
Alberico et al. 2015, Zarow et al. 2003, Damier et al. 1999, Gibb and Lees 1991, Kempster et al. 1989, 
Halliday et al. 1996). Interestingly, the neuropathological process does not homogeneously affect the 
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full extent of the dopaminergic SN. A characteristic topology of neurodegeneration can be observed: 
neurons of the ventrolateral and caudal subregion, called ventral tier are primarily affected (around 
70-90% cell loss), whereas neurons in the dorsal tier are relatively resistant to the degenerative process 
(25-70% cell loss) (Damier et al. 1999, Fearnley and Lees 1991, Halliday et al. 1996, Hirsch et al. 
1997). In consent with these findings is the uneven pattern of DA depletion in the STR. The putamen, 
mostly receiving input from the ventral tier of the SN, shows almost complete DA depletion (<1% 
of DA remaining), whereas the caudate nucleus has still substantial levels of DA (~40% of DA 
remaining) (Fig. 6b) (Kish et al. 1988, Waters et al. 1988, Fahn et al. 1971). One study showed that 
the cell loss of pigmented, neuromelanin-containing SN neurons is less than the loss of TH-positive 
cells at all studied timepoints, indicating that prior to cell death, dopaminergic neurons become 
dysfunctional and decrease their dopaminergic phenotypic expression (ghost cells) (Kordower et al. 
2013). This suggests that at the time of the manifestation of the cardinal motor symptoms, symptoms 
most likely occur due to nigrostriatal dysfunction rather than frank neurodegeneration (Kordower et 
al. 2013). Besides neurodegeneration, the SN pars compacta also exhibits severe LB and LN 
pathology (Braak et al. 2003, Gibb and Lees 1989, Seidel et al. 2015). In fact, a combination of nigral 
Lewy pathology and neurodegeneration of the dopaminergic SN is highly specific for PD and even a 
prerequisite for the definite neuropathological diagnosis (Gelb et al. 1999, Dickson et al. 2009). 
The A8 dopaminergic neurons of the RRF show minor or no degenerative changes in PD (McRitchie 
et al. 1997), whereas the dopaminergic neurons of the VTA (A10) show abundant LB/LN pathology 
(Seidel et al. 2015) and substantial neurodegeneration in PD. The reported cell loss of neuromelanin-
pigmented VTA neurons in PD ranges between 40% and 77%, on average 53% (Hirsch et al. 1988, 
German et al. 1989, Alberico et al. 2015, Javoy-Agid et al. 1984, Bogerts et al. 1983, Uhl et al. 1985, 
Waters et al. 1988, Damier et al. 1999, McRitchie et al. 1997, Javoy-Agid and Agid 1980). A direct 
comparison of the VTA and SN cell counts is ‒ due to the different samples and statistical methods 
‒ difficult. Only a few studies directly compared nigral and ventral tegmental neuromelanized cell 
counts by investigating the same midbrain tissue samples. According to their results, the degree of 
neurodegeneration in the SN usually exceeds that of the VTA by 20% on average (Damier et al. 1999, 
German et al. 1989, Hirsch et al. 1988). This suggests that, although these two cell populations have 
a lot of common traits, certain factors partially decrease the susceptibility of VTA (A10) neurons to 
neurodegeneration, and/or increase the vulnerability of SN (A9) neurons.  
The diencephalic dopaminergic neuronal populations (A11-A15) have not raised much attention in 
PD yet, although their possible involvement in the disease process might contribute to certain 
autonomic and neuroendocrine dysfunctions seen in PD patients (Politis et al. 2008, Chaudhuri and 
Schapira 2009). It is reported that virtually all nuclei of the hypothalamus exhibit LB pathology to 
some extent after a certain disease duration (Langston and Forno 1978). The most severely affected 
hypothalamic regions are the tuberomammillary nucleus and the lateral and posterior hypothalamic 
nuclei, regions that do not contain dopaminergic cell groups (Langston and Forno 1978, Braak et al. 
2003, Braak et al. 2004). Interestingly, the tuberoinfundibular region which exhibits the highest 
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density of hypothalamic dopaminergic neurons (A12) is relatively spared of LB pathology (Langston 
and Forno 1978). Nevertheless, to date no study exists which investigated LB formation specifically 
in hypothalamic dopaminergic cells. In addition, studies on hypothalamic dopaminergic 
neurodegeneration are also sparse. Only one study aimed to quantify pigmented neuronal cell counts 
in hypothalamic nuclei of PD patients. Interestingly, no significant cell loss was detected (Matzuk and 
Saper 1985). Taken together, studies of the hypothalamic dopaminergic system in PD are sparse and 
their results are controversial. 
The olfactory bulb is one of the first brain regions affected during PD (Braak et al. 2003) and 
hyposmia is present in up to 90% of PD patients (Doty et al. 1988, Haehner et al. 2011), often 
preceding the classical motor symptoms by more than a decade (Kalia and Lang 2015). Several studies 
detected dense accumulation of LBs in granule-, mitral- and tufted cells and the anterior olfactory 
nucleus (Ubeda-Bañon et al. 2010, Sengoku et al. 2008, Braak et al. 2004). Interestingly, the 
periglomerular layer, in which the dopaminergic A16 neurons are localized, is relatively spared of the 
α-synucleinopathy and LBs only occasionally co-localize with TH immunoreactivity (Ubeda-Bañon 
et al. 2010, Sengoku et al. 2008, Cave et al. 2016). Studies estimating the number of bulbar 
dopaminergic neurons are contentious. Two independent studies reported that TH-positive neuronal 
count was doubled in the olfactory bulbs of PD patients compared to healthy controls (Huisman et 
al. 2004, Mundiñano et al. 2011), while other studies revealed no significant difference between PD 
and healthy controls (Cave et al. 2016, Ubeda-Bañon et al. 2010, Huisman et al. 2008). Taken together, 
dopaminergic cells of the olfactory bulb are spared of the α-synucleinopathy. However, whether their 
neuronal numbers increase during the disease duration and whether this change arises as a 
consequence of the disease process or DA replacement therapy needs to be further investigated.  
Data on the retinal dopaminergic system (A17) in PD are sparse. A very recently published study was 
the first one to examine and describe phosphorylated α-synuclein-positive, LB- and LN-like 
inclusions in the retina of PD patients (Ortuño-Lizarán et al. 2018). Morphological changes were 
exclusively found in the ganglion cell layer and exclusively co-localized with ganglionic cell markers 
thereby excluding the possibility of LB-formation in dopaminergic amacrine cells. However, despite 
the lack of α-synucleinopathy in retinal dopaminergic cells, neurochemical evidence of a dysfunctional 
retinal DA neurotransmission exists. Retinal dopaminergic cells of PD patients show decreased TH-
immunoreactivity (Nguyen-Legros 1988), and simultaneously significantly lower levels of retinal DA 
were measured (Harnois and Di Paolo 1990). 
It has been hypothesized for a long time that a dysfunctional DA homeostasis might contribute to 
the selective vulnerability of catecholaminergic neurons in PD (Lotharius 2002, Lohr et al. 2014, Pifl 
et al. 2014, Uhl 1998, Caudle et al. 2007, Post et al. 2018, Segura-Aguilar et al. 2014, Gandhi et al. 
2012, Bayersdorfer et al. 2010, Surmeier 2018, Surmeier et al. 2017). Moreover, DA seems to promote 
the formation and secretion of SDS-resistant α-synuclein oligomers thereby eventually contributing 
to the initiation and progression of the disease (Lee et al. 2011). Despite this central role of DA, 
extramesencephalic dopaminergic systems have not been systematically investigated for α-
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synucleinopathy and/or neurodegeneration. Substantial literature exists on the ventral mesencephalic 
dopaminergic (A8-A10) nuclei considering their involvement in the disease process. These 
comparative data allow to clearly recognize a spectrum of susceptibility, in which the nigral 
dopaminergic cells of the ventral tier (A9) are the most vulnerable, followed by the VTA (A10), the 
dorsal tier of the SN (A9), and the RRF (A8). Identifying the factors which render certain neurons 
particularly vulnerable or resistant to the disease process remains a key challenge. It has been 
suggested that the different protein expression pattern, and thus the interaction of various proteins 
influences the susceptibility of these neuronal populations (Double et al. 2010). Specific proteins, and 
protein expression patterns (proteomes) which could account for the observed spectrum of 
vulnerability within the mesencephalic dopaminergic cell populations have been found. These are of 
interest for cellular metabolism but also for the electrophysiological firing patterns of these cell 
groups. Whereas the pacemaking of the less vulnerable VTA neurons relies on voltage-dependent 
Na+ channels (Puopolo et al. 2007), adult nigral neurons use L-type voltage gated Ca2+ channels of 
the Cav1.3 subtype to maintain autonomous pacemaking leading to sustained Ca2+ influx to the 
cytosol (Chan et al. 2007, Nedergaard et al. 1993). In the most vulnerable ventral tier of the SN, latter 
is combined with a substantially lower intracellular Ca2+ buffering capacity due to the absence of 
calbindin and significantly lower expression levels of parvalbumin and calretinin compared to the 
dorsal tier of the SN or the VTA, respectively (Chung et al. 2005, Yamada et al. 1990, Parent et al. 
1996, McRitchie et al. 1996). As a consequence, these neurons have a high intracellular Ca2+-burden 
leading to high energy demands due to ATP-dependent Ca2+ extrusion mechanisms (Surmeier et al. 
2011, Chan et al. 2010). Furthermore, metabolic studies have shown that nigral neurons have an 
almost 3-fold higher basal oxidative phosphorylation rate than VTA neurons and thus a substantially 
elevated basal oxidative stress level and a significantly lower reserve respiratory capacity (Pacelli et al. 
2015). This means that nigral neurons are less capable of increasing their ATP production when 
higher energy demands occur. For thourough reviews on additional potential vulnerability factors see 
(Double et al. 2010) and (Brichta and Greengard 2014). 
 
What we can learn from neuroimaging studies 
Neuroimaging studies become increasingly valuable tools to link pathological alterations with motor 
and non-motor symptoms, to investigate etiology and pathomechanisms, to monitor disease 
progression, to support differential diagnosis of parkinsonism and to assess the outcome of 
therapeutic approaches (Politis 2014). In this review we will focus on three major applications which 
are relevant regarding dopaminergic dysfunction in PD: (1) the variety of imaging agents allows us to 
investigate the changes in the dopaminergic systems and metabolic activity caused by PD and thereby 
broadens our understanding of the molecular and cellular disease pathogenesis and progression 
(Weingarten et al. 2015, Politis 2014). (2) PET, SPECT and MRI based imaging can be used in the 
clinical setting to assist differential diagnosis of idiopathic PD vs. atypical parkinsonian syndromes or 
other causes of parkinsonism (Kägi et al. 2010, Scherfler et al. 2007). (3) Neuroimaging studies can 
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be used to detect subclinical levels of dopaminergic dysfunction and thus facilitate the identification 
and risk stratification of prodromal PD patients (Meles et al. 2017, Heller et al. 2017). Apart from 
these indications, functional neuroimaging has various other applicabilities, such as assessing the 
therapeutic effect of deep brain stimulation or embryonic cell transplantation (Weingarten et al. 2015, 
Natale et al. 2018). 
 
Figure 5 | Available radiotracers for in vivo imaging of the dopaminergic systems.  
Radiotracers can be used to image the presynaptic dopaminergic activity (DA storage, VMAT2 and DAT 
availability) or the postsynaptic dopaminergic function (D2/D3-receptors) with PET and SPECT approaches. 
A general advantage of functional neuroimaging studies is their potential to assess in vivo dysfunction 
of neuronal circuits, i.e. how the affected neurons behave in their neuronal network once they have 
reached a dysfunctional state. Additionally, they enable the analysis of the spatio-temporal pattern of 
neuropathology, that is, the progression of cellular and regional dysfunction in space and time. 
Dopaminergic dysfunction has been one of the major interests over the past 30 years of imaging in 
PD. The development of different imaging agents and tracers enabled the assessment of presynaptic 
dopaminergic dysfunction and postsynaptic DA receptor changes (Fig. 5). As expected, the ventral 
midbrain (A8-A10) of PD patients exhibits a reduction of presynaptic dopaminergic tracer uptake 
indicating dopaminergic degeneration (Joutsa et al. 2015, Goldstein et al. 2008, Ito et al. 2002, Hsiao 
et al. 2014). As a consequence, brain regions receiving dopaminergic input from A8-A10, namely the 
putamen, caudate nucleus and ventral STR (nucleus accumbens and olfactory tubercle) show reduced 
tracer binding reflecting dopaminergic denervation (Pavese et al. 2011, Joutsa et al. 2015, Lewis et al. 
2012, Hsiao et al. 2014). It could be shown that the loss of tracer binding is uneven between the 
subregions of the STR: the dorsal putamen displays the most severe reduction, followed by the 
caudate nucleus and the ventral STR (Bohnen et al. 2011, Lewis et al. 2012, Hsiao et al. 2014). This 
is in accordance with the neuropathological studies describing a stereotypical pattern of ventral 
mesencephalic dopaminergic neurodegeneration resulting in uneven dopaminergic denervation of the 
STR (Fig. 6b) (Damier et al. 1999, Fearnley and Lees 1991, Waters et al. 1988, Halliday et al. 1996). 
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The decrease in striatal tracer binding significantly correlates with the degree of locomotor disability, 
particularly with bradykinesia and rigidity (Vingerhoets et al. 1997, Holthoff-Detto et al. 1997, Rinne 
et al. 2000, Otsuka et al. 1996). Interestingly, it does not correlate with the degree of rest tremor, 
suggesting that the neural substrate of this motor symptom might be distinct from the nigrostriatal 
pathway (Otsuka et al. 1996, Vingerhoets et al. 1997). Longitudinal follow-up PET tracer studies have 
estimated the progression of mesencephalic dopaminergic dysfunction over time and found that 
presynaptic dopaminergic function declines exponentially indicating that the progression of the 
disease tends to be faster at the early phases (Nandhagopal et al. 2009, Hilker et al. 2005). This finding 
is of potential importance in therapeutic trials testing compounds with disease modifying potential, 
if DAT SPECT is chosen as a surrogate marker for progression of PD. It would mean that such 
clinical trials should be preferentially performed in de novo PD patients or even in prodromal stages 
of PD with phenoconversion to manifest motor PD as a clinical endpoint (see also RBD – below).  
Distinct behavioral and pharmacological triggers can be used to detect dysfunctional patterns of brain 
activity and neurotransmitter release. Several studies have been conducted to measure changes of 
striatal DA release triggered by L-DOPA challenge and correlated this with different symptoms of 
PD. They have consistently found that L-DOPA induces striatal DA release and that the degree of 
L-DOPA-induced DA outflow strongly correlated with disease duration (La Fuente-Fernández et al. 
2004), Hoehn-Yahr stage (Pavese et al. 2006), and motor disability measured by the Unified 
Parkinson’s Disease Rating Scale (UPDRS) (Tedroff et al. 1996). This means, that patients who had 
a longer disease duration, higher Hoehn-Yahr stages or higher UPDRS scores have larger putamenal 
DA release upon L-DOPA administration. Furthermore, the amplitude of striatal DA release 
positively correlated with dyskinesia scores indicating that a failure in the regulation of DA release 
contributes to the development of L-DOPA-induced dyskinesias (Pavese et al. 2006, La Fuente-
Fernández et al. 2004), an adverse effect of L-DOPA affecting up to 90% of patients after 10 years 
of DA replacement therapy (Lopez et al. 2010, Hauser et al. 2007). 
Reduction of the hypothalamic 18F-DOPA uptake indicating monoaminergic dysfunction and 
reduced AADC activity has been reported in PD patients (Pavese et al. 2010, Moore et al. 2008, 
Pavese et al. 2011). However, since the hypothalamus, apart from its intrinsic dopaminergic neurons 
(A11-A15), receives dense monoaminergic innervation originating from the serotonergic median and 
dorsal raphe nuclei and noradrenergic A1 and A6 (locus coeruleus) cell groups (Palkovits et al. 1980, 
van de Kar and Lorens 1979), changes in 18F-DOPA PET reflect the net alterations of all these 
systems (Pavese et al. 2011). Consequently, direct conclusions on the hypothalamic dopaminergic 
system (A11-A15) cannot be drawn from 18F-DOPA results. Nevertheless, significant reduction of 
postsynaptic D2 and D3 receptors has been observed in a 11C-raclopride study indicating 
dopaminergic dysfunction in the hypothalamus of PD patients (Politis et al. 2008). 
Currently, the diagnosis of clinical PD is exclusively based on the presenting symptomatology (Table 
1) and neuroimaging techniques like SPECT, PET or conventional MRI are not recommended as a 
first-line diagnostic approach. However, under certain conditions (e.g. atypical symptomatology or 
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unclear response to dopaminergic treatment) imaging techniques can be of use to better differentiate 
idiopathic PD from atypical parkinsonian syndromes like multiple system atrophy (MSA) or 
progressive supranuclear palsy (PSP) and from secondary causes of parkinsonism (e.g. vascular 
parkinsonism, neoplasms or drug-induced parkinsonism). DAT SPECT using the 123I-Ioflupane 
ligand (DATScan) can be used to measure the strength of dopaminergic innervation of the STR 
(striatal DAT levels) and is thereby able to differentiate neurodegenerative forms of parkinsonism 
(e.g. PD, MSA, PSP) which normally show reduced striatal DAT levels, from essential tremor and 
healthy controls (normal striatal DAT levels) (Kägi et al. 2010, Scherfler et al. 2007). However, this 
technique does not allow to further distinguish idiopathic PD from the atypical parkinsonian 
syndromes (MSA, PSP). In this case one could perform a D2/D3 receptor SPECT with the ligand 
123I-iodobenzamide (123I-IBZM). PD patients generally show normal postsynaptic D2/D3 signal 
intensities, while MSA and PSP patients are commonly characterized by decreased postsynaptic 
D2/D3 receptor availability. However, a normal D2/D3 signal does not exclude MSA or PSP (Vlaar 
et al. 2007). Other possibilities to differentiate idiopathic PD from atypical parkinsonian syndromes 
are metabolic PET imaging with 18F-FDG (Hellwig et al. 2012, Juh et al. 2004), which relies on disease 
specific alterations of brain glucose metabolism, or MRI based approaches like T2 weighted structural 
MRI, voxel-based morphometry and diffusion tensor imaging (Price et al. 2004, Paviour et al. 2005, 
Ota et al. 2013). 
At the onset of motor symptoms and, consequently, at the time of diagnosis 30% of nigral cells have 
already been lost and only 50-60% of normal TH-immunoreactivity is present in the STR (Fearnley 
and Lees 1991, Greffard et al. 2006, Cheng et al. 2010, Kordower et al. 2013). The time period, in 
which the pathological process of PD has already started but the motor symptoms are not yet present 
is the so-called premotor or prodromal phase of PD (Kalia and Lang 2015). During this period, 
functional neuroimaging of the nigrostriatal system is able to detect subclinical levels of dopaminergic 
dysfunction and thus facilitates the identification and risk stratification of patients with prodromal 
PD (Bauckneht et al. 2018, Heller et al. 2017, Meles et al. 2017, Iranzo et al. 2010, Stiasny-Kolster et 
al. 2005, Piccini et al. 1999). Patients suffering from idiopathic RBD, a parasomnia characterized by 
the absence of atonia during REM sleep in combination with abnormal nocturnal behavior, represent 
a specific prodromal risk population for developing PD (Iranzo et al. 2013). Several studies found 
that RBD manifestation precedes the onset of PD, dementia with Lewy bodies and MSA, thereby 
representing an early and specific symptom of these neurodegenerative α-synucleinopathies (Postuma 
et al. 2012, Schenck et al. 2013). Applying DAT SPECT imaging with 123I-Ioflupane on RBD patients 
revealed a progressive decrease of presynaptic striatal DAT availability from “mild” or “subclinical” 
RBD to manifest RBD to PD (Heller et al. 2017). Moreover, 18F-FDG-PET imaging showed that a 
subgroup of RBD patients already possessed the same altered brain glucose metabolism pattern 
which is related to PD patients (Meles et al. 2017). Taken together, neuroimaging techniques can help 
to differentiate RBD patients from healthy controls, to monitor RBD disease progression, to stratify 
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the risk of phenoconversion to PD, and thereby identify and characterize eligible patients for 
neuroprotective trials (Heller et al. 2017, Bauckneht et al. 2018). 
 
Symptomatology ‘off’/‘on’ dopaminergic medication – conclusions of clinical 
studies 
Clinical drug studies investigating the potential of dopaminergic medication to improve, but also to 
worsen or even induce some of the PD symptoms are valuable tools to identify distinct symptoms 
which are linked to the dysfunctional dopaminergic neurotransmission.  
Physiological dopaminergic functions, such as voluntary motor control, require optimal DA levels in 
dopaminergic output regions. Both a hypodopaminergic and hyperdopaminergic state result in neural 
network dysfunction, and eventually in clinical symptoms. At the time of PD motor symptoms onset 
around 30% of dopaminergic nigral neurons are lost and 50-60% of their axon terminals show a 
marked decrease of TH immunoreactivity (Fearnley and Lees 1991, Greffard et al. 2006, Cheng et al. 
2010, Kordower et al. 2013). This indicates that even when the disease process started and moderate 
DA shortage is present in the STR, intrinsic mechanisms compensate the DA deficit retaining normal 
physiological functions and thereby an asymptomatic state (Fig. 6a) (Perez et al. 2008, Zigmond et al. 
1990, Garris et al. 1997, Bergstrom and Garris 2003, Obeso et al. 2004). Interestingly, patients with 
incidental LB disease, i.e. healthy individuals without apparent parkinsonism or dementia with 
LB/LN pathology upon autopsy, show a 27% cell loss of pigmented nigral neurons (Fearnley and 
Lees 1991) and a 33-50% decrease of striatal TH immunoreactivity (DelleDonne et al. 2008, Dickson 
et al. 2008, Beach et al. 2008). As PD progresses and the severity of hypodopaminergism increases, 
the compensatory mechanisms fail and symptoms of a hypoactive dopaminergic system manifest. 
Replenishment of DA neurotransmission in these hypodopaminergic regions via DA replacement 
therapy (e.g. L-DOPA, DA agonists) will ameliorate the manifestation of DA shortage (Fig. 6a, b) 
(Birkmayer and Hornykiewicz 1961, Cotzias et al. 1969). Concurrently, given the uneven nature of 
neurodegeneration across the dopaminergic systems of the brain in PD, doses of L-DOPA which are 
necessary to restore dopaminergic neurotransmission in the most severely depleted nigrostriatal 
system simultaneously ‘overdose’ the better preserved mesolimbic and mesocortical brain networks. 
Thus, dopaminergic treatment with the focus on, and the primary clinical aim of ameliorating the 
motor symptoms leads to overactivation of the mesolimbic and mesocortical systems thereby 
resulting in symptoms of hyperdopaminergism (Fig. 6b) (Gotham et al. 1988, Swainson et al. 2000, 
Voon et al. 2017, Vriend et al. 2014, Joutsa et al. 2015, Vaillancourt et al. 2013). Therefore, symptoms 
of a dysfunctional dopaminergic neurotransmission represent a continuum in which 
hypodopaminergic states develop as a consequence of disease progression, whereas 
hyperdopaminergic states emerge as side effects of DA replacement therapy. In the following section, 
we will briefly give an insight into the dopaminergic symptoms of PD. 
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The pioneering work of A. Carlsson showed that DA deficiency in the brain of rabbits resulted in 
parkinsonian symptoms which could be alleviated by administration of L-DOPA, a blood-brain 
barrier crossing precursor of DA (Carlsson 1959, Carlsson et al. 1957). Since then, both 
neuropathological and neuroimaging studies of PD patients showed that the degree of DA deficiency 
in the dorsal STR significantly correlates with the Hoehn-Yahr stage and UPDRS motor disability, 
especially with bradykinesia and rigidity scores (Hornykiewicz 1963, Morrish et al. 1995, Broussolle 
et al. 1999, Seibyl et al. 1995, Hsiao et al. 2014, Pavese et al. 2011, Nandhagopal et al. 2009, Price et 
al. 1978). Consequently, administration of L-DOPA significantly improves the two latter motor 
symptoms of PD (Birkmayer and Hornykiewicz 1961, Cotzias et al. 1969). Although dopaminergic 
replacement therapy is the most effective symptomatic treatment of PD, longterm L-DOPA 
administration leads to motor side effects, the so called L-DOPA induced dyskinesias (LIDs). LIDs 
are among the most common adverse effects of L-DOPA therapy and affect up to 80% of patients 
after 5 years, and up to 90% after 10 years of treatment (Hauser et al. 2007, Ahlskog and Muenter 
2001, Rajput et al. 1984, Jong et al. 1987). The term LIDs refers to a variety of motor side effects 
which can be classified based on the clinical movement pattern and the temporal correlation between 
the occurrence of the dyskinesia and the administration of dopaminergic medication (Luquin et al. 
1992, Pandey and Srivanitchapoom 2017, Bastide et al. 2015). Interestingly, severe nigrostriatal 
damage seems to be a prerequisite of LIDs when L-DOPA is administered in pharmacologically 
relevant doses. Neither healthy controls, nor non-human primates with only moderate DA deficiency 
develop LIDs as a result of longterm L-DOPA treatment (Boyce et al. 1990, Schneider 1989, 
Hagenah et al. 1999, Di Monte et al. 2000, Jenner 2008). This indicates that nigrostriatal 
hyperdopaminergism per se is not sufficient to induce dyskinesias, but other factors have to be 
involved additionally. It is hypothesized that a ‘dysregulated DA release’ is responsible for the 
development of LIDs (see above), which originates in the compensatory mechanisms and changes 
due to dopaminergic denervation of the STR. It was shown that sprouting of serotonergic axon 
terminals takes place in the STR of PD patients (Rylander et al. 2010). Serotonergic neurons, due to 
their partially overlapping protein expression with dopaminergic cells (e.g. AADC, VMAT2), are able 
to take up L-DOPA, convert it to DA and store it in synaptic vesicles (Tison et al. 1991, Arai et al. 
1995, Arai et al. 1994, Butcher et al. 1970). As a consequence, these neurons, although normally not 
relying on DA as a neurotransmitter, synthetize and release DA upon administration of L-DOPA 
(Carta et al. 2007). However, since they neither express D2 autoreceptors mediating the natural 
feedback of DA release, nor DAT to clear DA from the synaptic cleft, the dopaminergic 
neurotransmission becomes dysregulated resulting in swings of synaptic DA levels manifesting as 
LIDs (Mosharov et al. 2015, Carta and Bezard 2011). 
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Figure 6 | The relationship between DA levels and physiological functions/dysfunctions.  
a As a consequence of diverse compensatory mechanisms, mild to moderate changes of DA levels remain 
asymptomatic (plateau). When the severity of hypo- or hyperdopaminergism increases, compensatory 
mechanisms fail to retain physiological functions leading to dysfunctional neural circuits manifesting as clinical 
symptoms. Hypodopaminergic states develop as a consequence of disease progression, whereas 
hyperdopaminergic states emerge as side effects of DA replacement therapy. b Ventral mesencephalic 
dopaminergic (A8-A10) neurodegeneration shows a stereotypical pattern resulting in severe 
hypodopaminergism in the caudoputamen (CP, nigrostriatal pathway), and mild to moderate 
hypodopaminergism in the ventral STR (ACB – nucleus accumbens, mesolimbic pathway) and prefrontal 
cortex (PFC, mesocortical pathway). As a consequence, doses of DA replacement therapy which are necessary 
to remedy the nigrostriatal pathway simultaneously overdose the mesocortical and mesolimbic pathways. 
 
Cognitive deficits ranging from mild cognitive impairment (MCI) not yet qualifying as dementia to 
manifest dementia are common non-motor symptoms in PD with significant impact on the quality 
of life (Chaudhuri and Schapira 2009). MCI can be observed in prodromal and manifest PD affecting 
around 20% of patients at the time of diagnosis (Muslimovic et al. 2005, Aarsland et al. 2009a) and 
displays a major risk factor for the progression to PD dementia (PDD) (Hoogland et al. 2017, Hobson 
and Meara 2015, Pedersen et al. 2017). Cognitive impairment most commonly affects executive 
functions resulting in a ‘dysexecutive syndrome’ resembling to that seen in patients with frontal lobe 
damage (Owen et al. 1995, Taylor et al. 1986, Owen et al. 1993, Muslimovic et al. 2005, Rowe et al. 
2002). The pathophysiology of MCI and dementia in PD is heterogeneous and involves a 
combination and synergism of distinct pathological changes. These include cortical LB pathology 
(Mattila et al. 2000, Apaydin et al. 2002, Hurtig et al. 2000, Irwin et al. 2012, Compta et al. 2011), 
cortical cholinergic deficiency due to the degeneration of the nucleus basalis of Meynert (Mattila et 
al. 2001, Perry et al. 1991), noradrenergic loss as a consequence of locus coeruleus degeneration, 
cortical and limbic reduction of DA due to the degeneration of the mesolimbic and mesocortical 
dopaminergic systems (Rinne et al. 1989, Paulus and Jellinger 1991, Zweig et al. 1993, Ito et al. 2002, 
Scatton et al. 1983), potential occurrence of Alzheimer’s disease co-pathology (Boller et al. 1980, 
Paulus and Jellinger 1991, Irwin et al. 2012, Compta et al. 2011), and others – for a thourough review 
see (Halliday et al. 2014). This means that a DA deficit in certain brain regions contributes to the 
cognitive deficit seen in nondemented PD patients with MCI and in PDD patients (Rinne et al. 1989, 
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Paulus and Jellinger 1991, Zweig et al. 1993, Ito et al. 2002, Scatton et al. 1983). However, DA 
deficiency per se is not considered to be sufficient for the development of the full range of cognitive 
deficits (Bosboom et al. 2004, Caballol et al. 2007). Interestingly, studies examining the effects of L-
DOPA in PD patients with dysexecutive syndrome report beneficial, neutral, and detrimental effects 
(Gotham et al. 1988, Swainson et al. 2000, Kulisevsky 2000, Downes et al. 1989, Bowen et al. 1975, 
Kulisevsky et al. 1996, Lange et al. 1992, Pillon et al. 1989). This is due to the fact that executive 
functions can be split into different components, such as working memory, inhibition, attentional 
set-shifting, and planning, whose neurobiological correlates are distinct (Smith 1999, Rabinovici et al. 
2015). During an executive task, depending on the subdomain required, different neural networks are 
active including the prefrontal and parietal cortices, the basal ganglia, the thalamus and the cerebellum 
(Collette et al. 2005, Monchi et al. 2001, Monchi et al. 2006, Wager et al. 2004, Wager and Smith 
2003, Cools et al. 2004). As a consequence, cognitive tasks which rely on DA-depleted brain regions 
(dorsal STR) will be ameliorated by DA replacement therapy, whereas cognitive functions associated 
with relatively intact or less affected, DA-dependent brain regions (ventral STR and prefrontal cortex) 
will be impaired due to a relative ‘overactivation’ of these systems (Gotham et al. 1988, Cools et al. 
2001). This explains why studies investigating the effect of DA replacement therapy on cognitive 
function report both detrimental and beneficial effects: depending on the cognitive task, distinct 
subdomains of executive function are examined which all have a different grade of 
hypodopaminergism. 
Neuropsychiatric syndromes ranging from major depression to psychosis and impulse control 
disorders (ICDs) are highly prevalent in PD affecting the vast majority of PD patients during the 
course of the disease (Aarsland et al. 2009b). Major depression occurs in approximately 17% of PD 
patients (Reijnders et al. 2008), apathy is present in up to 60% (Yamanishi et al. 2013, Pedersen et al. 
2009), whereas the prevalence of anxiety in cross-sectional studies ranges between 20 and 49% (Chen 
et al. 2010, Dissanayaka et al. 2010, Kulisevsky et al. 2008, Nègre-Pagès et al. 2010, Nuti et al. 2004). 
All three disorders are suggested to be – even if partly – associated with a deficient mesolimbic 
dopaminergic neurotransmission, i.e. with a mesolimbic hypodopaminergic state (Remy et al. 2005, 
Voon et al. 2011, Weintraub et al. 2005). This notion is further supported by clinical trials 
investigating the efficacy of DA agonists in depressive syndromes showing significant improvement 
of these symptoms (Reichmann et al. 2003, Reichmann et al. 2002, Barone et al. 2010, Lemke et al. 
2005, Pahwa et al. 2007, Bodkin and Amsterdam 2002, Thobois et al. 2013). A wide range of ICDs, 
such as pathological gambling, compulsive sexual behavior, and binge eating are associated with 
dopaminergic treatment affecting around 13.6% of PD patients on DA replacement therapy 
compared to 1.7% of patients neither receiving DA agonists nor L-DOPA (Weintraub et al. 2010). 
ICDs are suggested to develop as a consequence of a dopaminergic hyperactivity in ventral striatal 
reward circuitry (mesolimbic system) resulting in an increased drive to perform a certain behavior, 
and to be maintained by an impaired learning from negative consequences due to prefrontal cortical 
hyperdopaminergism (mesocortical system) (Fig. 6b) (Weintraub 2008, Evans et al. 2006, O'Sullivan 
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et al. 2011, Steeves et al. 2009, Cilia et al. 2008). Interestingly, the largest multicenter study 
(DOMINION) investigating the occurrence of ICDs in 3090 PD patients found that the frequency of 
developing an ICD was 2-fold higher in patients receiving DA agonists compared to patients taking 
L-DOPA (14.0% vs. 7.2%) (Weintraub et al. 2010). This can be explained by a significantly higher 
affinity of DA agonists to D3 receptors compared to D1 and D2 receptors (Gerlach et al. 2003). While 
D1 and D2 receptors are more abundant in the dorsal STR (nigrostriatal pathway) mediating voluntary 
motor control, D3 receptors are predominantly found in the ventral STR (mesolimbic pathway) 
playing an important role in reward mechanisms (Sokoloff et al. 1990, Gurevich 1999). As a 
consequence, doses of DA agonists required to improve motor symptoms may overactivate the 
mesolimbic system resulting in ICDs (Weintraub 2008, Voon et al. 2017). The association between 
developing an ICD and a hyperdopaminergic state in the mesocortical and mesolimbic systems is 
further supported by longitudinal studies showing that DA agonist dose reduction or discontinuation, 
even in combination with an increased L-DOPA dose, significantly improves ICD symptoms 
(Mamikonyan et al. 2008). 
 
Concluding remarks 
Neuropathological analysis, neuroimaging studies and clinical trials have enabled us to better 
understand dopaminergic dysfunction in PD. It has become evident that, although being one of the 
core features of PD, nigrostriatal degeneration cannot be solely accountable for the wide range of 
PD symptoms. Despite the central role of DA in PD, extramesencephalic, i.e. diencephalic, olfactory 
bulbar and retinal dopaminergic systems have not been systematically investigated yet – not to speak 
of the dopaminergic system related to the gastrointestinal tract. The distinct dopaminergic systems 
have a surprisingly high neurobiological diversity suggesting that there is not one general type of 
dopaminergic neuron but rather a spectrum of different dopaminergic phenotypes. This 
heterogeneity on the cellular level could account for the observed differences in susceptibility of the 
dopaminergic systems to the disease process. To finally understand which factors render neurons 
particularly vulnerable, we first ought to investigate which neuronal populations are affected in the 
course of PD, with emphasis on neuronal cell groups sharing common traits, like the synthetic 
machinery, the metabolism and the overall reliance on DA as a neurotransmitter.  
Arvid Carlsson and his fundamental discovery of DA deficiency in PD paved the way for the still 
ongoing era of dopaminergic replacement therapy and fueled 50-years of research on the 
dopaminergic systems in PD. Within the last two decades, the research focus slowly shifted towards 
other important areas such as neuropathological research on other neurotransmitter systems involved 
in PD, identification of genetic mutations or environmental risk factors. A major focus of the basic 
research field has been set on unravelling the pathogenesis and progression of PD including research 
on α-synuclein aggregation and interneuronal trafficking on one side and the identification of cell-
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autonomous factors rendering certain cell groups more vulnerable to the disease process, like 
mitochondrial dysfunction or electrophysiological cell properties on the other side. 
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Introduction  
Neurodegeneration of Locus coeruleus (LC) neurons is a common feature of the early prodromal 
phase of Parkinson`s disease (PD) and occurs at Braak’s stage 2, actually years before the substantia 
nigra is affected. However, the mechanisms underlying α-synuclein accumulation and 
neurodegeneration in LC neurons are still unclear. In our present study we have developed a new 
mouse model to study the time dependent effects of cellular A53T-α-synuclein overexpression in the 
LC, regarding α-synuclein aggregation, changes in electrophysiological properties and noradrenergic 
cell loss.  
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Methods 
Serotype 1/2 recombinant AAV vectors carrying the genetic information of A53T-α-synuclein or 
luciferase were unilaterally injected in the right LC of C57Bl/6 wild-type mice to induce continuous 
overexpression of A53T-α-synuclein in LC neurons for 1, 3, 6 or 9 weeks. At each time point eight 
animals per group were sacrificed for immunohistochemical analysis, whereas four animals per group 
and time point were used for patch-clamp recordings of LC neurons in acute brainstem slices.  
 
Results  
We found that targeted overexpression of A53T-α-synuclein in the LC of wild-type mice caused 
progressive α-synuclein aggregation and significant loss of noradrenergic LC neurons in a time 
dependent manner, starting three weeks post-injection. Accumulation of α-synuclein in the LC was 
accompanied by transport of α-synuclein to various interconnected brain regions observed even after 
one week of A53T-α-synuclein overexpression. In our model, neurodegeneration of the LC was 
associated with significant changes in the electrophysiological properties of the neurons. Time 
dependently, A53T-α-synuclein overexpression induced alterations in action potential shape and 
increase in the pacemaking frequency. 
 
Conclusions 
Our data indicate that overexpressed A53T-α-synuclein accumulates steadily in LC neurons while 
simultaneously inducing major changes in electrophysiological properties of these noradrenergic cells 
which might ultimately result in cell death. 
 
BL is a DAAD fellow. WHC and LAM have received a grant by the intramural research fund of the Rhön-AG. 
WHO is supported by the Charitable Hertie Foundation, Frankfurt/Main, Germany. 
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8.5. Abstract 2  
Poster as first author at the 21st International Congress of Parkinson’s Disease and Movement 
Disorders, Vancouver, Canada (June 2017).  
 
Targeted overexpression of A53T-α-synuclein induces progressive neurodegeneration and 
electrophysiological changes of noradrenergic locus coeruleus neurons – a preclinical model 
of Parkinson's disease 
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Introduction  
Dysfunction of the noradrenergic locus coeruleus (LC) is an early hallmark of Parkinson's disease 
(PD). Neurodegeneration of LC neurons occurs in Braak’s stage 2, years before the substantia nigra 
is affected. The extensive loss of noradrenergic LC neurons in PD is responsible for a large amount 
of non-motor symptoms that occur in early stages of the disease. However, the mechanisms that 
render LC neurons prone to α-synuclein accumulation and neurodegeneration are still unclear. In our 
present study, we developed a new mouse model to study the time dependent effects of cellular 
A53T-α-synuclein overexpression in the LC, regarding the toxicity caused by α-synuclein 
accumulation, the alteration in electrophysiological properties and noradrenergic cell loss.  
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Methods  
Serotype 1/2 recombinant adeno-associated viral vectors (rAAV) carrying the genome for A53T-α-
synuclein or luciferase were unilaterally injected in the right LC of C57Bl/6 wildtype mice to induce 
continuous protein overexpression. At 1, 3, 6 and 9 weeks post injection, eight animals 
overexpressing either A53T or luciferase were sacrificed for immunohistochemical analysis. In 
addition, four animals per group and timepoint were used to study the biophysical characteristics of 
LC neurons by patch-clamp recordings in acute brainstem slices.  
 
Results 
We show, that targeted overexpression of A53T-α-synuclein in the LC of wildtype mice caused 
progressive α-synuclein accumulation and significant loss of noradrenergic LC neurons in the injected 
side in a time dependent manner, starting 3 weeks post-injection. Aggregated forms of α-synuclein 
were confirmed by Proteinase K resistance and Ser129 phosphorylation. Furthermore, 
overexpression of α-synuclein led to a progressive increase of astro- and microglia density in the 
injected LC region. In our model, neurodegeneration of LC cells was associated with significant 
changes of their electrophysiological properties. Time dependently, A53T-α-synuclein 
overexpression induced alterations in action potential shape and an acceleration of the pacemaking 
frequency. 
 
Conclusions 
Our data indicate that overexpressed A53T-α-synuclein accumulates steadily in LC neurons while 
simultaneously induces neuroinflammation and major changes in electrophysiological properties, 
which might be responsible for the observed cell death of LC neurons. 
 
Disclaimer: L.A. Matschke and WH. Chiu have received a grant by the intramural research fund of the Rhön-
AG. B. Lee is a DAAD fellow. W.H. Oertel is supported by the Charitable Hertie Foundation, Frankfurt/Main, 
Germany. 
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8.6. Abstract 3   
Poster as shared first author at the α-synuclein Meeting, Athens, Greece (September 2017). 
 
Targeted overexpression of human-A53T-α-synuclein in locus coeruleus neurons causes 
widespread transport of α-synuclein to interconnected brain regions 
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Dysfunction of the noradrenergic locus coeruleus (LC) is an early hallmark of Parkinson's disease 
(PD) and contributes to a variety of non-motor symptoms. LC cells exhibit a common at-risk 
phenotype compared to other neurons that undergo neurodegeneration in PD, like autonomous 
pacemaking and cytosolic Ca2+ oscillations. In our present study, we aimed to elucidate, whether a 
locally induced α-synucleinopathy can cause transport of α-synuclein to brain regions distant from 
side of injection.  
AAV1/2 carrying the gene for either human-A53T-α-synuclein or luciferase were unilaterally injected 
into the LC-region of wild-type mice to induce continuous protein overexpression. After 1, 3, 6 and 
9 weeks, the whole brain of four animals per group was immunohistochemically analyzed for deposits 
of human-α-synuclein or luciferase.   
Targeted overexpression of human-A53T-α-synuclein causes progressive α-synuclein accumulation 
at the side of injection. Aggregated forms of α-synuclein were confirmed by Proteinase K resistance 
and Ser129 phosphorylation. Furthermore, α-synucleinopathy in the LC-region leads to widespread 
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axonal transport of human-A53T-α-synuclein as early as 1 week post injection to interconnected brain 
areas, as the olfactory bulb, central amygdala and lateral septal nucleus. At early time-points, deposits 
of human-A53T-α-synuclein are mainly seen in axons but start to appear over time also in cell bodies 
in certain brain regions like the bed nuclei of the stria terminalis or the central amygdala. No protein 
transport was seen in luciferase injected animals. 
Our results show that overexpressed A53T-α-synuclein is transported anterogradely over long 
distances to anatomically connected brain regions. Occurrence of α-synuclein positive cell bodies in 
a subset of the affected brain regions indicates additional retrograde axonal transport of α-synuclein.          
 
Disclaimer: L.A. Matschke received a grant by the intramural research fund of the Rhön-AG. W.H. Oertel is 
supported by the Charitable Hertie Foundation, Frankfurt/Main, Germany. 
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